Compounds > natriuretic peptide, brain
Page last updated: 2024-08-03 14:11:22

natriuretic peptide, brain

Description

Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. [MeSH]

nesiritide : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID53325981
MeSH IDM0029829

Synonyms (20)

Synonym
l-seryl-l-prolyl-l-lysyl-l-methionyl-l-valyl-l-glutaminylglycyl-l-serylglycyl-l-cysteinyl-l-phenylalanylglycyl-l-arginyl-l-lysyl-l-methionyl-l-aspartyl-l-arginyl-l-isoleucyl-l-seryl-l-seryl-l-seryl-l-serylglycyl-l-leucylglycyl-l-cysteinyl-l-lysyl-l-valyl-
human brain natriuretic factor-32
natriuretic factor-32 (human brain clone lambdahbnp57)
l-histidine, l-seryl-l-prolyl-l-lysyl-l-methionyl-l-valyl-l-glutaminylglycyl-l-serylglycyl-l-cysteinyl-l-phenylalanylglycyl-l_arginyl-l-lysyl-l-methionyl-l-alpha-aspartyl-l-arginyl-l-isoleucyl-l-seryl-l-seryl-l-seryl-l-serylglycyl-l-leucylglycyl-l-cystein
natriuretic factor-32 (human brain clone lambda hbnp57)
brain natriuretic peptide-32 (human)
nesiritide [usan:inn]
natriuretic peptide type-b
human brain natriuretic peptide-32
natriuretic peptide, brain
natriuretic factor, brain
1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane, cyclic peptide deriv.
unii-p7wi8ul647
p7wi8ul647 ,
brain natriuretic factor
b-tye natriuretic peptide
07y2v56iup ,
unii-07y2v56iup
bnp (1-32), human
DTXSID101026612

Drug Classes (1)

ClassDescription
polypeptideA peptide containing ten or more amino acid residues.

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Atrial natriuretic peptide receptor 1Homo sapiens (human)IC500.0060AID551695

Bioassays (1)

Assay IDTitleYearJournalArticle
AID551695Displacement of [125I]ANP from NPR-A expressed in HeLa cells after 3 hrs by gamma counting2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
ISSN: 1464-3391		Intramolecular azo-bridge as a cystine disulfide bond surrogate: Somatostatin-14 and brain natriuretic peptide (BNP) analogs.

Research

Studies (15,640)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (0.24)18.7374
1990's807 (5.16)18.2507
2000's5146 (32.90)29.6817
2010's7477 (47.81)24.3611
2020's2172 (13.89)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,867 (11.44%)5.53%
Reviews1,649 (10.11%)6.00%
Case Studies342 (2.10%)4.05%
Observational590 (3.62%)0.25%
Other11,869 (72.74%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
terlipressin
0
polypeptide00low000000
neurokinin b
1
polypeptide202120213.0low000001
(4R)-4-[[(2S)-2-[[[2-(1-amino-2-methylbutyl)-4,5-dihydrothiazol-4-yl]-oxomethyl]amino]-4-methyl-1-oxopentyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5
0
polypeptide00low000000
baci-im
0
homodetic cyclic peptide;
polypeptide;
zwitterion		antibacterial agent;
antimicrobial agent		00low000000
bivalirudin
0
polypeptideanticoagulant;
EC 3.4.21.5 (thrombin) inhibitor		00low000000
atrial natriuretic factor
2,253
polypeptide1988202319.4high1952270097147783
thymalfasin
0
polypeptide00low000000
ganirelix
0
polypeptide00low000000
abarelix
0
polypeptideantineoplastic agent;
hormone antagonist		00low000000
nociceptin
0
organic molecular entity;
polypeptide		human metabolite;
rat metabolite		00low000000
teriparatide
0
polypeptide00low000000
forapin
0
peptidyl amide;
polypeptide		animal metabolite;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.13 (protein kinase C) inhibitor;
hepatoprotective agent;
neuroprotective agent;
venom		00low000000
astressin
0
homodetic cyclic peptide;
polypeptide		corticotropin-releasing factor receptor antagonist;
neuroprotective agent		00low000000
salmon calcitonin
0
heterodetic cyclic peptide;
peptide hormone;
polypeptide		bone density conservation agent;
metabolite		00low000000
liraglutide
7
lipopeptide;
polypeptide		glucagon-like peptide-1 receptor agonist;
neuroprotective agent		201420206.6low400070
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide
0
polypeptide00low000000
alx-0600
0
polypeptideantioxidant;
glucagon-like peptide-2 receptor agonist;
metabolite;
protective agent		00low000000
msh, 4-nle-7-phe-alpha-
0
polypeptidedermatologic drug00low000000
melanotan-1
0
polypeptidedermatologic drug00low000000
gonadorelin hydrochloride
0
polypeptide00low000000
arthrofactin
0
polypeptide00low000000
p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe
0
polypeptideapoptosis inhibitor;
human metabolite;
neuroprotective agent		00low000000
semaglutide
0
lipopeptide;
polypeptide		anti-obesity agent;
appetite depressant;
glucagon-like peptide-1 receptor agonist;
hypoglycemic agent;
neuroprotective agent		00low000000
cigb-300
0
heterodetic cyclic peptide;
polypeptide		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor		00low000000
calpastatin
0
polypeptideEC 3.4.22.52 (calpain-1) inhibitor;
EC 3.4.22.53 (calpain-2) inhibitor		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetylcarnitine
1
O-acylcarnitinehuman metabolite202120213.0low000001
gamma-aminobutyric acid
2
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule		2006201215.0low000110
aminolevulinic acid
1
4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		201520159.0low000010
acetaldehyde
1
aldehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent		2001200123.0low000100
acetone
3
ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent		201220189.7low000030
adenine
5
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2002201715.6low000320
ammonium hydroxide
1
azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant		2011201113.0low000010
beta-alanine
1
amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter		2011201113.0low000010
betaine
1
amino-acid betaine;
glycine derivative		fundamental metabolite202120213.0low000001
betaine aldehyde
1
quaternary ammonium ionAspergillus metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite		202120213.0low000001
carbon monoxide
8
carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent		2005201415.1low100620
carnitine
4
amino-acid betainehuman metabolite;
mouse metabolite		201320217.2low100031
methane
2
alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas		201520206.5low000020
choline
4
cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite		2007202112.5low000301
citric acid, anhydrous
1
tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite		201520159.0low000010
chlorine
13
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		1990202216.3low004252
gallic acid
1
trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite		201820186.0low000010
octanoic acid
1
medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite		202120213.0low000001
hydrogen sulfide
5
gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent		201120208.2low100050
3-hydroxybutyric acid
1
(omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid		human metabolite201720177.0low000010
n(g),n(g')-dimethyl-l-arginine
28
alpha-amino acid2005202112.5low30010171
3,4-dihydroxyphenylacetic acid
2
catechols;
dihydroxyphenylacetic acid		human metabolite2002201814.0low100110
creatine
15
glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical		2002201715.1low300960
cytosine
3
aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2006201614.3low000210
lactic acid
45
2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite		199720239.9low70211257
dimethyl sulfoxide
1
sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger		1991199133.0low001000
gamma-butyrobetaine
1
amino-acid betaineEscherichia coli metabolite;
human metabolite		202120213.0low000001
glycine
3
alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical		201120219.3low000021
glyceraldehyde
1
aldotriosefundamental metabolite202220222.0low000001
glycerol
2
alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent		2012201311.5low100020
hydrogen cyanide
1
hydracid;
one-carbon compound		Escherichia coli metabolite;
human metabolite;
poison		2011201113.0low000010
hydrogen carbonate
4
carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1991201717.8low001120
dalteparin
4
2005201715.0low400310
histamine
7
aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter		1997202114.7low002131
hydrogen
3
elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite		201120189.0low000030
hydroquinone
1
benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent		201820186.0low000010
iodine
1
diatomic iodinenutrient202120213.0low000001
kynurenine
2
aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline		human metabolite201920233.0low000011
2,3,4,5-tetrahydroxypentanal
1
hydroxyaldehyde;
pentose;
polyol		202120213.0low000001
thioctic acid
1
dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector		201720177.0low100010
methanol
1
alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite		2010201014.0low000100
inositol
3
cyclitol;
hexol		2006202011.3low100120
melatonin
6
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		200820229.2low100231
nickel
2
metal allergen;
nickel group element atom		epitope;
micronutrient		202020213.5low000011
niacinamide
1
pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor		201920195.0low000010
nitrates
16
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		1999202214.1low303832
nitroxyl
1
nitrogen oxoacid2012201212.0low000010
nitrites
12
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite1999202213.3low202352
diphosphoric acid
1
acyclic phosphorus acid anhydride;
phosphorus oxoacid		Escherichia coli metabolite202220222.0low000001
thiosulfates
1
divalent inorganic anion;
sulfur oxide;
sulfur oxoanion		human metabolite201620168.0low000010
sulfites
1
divalent inorganic anion;
sulfur oxide;
sulfur oxoanion		202220222.0low000001
spermidine
1
polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector		201520159.0low000010
spermine
1
polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent		2010201014.0low000100
sulfuric acid
1
sulfur oxoacidcatalyst2012201212.0low000010
taurine
4
amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite		201220235.0low100022
thiamine
1
primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201920195.0low000010
thymine
3
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite		2006202212.3low000201
trimethyloxamine
8
tertiary amine oxideEscherichia coli metabolite;
metabolite;
osmolyte		201620234.0low000044
trimethylamine
2
methylamines;
tertiary amine		Escherichia coli metabolite;
human xenobiotic metabolite		202120232.0low000002
uracil
5
pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		201120216.6low300041
uric acid
76
uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite		1998202210.2low701214410
urea
24
isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2003202211.5low7008151
normetanephrine
4
catecholamine2011201711.0low000040
my 5445
1
pyridazines;
ring assembly		1993199331.0low001000
1-anilino-8-naphthalenesulfonate
2
aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe201520197.0low100020
14,15-epoxy-5,8,11-eicosatrienoic acid
1
long-chain fatty acid2014201410.0low000010
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
3
oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor2007201016.0low000300
mercaptoethanol
1
alkanethiol;
primary alcohol		geroprotector202320231.0low000001
homovanillic acid
1
guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite		201820186.0low100010
phenytoin
1
imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent		2004200420.0low100100
5,8,11,14-eicosatetraynoic acid
1
long-chain fatty acid1991199133.0low001000
5-hydroxydecanoate
2
medium-chain fatty acid201320188.5low000020
hydroxyindoleacetic acid
1
indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite		2014201410.0low000010
acetaminophen
2
acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2008201214.0low000110
acetazolamide
5
monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		201220234.8low500023
albuterol
3
phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic		200620209.3low200120
alendronate
1
1,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor		2013201311.0low000010
amifostine anhydrous
1
diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent		2004200420.0low000100
pimagedine
2
guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor		2000200123.5low001100
theophylline
1
dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent		2010201014.0low000100
amiodarone
10
1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug1999201217.0low201630
amlodipine
16
dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent		2001201616.6low9001240
anastrozole
1
nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		201920195.0low100010
aspirin
19
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		2003202211.1low9007102
atenolol
13
ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic		2001201117.7low6001210
azathioprine
1
aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug		1998199826.0low001000
azosemide
3
monochlorobenzenes;
sulfonamide;
tetrazoles;
thiophenes		loop diuretic201220188.3low300030
baclofen
2
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant		200820238.5low100101
bamethan
1
201920195.0low000010
bendroflumethiazide
2
benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic		2001200222.5low100200
benzamidine
1
benzenes;
carboxamidine		serine protease inhibitor1995199529.0low001000
bepridil
2
pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent		2008201015.0low200200
berberine
2
alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker		200920209.5low000110
bevantolol
1
propanolamineanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker		2002200222.0low000100
bicalutamide
1
(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol		2008200816.0low100100
bisindolylmaleimide i
2
1996200523.5low001100
bisoprolol
19
secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent		1996202114.3low10011251
buformin
1
biguanidesantineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent		2003200321.0low100100
caffeine
2
purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic		2006200817.0low000200
verapamil
5
aromatic ether;
nitrile;
polyether;
tertiary amino compound		2009201412.6low300230
calmidazolium
1
imidazolium ionapoptosis inducer;
calmodulin antagonist		2006200618.0low000100
camphor, (+-)-isomer
1
bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite201720177.0low000010
candesartan cilexetil
7
biphenyls2000201720.3low203310
candesartan
29
benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		1997202115.6low18031781
carbamazepine
1
dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic		2001200123.0low000100
carmustine
1
N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent		2006200618.0low000100
carvedilol
87
carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent		1999202315.1low420359214
celecoxib
3
organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		2006201414.7low000210
celiprolol
2
aromatic ketone1995200424.5low101100
chloroquine
3
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		201320217.3low000021
chlorpromazine
1
organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug		201820186.0low000010
chlorthalidone
1
isoindoles;
monochlorobenzenes;
sulfonamide		202120213.0low100001
cifenline
2
diarylmethane2008201612.0low100110
cilostamide
1
quinolines2010201014.0low000100
cilostazol
2
lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent		2001200322.0low000200
clenbuterol
1
amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent		2010201014.0low000100
clonidine
1
clonidine;
imidazoline		1991199133.0low001000
deferiprone
1
4-pyridonesiron chelator;
protective agent		2008200816.0low100100
deferoxamine
4
acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore		2006201015.5low100400
diazoxide
1
benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent		202020204.0low000010
diclofenac
1
amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2011201113.0low000010
dichlorvos
1
alkenyl phosphate;
dialkyl phosphate;
organochlorine acaricide;
organophosphate insecticide		anthelminthic drug;
antibacterial agent;
antifungal agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor		2010201014.0low000100
pentetic acid
1
pentacarboxylic acidcopper chelator2006200618.0low000100
3,3'-diindolylmethane
1
indolesantineoplastic agent;
P450 inhibitor		201520159.0low000010
dipyridamole
5
piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent		2003201415.6low100320
disopyramide
1
monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug202020204.0low000010
valproic acid
1
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		202120213.0low000001
thiorphan
2
N-acyl-amino acid1996199628.0low002000
donepezil
1
aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent		202320231.0low100001
doxazosin
7
aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent		2002201117.1low500610
9-(2-hydroxy-3-nonyl)adenine
1
2006200618.0low000100
erythrosine
2
1996201021.0low001100
ether
1
ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant		2009200915.0low000100
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
1
aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore		201820186.0low000010
fenofibrate
5
aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic		2003201515.2low000320
fenoldopam
3
benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent		2004200916.7low000300
fentanyl
4
anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic		2004201416.2low200310
flecainide
2
aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug2008201910.5low200110
fluorouracil
10
nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic		2010201710.9low500190
fluoxetine
1
(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound		201920195.0low000010
furosemide
63
chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic		1994202212.7low280323316
gentamicin
1
202120213.0low000001
glimepiride
1
sulfonamide202320231.0low100001
glyburide
3
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		1999201716.7low101110
go 6976
2
indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor2005201116.0low000110
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide
1
isoquinolines;
sulfonamide		1993199331.0low001000
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
3
isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor1992201324.7low002010
fasudil
1
isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent		2013201311.0low000010
haloperidol
3
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist		1992202122.3low002001
hydralazine
12
azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent		1994202116.5low402631
hydrochlorothiazide
13
benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic		2007202212.2low700481
hydroxyurea
2
one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent		2007201413.5low000110
ibuprofen
13
monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic		2001201911.2low300490
lidocaine
3
benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic		2004201814.0low100210
idebenone
1
1,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor		2011201113.0low100010
indapamide
1
indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic		2004200420.0low100100
indomethacin
15
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		1999201713.9low201680
iodoacetamide
1
2010201014.0low000100
iohexol
1
benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic		202320231.0low000001
iothalamic acid
1
organic molecular entity2009200915.0low000100
avapro
13
azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		2004202113.5low600751
1-methyl-3-isobutylxanthine
7
3-isobutyl-1-methylxanthine1993201025.4low005200
isoflurane
2
organofluorine compoundinhalation anaesthetic2007201015.5low100200
2-propanol
1
secondary alcohol;
secondary fatty alcohol		protic solvent2013201311.0low000010
isoproterenol
55
catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent		1995202211.4low00413353
3-phenyllactic acid
1
2-hydroxy monocarboxylic acidhuman metabolite201820186.0low100010
lavendustin a
1
aromatic amine1999199925.0low001000
nordefrin
1
catecholamine2004200420.0low000100
lorazepam
1
benzodiazepine2011201113.0low000010
losartan
46
biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist		1994201617.3low200626140
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
1
chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector		2009200915.0low000100
6-anilino-5,8-quinolinedione
1
aminoquinoline;
aromatic amine;
p-quinones;
quinolone		antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor		2000200024.0low001000
mesalamine
1
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug201920195.0low000010
metformin
17
guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic		200620239.0low9004103
metoprolol
34
aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic		1995202115.9low210221101
midazolam
1
imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative		2004200420.0low000100
milrinone
28
bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent		2001202117.1low2002251
minoxidil
1
dialkylarylamine;
tertiary amino compound		201620168.0low000010
mitoxantrone
4
dihydroxyanthraquinoneanalgesic;
antineoplastic agent		2006201414.8low200310
molsidomine
3
ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent		2001200819.0low000300
apnea
2
purine nucleoside201820195.5low000020
activins
1
201720177.0low000010
neostigmine
1
quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor		2013201311.0low000010
nicardipine
2
benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound		1996201021.0low001100
nifedipine
7
C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent		1995201616.0low001330
nimesulide
1
aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		201520159.0low000010
nisoldipine
1
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester		2008200816.0low000100
nitroglycerin
53
nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic		1998202216.8low110335132
5-nitro-2-(3-phenylpropylamino)benzoic acid
2
nitrobenzoic acid202220231.5low000002
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
3
aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor		2004201513.0low000120
oxybutynin
1
acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic		2012201212.0low100010
pantoprazole
1
aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic		2012201212.0low100010
papaverine
1
benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent		2009200915.0low000100
pd 98059
6
aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		1996201521.3low003210
pentobarbital
1
barbituratesGABAA receptor agonist2009200915.0low000100
pentoxifylline
2
oxopurine2004200420.0low200200
perhexiline
1
piperidinescardiovascular drug2008200816.0low000100
phenoxybenzamine
2
aromatic amine1992201819.0low001010
4-phenylbutyric acid
2
monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug		2012201610.0low000020
phenyl biguanide
2
guanidinescentral nervous system drug2001201118.0low000110
moxonidine
4
organohalogen compound;
pyrimidines		2002200421.0low000400
pilsicainide
1
organic heterobicyclic compound;
secondary carboxamide		anti-arrhythmia drug;
sodium channel blocker		2008200816.0low100100
pimobendan
5
benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		1999201913.4low401130
pioglitazone
12
aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic		2002201716.2low3001020
potassium chloride
3
inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer1999201419.0low001110
prazosin
2
aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor		1996199628.0low002000
probucol
1
dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug		1999199925.0low001000
procainamide
1
benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker		202220222.0low000001
propofol
6
phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative		2002202010.5low500150
propranolol
5
naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic		1992201923.6low003110
risperidone
1
1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist		2013201311.0low000010
rofecoxib
3
butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		2004200619.0low000300
3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol
1
2004200420.0low000100
sevoflurane
7
ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor		2005202010.1low700160
sibutramine
1
organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor		2010201014.0low000100
linsidomine
3
morpholines2001200819.0low000300
fluoroacetic acid
1
haloacetic acid;
organofluorine compound		EC 4.2.1.3 (aconitate hydratase) inhibitor202020204.0low000010
sotalol
2
ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic		2008201910.5low100110
sulfasalazine
1
2011201113.0low000010
sulforaphane
1
isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite		201820186.0low000010
tetraethylammonium
3
quaternary ammonium ion2002201118.7low000210
thalidomide
5
phthalimides;
piperidones		2006201115.0low000410
thiotepa
1
aziridines2014201410.0low000010
ticlopidine
9
monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		2004201613.9low700540
troglitazone
2
chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent		2001200222.5low000200
tyramine
1
monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter		202120213.0low000001
urapidil
1
piperazines201720177.0low100010
urethane
1
carbamate esterfungal metabolite;
mutagen		2009200915.0low000100
w 7
2
1999200024.5low002000
pirinixic acid
1
aryl sulfide;
organochlorine compound;
pyrimidines		2003200321.0low000100
corticosterone
5
11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		2000202116.2low001301
prednisolone
4
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic		2002201614.5low200220
reserpine
1
alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic		1995199529.0low001000
phentolamine
1
imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent		2012201212.0low000010
sorbitol
1
glucitolcathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent		202020204.0low100010
thymidine
3
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite		1991200826.7low002100
hydroxyproline
6
4-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite		2006202111.0low000231
thyroxine
25
2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone		2000202312.3low20110122
methacetin
1
acetamides;
aromatic ether		2010201014.0low000100
carbachol
4
ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic		1997201119.5low001210
spironolactone
76
3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic		2001202211.6low330031387
aldosterone
223
11beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite		1988202216.6low71240101719
pentolinium tartrate
1
tartrate saltantihypertensive agent1999199925.0low001000
penicillamine
1
non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen		1997199727.0low001000
prednisone
8
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug		1998202115.6low401421
estrone
1
17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite		2013201311.0low100010
etiocholanolone
1
17-oxo steroid;
3alpha-hydroxy steroid;
androstanoid		human metabolite;
mouse metabolite		2008200816.0low000100
dehydroepiandrosterone
3
17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite		1989202219.0low010101
triiodothyronine
29
2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone		2000202312.1low20111143
biguanides
3
guanidines2001201315.7low000120
carbon tetrachloride
1
chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant		2009200915.0low000100
alanine
5
alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite		1992202014.2low101130
serine
1
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		202320231.0low000001
desoxycorticosterone acetate
1
corticosteroid hormone201520159.0low000010
glutamine
3
amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		201220226.0low100021
lysine
3
aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		201320226.0low000021
sucrose
1
glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent		2005200519.0low000100
adenosine diphosphate
4
adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite		2001202213.0low000211
bromodeoxyuridine
1
pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent		2013201311.0low000010
carbostyril
3
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite2001202213.0low000201
phenylephrine
21
phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent		1994202021.4low0010830
levodopa
1
amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug		2002200222.0low000100
edetic acid
14
ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector		1999202313.4low001733
phenylethyl alcohol
1
benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite		2006200618.0low000100
tyrosine
16
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		2000202014.1low502590
adenosine monophosphate
4
adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		202020223.0low000022
leucine
9
amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		1996202117.1low002421
methacholine chloride
1
quaternary ammonium salt2013201311.0low100010
methionine
3
aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical		1993200525.0low202100
phenylalanine
5
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2001202116.8low000401
desoxycorticosterone
10
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		1989201028.1low017200
colchicine
1
alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen		202120213.0low000001
cycloheximide
3
antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor		1994201220.3low001110
egtazic acid
1
diether;
tertiary amino compound;
tetracarboxylic acid		chelator1999199925.0low001000
sodium citrate, anhydrous
1
organic sodium saltanticoagulant;
flavouring agent		2010201014.0low100100
mannitol
3
mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent		1994200920.3low001200
cytarabine
2
beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent		2005200618.5low000200
histidine
2
amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		2005202310.0low000101
valine
21
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		2002201515.7low16001380
threonine
2
amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		201920195.0low000020
tryptophan
1
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2011201113.0low000010
arginine
46
arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical		1994202312.7low30215272
methyl bromide
1
bromohydrocarbon;
bromomethanes;
methyl halides		algal metabolite;
fumigant insecticide;
marine metabolite		202220222.0low000001
pentaerythritol tetranitrate
1
pentaerythritol nitrateexplosive;
vasodilator agent		2011201113.0low000010
dehydrocholic acid
1
12-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug2013201311.0low000010
methylprednisolone
5
6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic		201020189.6low400140
rotenone
2
organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin		201520187.5low000020
pyocyanine
1
iminium betaine;
phenazines		antibacterial agent;
bacterial metabolite;
biological pigment;
virulence factor		2011201113.0low000010
isosorbide dinitrate
9
glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent		2006201914.3low700630
quinoxalines
3
mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene		2007201016.0low000300
isatin
4
indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite		1998201520.8low003010
tolonium chloride
1
201620168.0low000010
benzoyl peroxide
1
carbonyl compound202120213.0low000001
cyclohexanol
1
cyclohexanols;
secondary alcohol		solvent2012201212.0low000010
pyrroles
36
pyrrole;
secondary amine		2006201613.4low190020160
thiophenes
10
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent201020229.8low500271
ergotamine
1
peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent		2008200816.0low000100
meglumine
1
hexosamine;
secondary amino compound		2013201311.0low000010
pregnenolone
1
20-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid		human metabolite;
mouse metabolite		1993199331.0low001000
20-alpha-dihydroprogesterone
1
20-hydroxypregn-4-en-3-onehuman metabolite;
mouse metabolite		2001200123.0low100100
yohimbine
1
methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist		1994199430.0low001000
1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt
1
organic molecular entity201820186.0low000010
catechin
5
catechinantioxidant;
plant metabolite		200920228.0low000131
thiamine pyrophosphate
1
organic chloride salt;
vitamin B1		2014201410.0low000010
homoarginine
3
homoarginine;
L-lysine derivative;
non-proteinogenic L-alpha-amino acid		biomarker;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
human metabolite;
rat metabolite;
xenobiotic metabolite		201620196.7low000030
quinazolines
7
azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines		2006202111.1low100241
indazoles
2
indazole200920228.5low000101
benzoxazoles
1
1,3-benzoxazoles;
mancude organic heterobicyclic parent		201920195.0low000010
adamantane
7
adamantanes;
polycyclic alkane		200620219.1low500151
cyclopentane
2
cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent2012201212.0low000020
isoxazoles
3
isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2011201312.0low100030
oxazoles
3
1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2006201810.0low200120
thiazoles
8
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2001202117.6low100611
pyrazines
12
diazine;
pyrazines		Daphnia magna metabolite201120199.6low4000120
hydrazine
1
azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor2001200123.0low000100
pirinitramide
1
nitrile2005200519.0low000100
evans blue
1
organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent		2001200123.0low000100
monocrotaline
11
pyrrolizidine alkaloid1999201912.5low001370
aminophylline
1
mixturebronchodilator agent;
cardiotonic drug		2012201212.0low100010
azacitidine
2
N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent2001201317.0low000110
aminoimidazole carboxamide
2
aminoimidazole;
monocarboxylic acid amide		mouse metabolite201120189.5low000020
citrulline
1
amino acid zwitterion;
citrulline		Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite		2014201410.0low100010
fluorobenzenes
25
monofluorobenzenesNMR chemical shift reference compound2008201511.6low14006190
imperatorin
1
psoralensEC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite		2012201212.0low000010
dihydralazine
1
phthalazines2012201212.0low000010
bicuculline
1
benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin		2010201014.0low000100
oleanolic acid
2
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite2014201410.0low100020
noramidopyrine
1
pyrazoles;
secondary amino compound		antipyretic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
opioid analgesic;
peripheral nervous system drug		1999199925.0low001000
luminol
3
201620225.3low000021
azomycin
1
C-nitro compound;
imidazoles		antitubercular agent201620168.0low000010
methoxyhydroxyphenylglycol
1
methoxybenzenes;
phenols		2010201014.0low000100
methamphetamine
3
amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic		201220189.7low000030
malondialdehyde
25
dialdehydebiomarker200520229.8low7007153
lithium carbonate
1
carbonate salt;
lithium salt		antimanic drug2003200321.0low100100
acetylcysteine
4
acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary		2004201812.0low100130
dehydroepiandrosterone sulfate
3
17-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite		2000201616.7low001110
phosfolan
1
phosphoric ester2011201113.0low000010
canrenone
4
steroid lactone2009201512.0low400130
isodesmosine
1
lysine derivative;
pyridinium ion		biomarker2013201311.0low000010
4-aminothiophenol
1
201820186.0low000010
cadmium sulfide
1
cadmium molecular entity202020204.0low000010
zinc oxide
2
zinc molecular entity201820214.5low000011
cupric sulfide
1
201820186.0low000010
vancomycin
1
glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite		2007200717.0low000100
d-alpha tocopherol
4
alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite		2005201613.5low400220
nitrofen
1
organic molecular entityEC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide		2008200816.0low000100
pimozide
1
benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist		1991199133.0low001000
azetidyl-2-carboxylic acid
4
azetidine-2-carboxylic acid2007201714.0low100310
fluorescein
1
2-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium		1996199628.0low001000
palmatine
1
berberine alkaloid;
organic heterotetracyclic compound		plant metabolite201720177.0low000010
fructosamine
3
201220198.3low000030
metanephrine
2
catecholamine201720177.0low000020
trimetazidine
6
aromatic amine2003202013.2low100330
buthionine sulfoximine
2
diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer		2011201511.0low000020
furoylglycine
1
furans;
N-acylglycine		human metabolite2012201212.0medium000010
iridium
1
cobalt group element atom;
platinum group metal atom		201720177.0low000010
manganese
1
elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient		1991199133.0low001000
mercury
1
elemental mercury;
zinc group element atom		neurotoxin202220222.0low000001
molybdenum
1
chromium group element atommicronutrient202020204.0low000010
palladium
1
metal allergen;
nickel group element atom;
platinum group metal atom		201920195.0low000010
platinum
3
elemental platinum;
nickel group element atom;
platinum group metal atom		201120217.7low000021
silver
8
copper group element atom;
elemental silver		Escherichia coli metabolite1990202213.1low002132
technetium
2
manganese group element atom2003201913.0low000110
titanium
1
titanium group element atom202120213.0low000001
tungsten
1
chromium group element atommicronutrient202120213.0low000001
cadmium
2
cadmium molecular entity;
zinc group element atom		202020204.0low000020
europium
1
f-block element atom;
lanthanoid atom		2014201410.0low000010
gadolinium
19
f-block element atom;
lanthanoid atom		199620239.8low0015103
gold
23
copper group element atom;
elemental gold		200620226.4low0002165
helium
1
monoatomic helium;
noble gas atom;
s-block element atom		food packaging gas2010201014.0low000100
xenon
1
monoatomic xenon;
noble gas atom;
p-block element atom		2010201014.0low000100
magnesium sulfate
2
magnesium salt;
metal sulfate;
organic magnesium salt		anaesthetic;
analgesic;
anti-arrhythmia drug;
anticonvulsant;
calcium channel blocker;
cardiovascular drug;
fertilizer;
tocolytic agent		2013201311.0low100020
mercuric chloride
1
mercury coordination entitysensitiser2014201410.0low000010
camptothecin
1
delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite		2006200618.0low100100
ferrous sulfate
2
iron molecular entity;
metal sulfate		reducing agent2005201713.0low000110
bromine
1
diatomic bromine202120213.0low000001
tricalcium phosphate
1
calcium phosphate2011201113.0low000010
chlorine
1
diatomic chlorine;
gas molecular entity		bleaching agent2008200816.0low000100
vasotocin
3
1998201021.7low002100
trolamine salicylate
4
201320218.8low100031
levamisole
1
6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator		2014201410.0low000010
isosorbide-5-mononitrate
5
glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent		2006201912.4low500230
tetradecanoylphorbol acetate
12
acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator		1991201426.1low0011010
sodium bisulfide
1
2011201113.0low000010
ornidazole
1
C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope		2011201113.0low000010
fluoroboric acid
1
boron fluoride1993199331.0low001000
deslanoside
1
12beta-hydroxy steroid;
14beta-hydroxy steroid;
cardenolide glycoside;
tetrasaccharide derivative		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
metabolite		1997199727.0low101000
daunorubicin
3
aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite		2000201018.3low001200
razoxane
4
N-alkylpiperazine1999201315.2low201030
carbimazole
1
1,3-dihydroimidazole-2-thiones;
carbamate ester		antithyroid drug;
prodrug		2006200618.0low000100
bromocriptine
2
indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist		2010201710.5low000110
phenyl acetate
3
benzenes;
phenyl acetates		201720225.0low200021
cetylpyridinium chloride anhydrous
2
chloride salt;
organic chloride salt		antiseptic drug;
surfactant		2011201212.5low100020
fludrocortisone
1
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid		adrenergic agent;
anti-inflammatory drug		2007200717.0low000100
ursodeoxycholic acid
3
bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite		201720215.7low100021
benzonidazole
1
C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug201620168.0low000010
4-methoxyamphetamine
20
200120239.5low2002162
8-bromo cyclic adenosine monophosphate
5
3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist		1992200626.8low004100
transferrin
9
201020218.9low100261
glutamic acid
4
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		1996202212.0low201111
glucaric acid
2
glucaric acidantineoplastic agent2007200717.0low100200
adenylyl imidodiphosphate
1
adenosine 5'-phosphate1998199826.0low001000
gallium citrate
1
2007200717.0low000100
oxcarbazepine
2
cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen		2001202113.0low000101
paclitaxel
6
taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent		2006201810.7low200240
etoposide
5
beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor		2005201415.0low100320
substance p
8
peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent		1989201921.8low113220
dobutamine
66
catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent		1998202016.6low200149160
ribavirin
2
1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		2006201115.5low000110
phorbol 12,13-dibutyrate
2
butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone		1992199331.5low002000
thiocholine
2
2005200618.5low000200
bezafibrate
2
aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic		2009201810.5low000110
diltiazem
5
5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent		1998201416.8low301130
ng-nitroarginine methyl ester
13
alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor1999201616.5low002740
pirfenidone
1
pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		201920195.0low000010
torsemide
4
aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic		2006201015.5low200400
epirubicin
12
aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor		2001201813.0low400480
desflurane
1
organofluorine compoundinhalation anaesthetic2007200717.0low100100
idarubicin
2
anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative		1998200522.5low001100
captopril
15
alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1992201919.9low704830
nicorandil
9
nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent		1999202211.2low401233
colforsin
3
acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist		1991200626.3low002100
bucindolol
1
2007200717.0low100100
fomesafen
4
aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide		2011201710.5low000040
lovastatin
1
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug		201520159.0low000010
enoximone
2
aromatic ketone2005200519.0low000200
simvastatin
7
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug		2006202013.4low500520
pravastatin
15
3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic		2006201712.3low600690
cabergoline
1
N-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist		2009200915.0low000100
quinapril
2
dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		2009201213.5low200110
cilazapril, anhydrous
1
dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		2002200222.0low000100
ranolazine
6
aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol		2010201412.5low200240
fura-2
2
2000200720.5low001100
esmolol
6
aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound		1997201715.0low301230
clopidogrel
11
methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor		2004202211.6low800551
mibefradil
1
tetralinsT-type calcium channel blocker202020204.0low000010
toborinone
1
quinolines2001200123.0low000100
remifentanil
2
alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative		201420178.5low200020
atorvastatin
42
aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic		2006202211.9low240018231
irinotecan
1
carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug		2006200618.0low100100
valsartan
119
biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		200220236.4low4600127334
3-iodobenzylguanidine
35
organoiodine compound2000202217.2low11022931
simendan
86
2001202313.8low310050324
tirofiban
7
L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist		2004202111.4low600241
adenosine
13
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		1997201715.4low301750
ferric citrate
1
iron chelateanti-anaemic agent;
nutraceutical		201920195.0low000010
venlafaxine hydrochloride
1
hydrochloride2012201212.0low000010
rolofylline
2
oxopurine2013201311.0low000020
motropin
1
2003200321.0medium000100
glucose, (beta-d)-isomer
22
D-glucopyranoseepitope;
mouse metabolite		201120224.1low14000139
chloroquine diphosphate
1
202120213.0low000001
1,5-anhydroglucitol
1
anhydro sugarhuman metabolite2012201212.0low100010
epigallocatechin gallate
3
flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite		200920227.3low000111
aica ribonucleotide
2
1-(phosphoribosyl)imidazolecarboxamide;
aminoimidazole		cardiovascular drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		201120189.5low000020
testosterone undecanoate
1
steroid ester201620168.0low100010
iopamidol
1
benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic		2014201410.0low000010
cephalosporin c
1
cephalosporinfungal metabolite2002200222.0low000100
lercanidipine
1
diarylmethane201720177.0low000010
azelnidipine
4
isopropyl ester2007201714.0low100310
telmisartan
10
benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic		2005202111.5low600451
1,7-phenanthroline
2
phenanthroline2013201410.5low000020
triazoles
7
1,2,3-triazole2010201911.0low200160
fluorodeoxyglucose f18
5
2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose		2007202112.4low000311
sertraline
1
dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor		201920195.0low000010
zoledronic acid
2
1,1-bis(phosphonic acid);
imidazoles		bone density conservation agent2001200222.5low000200
cromakalim
1
1999199925.0low001000
atipamezole
1
202220222.0low000001
alacepril
2
dipeptide;
thioacetate ester		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor1994199529.5low102000
nipradilol
1
organic molecular entity2002200222.0low000100
leupeptin
3
aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor		2004201115.7low000210
rosiglitazone
7
aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug		2003201116.0low500520
4-phenylbutylamine
1
benzenes;
phenylalkylamine;
primary amino compound		202220222.0low000001
adriamycinol
1
aminoglycoside;
anthracycline antibiotic;
aromatic ether;
deoxy hexoside;
p-quinones;
phenols;
polyol;
tetracenequinones		cardiotoxic agent;
drug metabolite		201620168.0low100010
ferroin
1
2013201311.0low000010
bromates
1
bromine oxoanion;
monovalent inorganic anion		201820186.0low000010
3,4-dihydroxymandelic acid
1
2-hydroxy monocarboxylic acid;
catechols		antioxidant;
drug metabolite;
human metabolite;
mouse metabolite		201820186.0low100010
fibrinogen
30
iditolfungal metabolite2003202211.3low30013143
homocysteine
44
amino acid zwitterion;
homocysteine;
serine family amino acid		fundamental metabolite;
mouse metabolite		2002202212.8low40024164
alpha,beta-methyleneadenosine 5'-triphosphate
1
nucleoside triphosphate analogue201620168.0low000010
phenylacetylglutamine
2
N(2)-phenylacetylglutaminehuman metabolite202320231.0low100002
mci 9038
1
peptide2004200420.0low000100
isosteviol
1
diterpenoid201920195.0low000010
cobalt
1
cobalt group element atom;
metal allergen		micronutrient201620168.0low000010
fulvestrant
1
17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist		2010201014.0low000100
mizoribine
1
imidazolesanticoronaviral agent2011201113.0low000010
arginyl-glycyl-aspartic acid
1
oligopeptide2006200618.0low000100
vitamin b 6
1
2004200420.0low000100
bosentan anhydrous
26
primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist		1997202115.2low7021671
prolinedithiocarbamate
2
2004201514.5low000110
artesunic acid
1
201920195.0low100010
bradykinin, des-arg(9)-
1
oligopeptidebradykinin receptor B2 agonist2005200519.0low000100
((18)O)water
1
isotopically modified compound;
water		202020204.0low000010
racecadotril
1
N-acyl-amino acid1996199628.0low001000
perindopril
14
alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		2001202017.6low7001310
procyanidin
2
proanthocyanidin201520225.5low000011
schizandrin b
3
2010201711.3low000120
kt 5823
10
gamma-lactam;
hemiaminal;
indolocarbazole;
methyl ester;
organic heterooctacyclic compound		EC 2.7.11.12 (cGMP-dependent protein kinase) inhibitor1994201815.6low001720
deoxyglucose
2
2012201610.0low100020
tadalafil
10
benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		201320227.3low400082
1-phenyl-2-decanoylamino-3-morpholino-1-propanol
1
201520159.0low000010
landiolol
2
morpholines201220189.0low100020
tanshinone
1
abietane diterpenoidanticoronaviral agent2011201113.0low000010
gallium nitride
1
201920195.0low000010
asiatic acid
1
monocarboxylic acid;
pentacyclic triterpenoid;
triol		angiogenesis modulating agent;
metabolite		2014201410.0low000010
efonidipine
4
C-nitro compound;
carboxylic ester;
dihydropyridine;
tertiary amino compound		2007200916.2low200400
lithospermate b
1
201920195.0low000010
iodofiltic acid
4
2006201413.8low100220
caprylates
1
fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite		202120213.0low000001
rc 3095
1
201620168.0low000010
pd 142893
1
201920195.0low000010
gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate
1
201520159.0low000010
ud cg 212 cl
1
2003200321.0low100100
astragaloside a
4
201420235.8low000022
celastrol
1
monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite		201620168.0low000010
peroxynitrous acid
3
nitrogen oxoacid201220179.7low100030
imatinib mesylate
5
methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor		2006201714.0low000320
almotriptan
1
indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent		2002200222.0low000100
mk 0663
1
bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug		2011201113.0low000010
sq 28603
1
1992199232.0low001000
n(6)-carboxymethyllysine
2
L-lysine derivative;
non-proteinogenic L-alpha-amino acid		antigen201320198.0low000020
angiotensin ii, des-phe(8)-
3
amino acid zwitterion;
angiotensin		vasodilator agent201620215.0low000021
n,n-dimethylarginine
28
dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor2005202112.5low30010171
3-(2,2,2-trimethylhydrazine)propionate
1
ammonium betainecardioprotective agent;
EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor;
neuroprotective agent		2014201410.0low100010
bq 610
1
2000200024.0low001000
methotrexate
4
dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent		201220218.5low300031
sulbactam
1
penicillanic acids202220222.0low000001
olmesartan medoxomil
7
biphenyls2002201218.1low200520
sch 42495
2
1993199928.0medium202000
omega-n-methylarginine
7
amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		1997201420.4low202410
ivabradine
20
aromatic ether;
benzazepine;
carbobicyclic compound;
tertiary amino compound		cardiotonic drug200620229.9low11002162
febuxostat
3
1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile		EC 1.17.3.2 (xanthine oxidase) inhibitor201820224.3low200021
phenylacetic dipalmitate
1
202320231.0medium100001
pomalidomide
1
aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator		2010201014.0low000100
proline
4
amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		2002201516.0low000220
docetaxel anhydrous
2
secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent		2011201511.0low000020
ezetimibe
2
azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite		2003202012.5low000110
tezosentan
10
2002201717.3low200820
clevidipine
1
dihydropyridine2010201014.0low000100
rp 73401
1
aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide		anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor		2007200717.0low000100
schizandrin a
2
201720224.5low000011
naproxen
1
methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2006200618.0low000100
olmesartan
4
biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent		2004201016.5low200400
atrasentan
4
pyrrolidines2000202214.5low201111
silver tetrafluoroborate
2
1990199034.0high002000
pyropheophorbide a
1
202120213.0low000001
citrulline malate
1
2014201410.0low100010
my 12-62c
1
monohydroxyquinoline;
quinolone		antibacterial agent;
iron chelator;
metabolite;
signalling molecule		2011201113.0low000010
3,3',5-triiodothyronamine
1
2003200321.0low000100
symmetric dimethylarginine
5
amino acid zwitterion;
dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor201220208.2low000050
17 alpha-hydroxyprogesterone caproate
1
corticosteroid hormone2011201113.0low000010
biotin
6
biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite		2006201910.8low000330
angiotensin ii
227
amino acid zwitterion;
angiotensin II		human metabolite1988202317.0low4144598737
atropine
4
1992200628.0low003100
trimix
1
2010201014.0low000100
ropivacaine
1
piperidinecarboxamide;
ropivacaine		local anaesthetic2013201311.0low100010
sb 203580
9
imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent		1999201618.4low003330
lu 135252
2
2002200421.0low200200
piboserod
1
2009200915.0low100100
organophosphonates
2
divalent inorganic anion;
phosphite ion		2002201117.5low000110
orbofiban
1
2006200618.0low100100
6-(n-(4-aminobutyl)-n-ethyl)amino-2,3-dihydrophthalazine-1,4-dione
1
phthalazines202220222.0low000001
rs 127445
1
201520159.0low000010
n-propionylprocainamide
1
202220222.0low000001
lapatinib
1
furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		201820186.0low100010
butyrylcarnitine
1
O-butanoylcarnitine;
saturated fatty acyl-L-carnitine		metabolite201520159.0low000010
deferasirox
1
benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator2010201014.0low000100
dabigatran
3
aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines		anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor		201520216.3low100021
tbc-11251
2
benzodioxoles2011201212.5low100020
tolvaptan
14
benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist		200820238.0low200284
alagebrium
2
2003200321.0low000200
lenalidomide
4
aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator		2010202111.0low000211
senicapoc
1
2011201113.0low000010
estradiol 3-benzoate
1
17beta-hydroxy steroid;
benzoate ester		estrogen receptor agonist;
xenoestrogen		2004200420.0low000100
cortisone
1
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite		201920195.0low000010
3-nitrotyrosine
4
2-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid		201220179.0low100040
benzofurans
1
201620168.0low000010
wortmannin
2
acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent		2010201611.0low000110
bortezomib
15
amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor		201120216.7low0000132
bardoxolone methyl
1
cyclohexenones2014201410.0low100010
dihydropyridines
13
2002202213.9low300931
leupeptins
3
2004201115.7low000210
glycogen
2
2009201114.0low000110
n-acetylneuraminic acid
1
N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite		2014201410.0low000010
fibrin
2
peptide2008201711.5low000110
bradykinin
5
oligopeptidehuman blood serum metabolite;
vasodilator agent		1992201321.4low102210
elastin
2
oligopeptide2011201411.5low000020
mevalonic acid
1
3,5-dihydroxy-3-methylpentanoic acid2013201311.0low000010
oxytocin
8
heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent		1997201913.9low001340
ouabain
3
11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite		1997201117.7low101020
puromycin
1
puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor		1999199925.0low001000
nitroarginine
2
guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid		1995201121.0low001010
arbutin
1
beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite		202020204.0low000010
meropenem
1
alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen		2007200717.0low000100
digitoxin
2
cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor1991200028.5low002000
abacavir
1
2,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor		2013201311.0low000010
phalloidine
1
homodetic cyclic peptide202220222.0low000001
indican
3
beta-D-glucoside;
exopolysaccharide;
indolyl carbohydrate		201320169.0low000030
ryanodine
2
1996200623.0low001100
lignans
4
201020229.0low000121
bq 123
6
cyclic peptide1992200626.7low005100
n-formylmethionine leucyl-phenylalanine
5
tripeptide1996202015.2low002030
candoxatrilat
4
1992200427.8low003100
actinonin
1
2007200717.0low000100
eplerenone
15
3-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent		2004201910.2low7003120
temocapril hydrochloride
2
dipeptide1992200326.5low001100
ao 128
2
organic molecular entity2006202011.0low100110
acetyl coenzyme a
1
acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite		2011201113.0low000010
trichostatin a
2
antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector		2009201412.5low000110
tretinoin
5
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		1995201021.4low002300
arachidonic acid
8
icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite		2008202210.4low000251
phosphoramidon
5
deoxyaldohexose phosphate;
dipeptide		bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor		1990201126.6low004010
resveratrol
4
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		2007202010.8low100130
tacrolimus
5
macrolide lactambacterial metabolite;
immunosuppressive agent		2002202214.0low100311
pectins
1
D-galactopyranuronic acid202120213.0low000001
cocaine
4
benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		1996201415.5low001030
cocaine
5
benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		1996201414.8low001040
eicosapentaenoic acid
1
icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical		2006200618.0low000100
thapsigargin
3
butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor		2000200620.7low001200
fosfomycin
1
epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor		201620168.0low000010
y 27632
2
aromatic amide1999201019.5low001100
prostaglandin d2
2
prostaglandins Dhuman metabolite;
mouse metabolite		2001200620.5low000200
eptifibatide
1
homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor		201720177.0low100010
h 89
3
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide1996200125.7low002100
imidazolidines
4
azacycloalkane;
imidazolidines;
saturated organic heteromonocyclic parent		1997201321.0low302110
thymopentin
2
oligopeptide201320179.0low200020
phorbol-12,13-didecanoate
1
1993199331.0low001000
dactinomycin
8
actinomycinmutagen1993200525.6low007100
melphalan
9
L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent		2006202011.8low100360
enkephalin, leucine
5
pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite		1989200827.0low012200
tenofovir
2
nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor		2002201117.5low000110
sodium bicarbonate
3
one-carbon compound;
organic sodium salt		antacid;
food anticaking agent		2009201812.0low000210
dipyrone
1
organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug		1999199925.0low001000
carbenoxolone sodium
1
triterpenoid2011201113.0low000010
isomethyleugenol
1
isomethyleugenol2013201311.0low000010
stilbenes
3
stilbene2007201313.0low100120
buprenorphine
1
morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic		201920195.0low000010
arginine vasopressin
43
vasopressincardiovascular drug;
hematologic agent;
mitogen		1988201921.3low131171960
pyrophosphate
1
diphosphate ion202220222.0low000001
s 1033
1
(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		2012201212.0low000010
omapatrilat
18
dipeptide1999201519.7low3041130
benidipine
2
2002200520.5low000200
nsc 4347
1
202120213.0low000001
etomidate
1
ethyl ester;
imidazoles		intravenous anaesthetic;
sedative		201620168.0low000010
curcumin
2
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		2010201710.5low000110
necrostatin-7
1
201520159.0medium000010
methimazole
1
1,3-dihydroimidazole-2-thionesantithyroid drug2012201212.0low000010
capsaicin
1
capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker		201620168.0low000010
D-fructopyranose
2
cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent2011201312.0low100020
digoxin
24
cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope		1997202215.2low8021381
tamoxifen
2
stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator		2006201513.5low000110
nadp
2
200920219.0low000101
ace-011
1
202120213.0low100001
u 0126
5
aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent		2004201516.2low000410
lithium
5
alkali metal atom1998201817.8low302210
nitrogen dioxide
2
nitrogen oxide201820224.0low000011
rtki cpd
1
2014201410.0low000010
8-bromoguanosino-3',5'-cyclic monophosphorothioate
1
1999199925.0low001000
cystine
1
2011201113.0low000010
rasagiline
2
indanes;
secondary amine;
terminal acetylenic compound		EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent		2011201113.0low000020
dasatinib
1
1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor		201820186.0low000010
calixarenes
1
202020204.0low000010
ovalbumin
1
1998199826.0low001000
osteoprotegerin
14
long-chain fatty acid2008201910.5low1003110
cathepsin g
1
202220222.0low000001
icodextrin
4
2007202212.2low200301
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
1
benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor201920195.0low000010
4-cresol sulfate
1
aryl sulfategut flora metabolite;
human metabolite;
uremic toxin		201620168.0low000010
sphingosine
2
sphing-4-eninehuman metabolite;
mouse metabolite		2006201613.0low000110
quercetin
2
7-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger		2012201311.5low000020
bilirubin
21
biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite		199220229.5low1014106
dinoprostone
14
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		2004201813.3low500770
dinoprost
8
monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite		1999201617.5low102420
luteolin
1
3'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist		201920195.0low000010
calcitriol
7
D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical		1996201813.9low101330
calcitriol
6
D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical		1996201813.5low101230
vitamin k semiquinone radical
4
201620186.8low100040
leukotriene b4
1
dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent		2008200816.0low000100
thromboxane a2
2
epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite2014201410.0low100020
8,11,14-eicosatrienoic acid
2
fatty acid 20:3;
long-chain fatty acid		fungal metabolite;
human metabolite;
nutraceutical		2009201412.5low000110
alprostadil
8
prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent		2002201915.1low300620
5-hydroxy-6,8,11,14-eicosatetraenoic acid
1
HETEhuman metabolite;
mouse metabolite		201620168.0low000010
vitamin d 2
7
hydroxy seco-steroid;
seco-ergostane;
vitamin D		bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide		2007201512.3low300250
cholecalciferol
5
D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite		2010201711.0low300230
rutin
1
disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite		201620168.0low000010
kaempferol
1
7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite		201720177.0low000010
leukotriene d4
1
dipeptide;
leukotriene;
organic sulfide		bronchoconstrictor agent;
human metabolite;
mouse metabolite		1998199826.0low001000
genistein
3
7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		1999201117.3low001110
eprosartan
1
dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic		2010201014.0low100100
paricalcitol
6
hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug2007201512.2low300240
11-octadecenoic acid
1
vaccenic acid2011201113.0low000010
cucurbitacin i
1
cucurbitacin;
tertiary alpha-hydroxy ketone		antineoplastic agent;
plant metabolite		201620168.0low000010
humulene
1
alpha-humulene202120213.0low000001
baicalein
1
trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger		2011201113.0low000010
caffeic acid phenethyl ester
1
alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent		2006200618.0low000100
coenzyme q10
10
ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite		200820228.4low700172
cilnidipine
2
2-methoxyethyl ester;
C-nitro compound;
dihydropyridine		antihypertensive agent;
calcium channel blocker;
cardiovascular drug		201420178.5low000020
8-epi-prostaglandin f2alpha
5
F2-isoprostanebiomarker;
bronchoconstrictor agent;
vasoconstrictor agent		2006201216.4low100410
pitavastatin
5
cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic)		antioxidant200820237.0low100122
thromboxane b2
1
thromboxanes Bhuman metabolite;
mouse metabolite		2008200816.0low000100
4-hydroxy-2-nonenal
3
4-hydroxynon-2-enal;
4-hydroxynonenal		2005201115.0low100120
sphingosine 1-phosphate
2
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent		2006201613.0low000110
phenylephrine hydrochloride
1
hydrochloride2005200519.0low000100
nalmefene
1
morphinane alkaloid2010201014.0low100100
naloxone
5
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist		1991200228.6low004100
sirolimus
4
antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		2005201912.8low000220
topiroxostat
2
201820214.5low100011
morphine
10
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		1991202022.2low105320
morphine
11
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		1991202020.9low105330
a 192621
1
2002200222.0low000100
cicaprost
1
monoterpenoid1999199925.0low001000
deamino arginine vasopressin
1
heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist		1997199727.0low001000
dexmedetomidine
6
medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative		200920226.7low300123
fluprostenol
1
(trifluoromethyl)benzenes;
hydroxy monocarboxylic acid;
prostaglandins Falpha		abortifacient;
antiglaucoma drug;
antihypertensive agent;
female contraceptive drug;
prostaglandin receptor agonist		201620168.0low000010
goserelin
2
organic molecular entity2008201910.5low200110
iloprost
2
carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent		2011201511.0low100020
15-deoxy-delta(12,14)-prostaglandin j2
1
prostaglandins Jelectrophilic reagent;
insulin-sensitizing drug;
metabolite		2001200123.0low000100
lysophosphatidylcholines
2
1-O-acyl-sn-glycero-3-phosphocholine1999200024.5low002000
mdl 100907
1
2006200618.0low000100
neurokinin a
1
1999199925.0low001000
neurokinin b
1
polypeptide202120213.0low000001
pd 123319
3
imidazopyridineangiotensin receptor antagonist;
endothelin receptor antagonist;
vasoconstrictor agent		2002200620.3low000300
kn 93
4
monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector		1999201117.5low001210
icariin
1
flavonols;
glycosyloxyflavone		antioxidant;
bone density conservation agent;
EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
phytoestrogen		2011201113.0low000010
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone
2
agonist2012201212.0low000020
ag-490
1
catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor		2014201410.0low000010
su 11248
4
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		2010201611.2low000220
lead
1
carbon group element atom;
elemental lead;
metal atom		neurotoxin2013201311.0low000010
12-hydroxy-5,8,10,14-eicosatetraenoic acid
1
201620168.0low000010
15-hydroxy-5,8,11,13-eicosatetraenoic acid
1
201620168.0low000010
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
1
2009200915.0low000100
rubidium
1
alkali metal atom1991199133.0low001000
strontium
1
alkaline earth metal atom201820186.0low000010
bismuth
1
metal atom;
pnictogen		202020204.0low000010
thallium
1
boron group element atom2014201410.0low100010
arsenic
1
metalloid atom;
pnictogen		micronutrient2012201212.0low000010
naltrexone
1
cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic		2010201014.0low100100
gallium
2
boron group element atom2007201911.0low000110
lisinopril
10
dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor1995202221.4low403601
benazepril
3
benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		201520207.3low100030
ramipril
15
azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug		1996201917.0low10011130
candoxatril
7
1991201526.7medium406010
sulfur
1
chalcogen;
nonmetal atom		macronutrient201720177.0low100010
enalapril
35
dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug		1994202213.5low180611135
fumarates
20
butenedioate;
C4-dicarboxylate		human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite		2007202011.1low10006140
cysteine
3
cysteiniumfundamental metabolite1990202115.7low001011
thyronines
2
thyronine201220227.0low000011
silicon
2
carbon group element atom;
metalloid atom;
nonmetal atom		2008201313.5low000110
crotonic acid betaine
1
4-(trimethylammonio)but-2-enoate202120213.0low000001
phosphorus
5
monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient201020179.4low000140
enalaprilat anhydrous
2
dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor		1999200323.0low101100
imidapril
4
dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		1997201321.0low302110
bakuchiol
1
201820186.0low000010
ximelagatran
1
amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor		2003200321.0low000100
ici 118551
1
aromatic ether;
indanes;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist2004200420.0low000100
trandolapril
2
dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		2007201314.0low200110
sch 32615
6
1996200226.3medium205100
pregabalin
2
gamma-amino acidanticonvulsant;
calcium channel blocker		201920204.5low000020
uroguanylin
1
201720177.0low000010
oxyhyponitrite
1
2012201212.0low000010
aliskiren
20
monocarboxylic acid amide;
monomethoxybenzene		antihypertensive agent2007202011.1low10006140
docosapentaenoic acid
1
docosapentaenoic acid;
omega-3 fatty acid		algal metabolite;
human metabolite		201620168.0low000010
ono 1301
2
2013201410.5low000020
uk 81,252
2
2000200223.0medium001100
selenium
5
chalcogen;
nonmetal atom		micronutrient201320208.8low300050
tellurium
1
chalcogen;
metalloid atom		202020204.0low000010
1,1-diethyl-2-hydroxy-2-nitrosohydrazine
1
organic anion2001200123.0low000100
salvianolic acid B
1
1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol		anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite		201620168.0low000010
technetium tc 99m pyrophosphate
4
201420225.2low000031
beta-escin
7
1997202112.0low001231
s-nitroso-n-acetylpenicillamine
7
nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent		1997201614.9low001420
gadolinium dtpa
9
gadolinium coordination entityMRI contrast agent2004201714.6low000630
ergoline
1
diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound		2009200915.0low000100
adenosine-3',5'-cyclic phosphorothioate
1
nucleoside 3',5'-cyclic phosphorothioate2000200024.0low001000
sq-23377
1
cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite		1999199925.0low001000
eritoran
1
lipid As2011201113.0low100010
beraprost
2
enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol		anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent		2001200919.0low000200
u 62840
8
carbotricyclic compound;
carboxylic acid		antihypertensive agent;
cardiovascular drug;
human blood serum metabolite;
platelet aggregation inhibitor;
vasodilator agent;
vitamin K antagonist		200720208.8low300260
lu 208075
12
diarylmethane2008202010.1low6001110
vildagliptin
3
amino acid amide2006201513.0low200120
staurosporine
5
ammonium ion derivative1993199929.0low005000
phosphocreatine
4
phosphagen;
phosphoamino acid		human metabolite;
mouse metabolite		200620229.2low100202
desvenlafaxine succinate
1
2012201212.0low000010
bay 58-2667
6
aromatic ether;
benzoic acids;
dicarboxylic acid;
tertiary amino compound		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent		2006201415.3low000510
sacubitril
20
biphenyls202020231.8low6000119
abiraterone acetate
1
pyridines;
sterol ester		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug		2011201113.0low000010
ezetimibe, simvastatin drug combination
1
202120213.0low100001
sincalide
2
oligopeptide2000202014.0low001010
istaroxime
1
2008200816.0low000100
paliperidone palmitate
1
1,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		2013201311.0low000010
flag peptide
1
peptide2010201014.0low000100
sm 346
1
201820186.0low000010
mocetinostat
63
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		2001202112.5low70032292
ticagrelor
9
aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines		P2Y12 receptor antagonist;
platelet aggregation inhibitor		201220226.1low600081
rivaroxaban
3
aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		2011201810.7low100030
dapagliflozin
12
aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201120234.0low800066
xestospongin a
1
2006200618.0low000100
selexipag
4
aromatic amine;
ether;
monocarboxylic acid amide;
N-sulfonylcarboxamide;
pyrazines;
tertiary amino compound		orphan drug;
platelet aggregation inhibitor;
prodrug;
prostacyclin receptor agonist;
vasodilator agent		201720195.5low200040
casopitant
2
piperidines2011201113.0low000020
n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide
1
piperazines;
pyridines		2013201311.0low000010
mre 269
1
aromatic amine;
ether;
monocarboxylic acid;
pyrazines;
sulfonamide;
tertiary amino compound		drug metabolite;
orphan drug;
platelet aggregation inhibitor;
prostacyclin receptor agonist;
vasodilator agent		201720177.0low100010
darapladib
1
201720177.0low100010
3-iodothyronamine
2
aromatic ether201220227.0low000011
aluminum oxide
1
2013201311.0low000010
cgp 20712a
1
2004200420.0low000100
n-(1-methylethyl)-1,1,2-trimethylpropylamine
3
2009201711.0low000120
linagliptin
2
aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		2011201710.0low100020
dimethylarginine
5
2008201313.0low000140
apixaban
4
aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		201320206.8low400040
aleglitazar
2
201820186.0low200020
betrixaban
1
benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor		201720177.0low100010
sb 215505
1
2006200618.0low000100
ipragliflozin
2
glycoside201920223.5low100011
oxadiazoles
3
2007201016.0low000300
ucn 1028 c
1
1996199628.0low001000
acebutolol
1
alpha-D-glucosyl-(1->4)-D-mannopyranose201620168.0low000010
pirarubicin
2
anthracycline2005201912.0low100110
bay 63-2521
12
aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator		201320226.8low4000111
alogliptin
4
nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent		201120217.2low300031
dorsomorphin
1
aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines		bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor		2013201311.0low000010
carfilzomib
1
epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor		201620168.0low000010
sitagliptin phosphate
8
201120228.6low300062
crizotinib
1
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor		201520159.0low000010
omecamtiv mecarbil
5
ureas201020237.2low200122
trametinib
1
acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		201920195.0low000010
losartan potassium
30
1999201616.4low9012450
d-arg-dmt-lys-phe-nh2
1
201620168.0low000010
empagliflozin
14
aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201920233.4low1000077
calcimycin
2
benzoxazole1993200923.0low001100
marinobufagenin
1
epoxy steroid;
steroid hormone		EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope		201820186.0low000010
pituitrin
63
1990201817.6low901034190
yessotoxin
1
ciguatoxin201520159.0low000010
ferrous citrate
1
201520159.0low000010
icatibant
1
2004200420.0low000100
desmosine
1
aromatic amino acid2013201311.0low000010
macitentan
8
aromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides		antihypertensive agent;
endothelin receptor antagonist;
orphan drug		201720234.9low400071
cytochrome c-t
4
201120209.0low100040
cosyntropin
1
2000200024.0low001000
cholecystokinin
5
1996201913.4low001130
dynorphins
1
1994199430.0low001000
atrial natriuretic factor
2,253
polypeptide1988202319.4high1952270097147783
106-dephenylalanyl-107-deglycyl-115-dearginyl-116-deglutamine-atriopeptin (103-126)
2
1993199430.5high002000
endothelin 1, ala(1,3,11,15)-
1
1994199430.0low001000
humanin
1
201820186.0low000010
anantin
5
2001201614.8high000320
gastrins
1
2003200321.0low000100
glucagon
1
peptide hormone201820186.0low000010
big gastrin
1
2003200321.0low000100
beta-endorphin
1
201720177.0low000010
thymosin beta(4)
1
201520159.0low100010
neuropeptide y
9
1992201918.3low004140
peptide phi
1
1999199925.0low001000
anaritide
1
2009200915.0low000100
ularitide
34
1989201820.6medium21131370
brain natriuretic peptide, porcine
19
1992200227.0high2017200
s6c sarafotoxin
1
2005200519.0low100100
iberiotoxin
1
2010201014.0low000100
angiotensinogen
8
1999202017.1low001610
irl 1620
1
1994199430.0low001000
m40
1
201520159.0low000010
oligonucleotides
4
1991201621.5low001210
liraglutide
7
lipopeptide;
polypeptide		glucagon-like peptide-1 receptor agonist;
neuroprotective agent		201420206.6low400070
glucagon-like peptide 1
13
201120217.8low3000112
vivit peptide
1
2006200618.0low000100
incretins
4
201520216.2low400031
c-peptide
5
2005201214.0low300230
cardiodilation-atrial natriuretic peptide
3
1989199532.3low012000
natriuretic peptide, c-type
358
1990202321.1high901621236112
ferrous gluconate
1
2009200915.0low100100
endothelin-1
242
1993202216.4low29040117823
phosphatidylcholines
3
1,2-diacyl-sn-glycero-3-phosphocholine2003201513.3low100120
amikacin
1
201920195.0low000010
chlorophyll a
1
chlorophyll;
methyl ester		cofactor202120213.0low000001
ubiquinone
11
200820228.8low800182
ethyl glucuronide
1
beta-D-glucosiduronic acidhuman urinary metabolite201920195.0low000010
prednylidene
1
21-hydroxy steroid2014201410.0low000010
dinophysistoxin 1
1
ketalanimal metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
marine metabolite;
toxin		201520159.0low000010
calpain
1
202020204.0low000010
technetium tc 99m sestamibi
9
1999202314.9low201521
15-deoxyprostaglandin j2
1
2006200618.0low000100
sodium houttuyfonate
1
202220222.0low000001
bucladesine
3
3',5'-cyclic purine nucleotide1995199628.3low003000
potassium bromate
1
bromate salt;
potassium salt		flour treatment agent201820186.0low000010
ro13-9904
2
201320217.0low000011
sodium pertechnetate tc 99m
1
201920195.0low000010
preminent
2
2012201311.5low100020
picrotoxin
1
1993199331.0low001000
canagliflozin
13
C-glycosyl compound;
organofluorine compound;
thiophenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor		201720234.1low1000085
florbetapir f 18
1
(18)F radiopharmaceutical;
aromatic ether;
organofluorine compound;
pyridines;
substituted aniline		radioactive imaging agent202020204.0low000010
ponatinib
1
(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
oxymatrine
1
2014201410.0low000010
cardiovascular agents
155
1996202312.8low510664778
neurotensin
2
peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary		1996200822.0low001100
apelin-13 peptide
2
oligopeptideantihypertensive agent;
autophagy inhibitor;
biomarker;
human metabolite;
neuroprotective agent		2006201712.5low000110
atrial natriuretic factor (4-23)nh2, de-gln(18)-de-ser(19)-de-gly(20,22)-de-leu(21)-
10
1991201524.2medium106310
cabozantinib
1
aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor		201920195.0low000010
mannans
1
2013201311.0low000010
11,12-epoxy-5,8,14-eicosatrienoic acid
2
11,12-EEThuman xenobiotic metabolite2009201412.5low000110
glycolipids
2
201520235.0low000011
piperidines
16
200620219.7low6003103
thymosin
1
201520159.0low100010
interleukin-8
22
2006201911.7low3008140
fosinopril
2
2003200420.5low000200
arry-371797
1
202220222.0medium000001
gyy 4137
1
organic molecular entity201520159.0low000010
abt-199
1
aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor		202020204.0low000010
vasoactive intestinal peptide
4
1999201021.2low001300
heme
1
2007200717.0low000100
heparitin sulfate
2
201920204.5low100020
neuromedin b
1
202120213.0low000001
arginyl-glycyl-glutamic acid
1
oligopeptide2000200024.0low001000
ascorbic acid
2
ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent		2008201114.5low100110
vericiguat
13
aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine		antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent		201520233.6medium500067
warfarin
11
benzenes;
hydroxycoumarin;
methyl ketone		200920188.9low5001100
phenprocoumon
1
hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor		201820186.0low000010
omega-agatoxin iva
1
201620168.0low000010
epidermal growth factor
5
1994201320.0low001310
gastrin-releasing peptide
7
201320228.0low000061
calca protein, human
24
2004201612.5low2008160
transforming growth factor beta
38
1993202117.6low2072191
okadaic acid
2
ketal1999201517.0low001010
bay 94-8862
6
201320198.5low300060
bgp 15
1
202120213.0low000001
rome
2
2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-olEC 2.7.1.91 (sphingosine kinase) inhibitor2010201710.5low000110
ivosidenib
1
cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor		202120213.0low000001
cytosinine
1
201620168.0medium000010
vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-o-methyl-tyr(2)-thr(4)-orn(8)-tyr(9)-nh2
1
2010201014.0low000100
oligomycins
1
201820186.0low000010
calcium fructoborate
1
2013201311.0low100010
praliciguat
1
aminopyrimidine;
isoxazoles;
monofluorobenzenes;
organofluorine compound;
pyrazoles;
secondary amino compound;
tertiary alcohol		anti-inflammatory agent;
antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent		202020204.0low000010
nitrophenols
4
2007200916.2low200400
carboxypeptidase b
1
201920195.0low000010
acth (1-24), phe(2)-nle(4)-
1
2000200024.0medium001000
calpastatin
1
polypeptideEC 3.4.22.52 (calpain-1) inhibitor;
EC 3.4.22.53 (calpain-2) inhibitor		202020204.0low000010
angiotensin i
7
angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent		1996202115.7low003121
ferric oxide, saccharated
2
2007200717.0low100200
adrenomedullin
164
1995202214.5low16024587210
epoetin alfa
1
2013201311.0low100010
vitamin b 12
6
2004202014.3low000420
aconitine
1
201920195.0low000010
insulin glargine
1
201720177.0low100010
s 8932
2
aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug		202020204.0low000020
cyclosporine
8
1998201815.8low102240
antipain
1
2004200420.0low000100
peptide yy
2
2011201212.5low100020
digitonin
1
1991199133.0low001000
technetium tc-99m tetrofosmin
3
2007202211.3low000201
thromboplastin
2
1999201616.5low001010
muramidase
1
2012201212.0low000010
amyloid beta-peptides
1
201720177.0low000010
exudates
2
201020199.5low000110
angiogenin
2
2008201114.5low000110
levoleucovorin
1
5-formyltetrahydrofolic acidantineoplastic agent;
metabolite		2010201014.0low100100
cyclic gmp
294
3',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		1988202321.1low3861231134012
deoxyguanosine
8
purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2002201613.5low100260
guanosine monophosphate
10
guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite		1994202211.7low302224
guanine
1
2-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2006200618.0low000100
hypoxanthine
1
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite201920195.0low000010
inosine
1
inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		201920195.0low000010
sapropterin
1
5,6,7,8-tetrahydrobiopterincoenzyme;
cofactor;
diagnostic agent;
human metabolite		2011201113.0low100010
folic acid
6
folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient		2004202016.0low100510
3-methyladenine
1
201720177.0low000010
guanosine 5'-o-(3-thiotriphosphate)
1
nucleoside triphosphate analogue1995199529.0low001000
neopterin
14
2006202211.0low100491
clozapine
2
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic		2011201511.0low100020
oxypurinol
2
pyrazolopyrimidinedrug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor		2008200816.0low100200
zaprinast
2
triazolopyrimidines1989200726.0low010100
allopurinol
11
nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger		2005201812.7low700560
2,2'-(hydroxynitrosohydrazono)bis-ethanamine
1
2007200717.0low000100
guanylyl imidodiphosphate
1
nucleoside triphosphate analogue1995199529.0low001000
bl 4162a
1
imidazoquinazolineanticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor		201520159.0low100010
norclozapine
1
dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist		201520159.0low100010
sildenafil citrate
39
citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		2003202313.0low150020172
da 8159
1
sulfonamide2013201311.0low100010
8-bromocyclic gmp
19
3',5'-cyclic purine nucleotide;
organobromine compound		muscle relaxant;
protein kinase G agonist		1991201024.3low0091000
8-hydroxy-2'-deoxyguanosine
9
guanosinesbiomarker2002201912.6low100270
8-((4-chlorophenyl)thio)cyclic-3',5'-gmp
1
3',5'-cyclic purine nucleotide;
aryl sulfide;
organochlorine compound;
ribonucleotide		protein kinase agonist2002200222.0low000100
noc 9
1
1999199925.0low001000
l 2286
4
2006202111.5high000211
dibutyryl cyclic gmp
1
2000200024.0low001000
eye
6
1991201820.5low003120
ferric carboxymaltose
1
201620168.0low000010
concanavalin a
1
2013201311.0low000010
cenderitide
2
2013201410.5medium000020
cep-11004
1
2010201014.0low000100
leptin
20
2003202010.7low3005150
pyrimidinones
1
201920195.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2019 Novel Coronavirus Disease0
125
202020232.8low30003590
3-Methylglutaconic Aciduria, Type II0
1
2011201113.0low000010
47,XX,+210
5
1996202212.0low101121
48,XXYY Syndrome0
1
2012201212.0low000010
A-V Dissociation0
13
2001202114.4low300832
Abdomen, Acute0
1
2010201014.0low000100
Abdominal Aortic Aneurysm0
7
200620219.1low000151
Abdominal Compartment Syndrome0
1
2013201311.0low000010
Abdominal Migraine0
3
2011201610.0low000030
Abdominal Neoplasms0
1
201720177.0low000010
Abdominal Obesity0
6
201120219.5low000051
Abdominal Pain0
2
202020213.5low000011
Abnormal Deep Tendon Reflex0
2
2003201714.0low000110
Abnormalities, Autosome0
1
2012201212.0low000010
Abnormalities, Cardiovascular0
5
200720235.2low200113
Abnormalities, Multiple0
1
2013201311.0low000010
Abnormality, Heart0
246
1993202311.3low16057913824
Abnormality, Torsion0
2
2009201114.0low000110
Absence Seizure0
7
2005202010.4low000340
Accessory Atrioventricular Bundle0
2
201620177.5low000020
ACD-MPV0
7
2004202012.3low000250
Ache0
5
2007201912.4low100320
Acid Alpha-Glucosidase Deficiency0
2
2006200916.5low000200
Acid beta-Glucosidase Deficiency0
1
2004200420.0low000100
Acid-Base Imbalance0
1
201520159.0low000010
Acidosis0
1
201920195.0low000010
Acidosis, Diabetic0
2
202120213.0low100002
Acidosis, Lactic0
3
200820209.0low100120
Acne0
1
2012201212.0low000010
Acne Vulgaris0
1
2012201212.0low000010
Acoustic Neuroma0
1
201720177.0low000010
Acquired Autoimmune Hemolytic Anemia0
1
2012201212.0low000010
Acquired Meningomyelocele0
1
2013201311.0low000010
Acquired Metabolic Diseases, Brain0
1
2009200915.0low000100
Acrocephaly0
1
201620168.0low000010
Acromegaly0
8
2007202212.6low000521
Active Hyperemia0
14
200820229.4low1002102
Acute Anterior Wall Myocardial Infarction0
21
200920239.0low8003144
Acute Autoimmune Neuropathy0
1
2006200618.0low000100
Acute Bacterial Prostatitis0
2
201220198.5low000020
Acute Biphenotypic Leukemia0
1
2012201212.0low000010
Acute Brain Injuries0
11
2002202314.5low100821
Acute Confusional Senile Dementia0
11
2001202211.9low000461
Acute Coronary Syndrome0
284
2005202310.4low53008717324
Acute Disease0
863
1992202312.8low14401738440656
Acute Edematous Pancreatitis0
5
201220234.8low100023
Acute Hemolytic Transfusion Reaction0
7
2005201911.9low000340
Acute Hypercapnic Respiratory Failure0
45
1997202113.9low30219222
Acute Idiopathic Facial Neuropathy0
1
202120213.0low000001
Acute Inferior Myocardial Infarction0
1
2012201212.0low000010
Acute Ischemic Stroke0
26
202020232.4low1000620
Acute Kidney Failure0
119
200320239.2low1400237719
Acute Kidney Injury0
119
200320239.2low1400237719
Acute Liver Injury, Drug-Induced0
1
201620168.0low000010
Acute Lung Injury0
15
2008201711.8low0005100
Acute Lung Injury, Transfusion-Related0
1
202020204.0low100010
Acute Lymphoid Leukemia0
9
2006201911.7low100270
Acute Mesenteric Arterial Embolus0
1
201720177.0low000010
Acute Myelogenous Leukemia0
4
200520239.5low000121
Acute Necrotizing Encephalitis, Herpetic0
1
201920195.0low000010
Acute Necrotizing Pancreatitis0
2
2011201212.5low000020
Acute Onset Aura Migraine0
2
201620206.0low000020
Acute Onset Vascular Dementia0
3
2006201314.7low000210
Acute Pain0
3
201320169.7low100030
Acute Post-operative Pain0
4
2004202113.8low300211
Acute Post-Traumatic Stress Disorder0
3
201220207.7low000030
Acute Promyelocytic Leukemia0
1
2010201014.0low000100
Acute Respiratory Distress Syndrome0
46
2002202311.5low50020206
Acute Rheumatic Fever0
2
2008201015.0low000200
Acute Symptom Flare0
2
201520225.5low200011
Acute-Phase Reaction0
3
2007201215.0low000210
Adamantiades-Behcet Disease0
2
2008201114.5low000110
Addison Disease0
2
201520216.0low000011
Addison's Disease0
2
201520216.0low000011
Adenitis0
2
202120222.5low000002
Adenocarcinoma0
6
2005201814.5low000420
Adenocarcinoma Of Kidney0
5
2006201912.4low000320
Adenocarcinoma of Lung0
1
201820186.0low000010
Adenocarcinoma, Basal Cell0
6
2005201814.5low000420
Adenohypophyseal Diseases0
1
2005200519.0low000100
Adenohypophyseal Hyposecretion0
2
2012201212.0low100020
Adenoma0
2
2005201315.0low000110
Adenoma, Basal Cell0
2
2005201315.0low000110
Adenoma, Prostatic0
1
2005200519.0low000100
Adenovirus Infections, Human0
1
201520159.0low000010
Adiadochokinesis0
1
201620168.0low000010
Adipocere0
7
201020209.3low000160
Adolescent Obesity0
1
202020204.0low000010
ADPKD0
3
1996202014.7low101020
Adrenal Cancer0
7
1990202122.9low104111
Adrenal Cortex Cancer0
2
2007201314.0low000110
Adrenal Cortex Neoplasms0
2
2007201314.0low000110
Adrenal Gland Diseases0
1
2007200717.0low000100
Adrenal Gland Hypofunction0
1
202120213.0low000001
Adrenal Insufficiency0
1
202120213.0low000001
Adrenocortical Carcinoma0
1
2007200717.0low000100
Adrenocorticotropic Hormone, Inappropriate Secretion0
1
2009200915.0low000100
Adverse Drug Event0
6
2002201815.7low100510
Adverse Effects, Long Term0
1
201620168.0low000010
Age-Related Osteoporosis0
2
201420216.5low000011
Agenesis of Hemidiaphragm0
17
200820226.5low100377
Aging0
112
1992202313.8low1101340554
Agitation, Psychomotor0
1
2014201410.0low000010
Agnogenic Myeloid Metaplasia0
1
202020204.0low000010
AIDS Seroconversion0
1
2013201311.0low000010
Airflow Obstruction, Chronic0
148
2001202310.9low800429511
Airway Hyper-Responsiveness0
1
2011201113.0low000010
Airway Obstruction0
7
2007201911.9low000340
Airway Remodeling0
1
2013201311.0low000010
AL Amyloidosis0
38
201120225.9low5000308
Albright Hereditary Osteodystrophy0
2
201620206.0low000020
Albuminuria0
95
1999202312.9low140142484
ALCAPA0
1
202020204.0low000010
Alcohol Abuse0
5
2001202110.6low100221
Alcohol Drinking0
15
1996202010.4low0013110
Alcohol Problem0
1
201620168.0low000010
Alcohol-Related Disorders0
1
201620168.0low000010
Alcoholic Cardiomyopathy0
2
2001201914.0low000110
Alcoholic Cirrhosis0
3
2009201213.7low000210
Alcoholic Intoxication0
1
1995199529.0low001000
Alcoholism0
5
2001202110.6low100221
Aldosteronism0
8
1994201916.6low002240
Alkalosis, Respiratory0
1
202120213.0low000001
Allergic Angiitis0
1
201620168.0low000010
Allergic Reaction0
2
2009201711.0low100110
Allergic Rhinitis0
1
201620168.0low000010
Allodynia0
1
2010201014.0low000100
Alloxan Diabetes0
29
1995202213.0low00310133
Alopecia Areata0
1
202120213.0low000001
Alopecia Circumscripta0
1
202120213.0low000001
alpha-Galactosidase A Deficiency0
9
2009201910.7low000270
Altidudinal Hemianopia0
1
2005200519.0low000100
Altitude Hypoxia0
16
2001201711.7low1003130
Altitude Sickness0
16
2001201711.7low1003130
Alveolitis, Fibrosing0
7
2003201614.9low100340
Alzheimer Disease0
11
2001202211.9low000461
Ambulation Difficulty0
1
2013201311.0low100010
Amenorrhea0
1
2011201113.0low100010
Amentia0
17
200620228.9low1004121
American Trypanosomiasis0
25
2002202312.8low0001474
Amnesia0
2
1992199331.5low002000
Amnesia-Memory Loss0
2
1992199331.5low002000
Amnionitis0
2
201220208.0low000020
Amphetamine Abuse0
1
2013201311.0low000010
Amphetamine-Related Disorders0
1
2013201311.0low000010
Amyloid Neuropathies, Familial0
22
200820228.0low3002182
Amyloid Neuropathy Type 10
22
200820228.0low3002182
Amyloidosis0
90
1991202311.0low60318609
Amyotonia Congenita0
1
201920195.0low000010
Anaphylactic Reaction0
1
201620168.0low000010
Anaphylaxis0
1
201620168.0low000010
Anaplastic Astrocytoma0
2
1990199133.5low002000
Anasarca0
59
1993202211.4low90314357
Anemia0
77
2004202213.0low130045302
Anemia, Aplastic0
1
201720177.0low000010
Anemia, Cooley's0
17
2006202314.1low2001241
Anemia, Hemolytic0
3
2006201812.3low000120
Anemia, Hemolytic, Acquired0
3
2006201812.3low000120
Anemia, Hemolytic, Autoimmune0
1
2012201212.0low000010
Anemia, Hemolytic, Congenital0
1
2010201014.0low000100
Anemia, Hemolytic, Hereditary0
1
2010201014.0low000100
Anemia, Hypoplastic0
1
201720177.0low000010
Anemia, Iron-Deficiency0
12
2006202210.0low100471
Anemia, Sickle Cell0
18
2006202111.7low2007101
Anemias, Iron-Deficiency0
12
2006202210.0low100471
Anesthesia0
15
1989202117.0low212831
Aneurysm0
5
2007202010.6low000230
Aneurysm, Anterior Cerebral Artery0
8
1997202216.5low002321
Aneurysm, Aortic0
7
2007201910.9low100340
Aneurysm, Arteriovenous0
6
1996202115.0low001311
Aneurysm, Coronary0
6
2009202310.3low000312
Aneurysm, Ruptured0
2
2003200420.5low000200
Aneurysm, Thoracic Aortic0
5
200820209.8low000140
Angiitis0
4
2004201913.2low000220
Angina at Rest0
98
1996202216.1low130265301
Angina Pectoris0
69
1995202016.5low90742200
Angina Pectoris with Normal Coronary Arteriogram0
2
2001201814.5low100110
Angina Pectoris, Stable0
11
201120209.0low3000110
Angina Pectoris, Variant0
2
1994201121.5low001010
Angina, Stable0
11
201120209.0low3000110
Angina, Unstable0
98
1996202216.1low130265301
Angioblastic Meningioma0
2
201620206.0low000020
Angioedema0
1
201720177.0low000010
Angiogenesis, Pathologic0
8
2005201811.1low000350
Angiomyxoma0
2
202320231.0low000002
Angioneurotic Edema0
1
201720177.0low000010
Angiosarcoma0
1
2006200618.0low000100
Angiospasm, Intracranial0
9
2000201218.9low001620
Angor Pectoris0
69
1995202016.5low90742200
Ankylosing Spondylarthritis0
2
2013201311.0low000020
Anomalous Left Coronary Artery0
2
202020213.5low000011
Anomalous Ventricular Excitation Syndrome0
3
2008201710.3low000120
Anorectal Diseases0
2
201920204.5low100020
Anorexia0
1
201720177.0low000010
Anorexia Nervosa0
2
2003201117.0low000110
Anoxemia0
73
1992202314.1low801419337
Anoxia-Ischemia, Brain0
6
2009202210.7low000141
ANS (Autonomic Nervous System) Diseases0
8
2006201813.8low200530
Anterior Cerebral Circulation Infarction0
4
2005202112.0low000211
Anterior Cervical Pain0
1
202220222.0low000001
Anterior Choroidal Artery Infarction0
13
2002202311.8low100553
Anterior Circulation Transient Ischemic Attack0
26
2005202310.7low1006191
Anterior Fascicular Block0
17
2001202213.1low300791
Anterior Wall Myocardial Infarction0
21
200920239.0low8003144
Anti-MuSK Myasthenia Gravis0
1
2011201113.0low000010
Antidiuretic Hormone, Inappropriate Secretion0
5
2000201813.0low001130
Anuria0
1
202220222.0low000001
Anxiety0
17
199620238.8low102285
Anxiety Disorders0
5
200820227.0low000113
Anxiety Neuroses0
5
200820227.0low000113
Aortic Aneurysm0
7
2007201910.9low100340
Aortic Aneurysm, Abdominal0
7
200620219.1low000151
Aortic Aneurysm, Ruptured0
2
201520159.0low000020
Aortic Aneurysm, Thoracic0
5
200820209.8low000140
Aortic Coarctation0
9
1997201416.6low201620
Aortic Diseases0
8
200620229.4low000251
Aortic Dissection0
12
200720228.3low100291
Aortic Heart Disease0
1
202020204.0low000010
Aortic Incompetence0
41
2003202311.9low20017213
Aortic Stenosis0
208
1997202310.4low15026411428
Aortic Stenosis, Subvalvular0
1
2008200816.0low000100
Aortic Valve Disease0
1
202020204.0low000010
Aortic Valve Disease 10
1
202020204.0low000010
Aortic Valve Insufficiency0
41
2003202311.9low20017213
Aortic Valve Prolapse0
1
201520159.0low000010
Aortic Valve Stenosis0
208
1997202310.4low15026411428
Aortitis Syndrome0
2
201420159.5low000020
Ape Diseases0
2
201120199.0low000020
Apical Ballooning Syndrome0
67
200820229.1low4006583
Apnea0
2
201820195.5low000020
Apnea, Central0
17
2003202213.1low600971
Apnea, Obstructive Sleep0
64
2005202311.2low140020422
Apnea, Sleep0
45
1998202212.6low100120213
Apolipoprotein B-100, Familial Defective0
2
2010201710.5low000110
Apoplexy0
306
199920239.5low36016720236
Appendiceal Cancer0
1
201820186.0low000010
Appendiceal Neoplasms0
1
201820186.0low000010
Appendicitis0
1
202120213.0low000001
Aqueductal Stenosis0
2
2013201410.5low000020
ARPKD0
1
201720177.0low000010
Arrhythmia0
116
1994202310.6low1601336913
Arrhythmia, Sinoatrial0
2
201620177.5low000020
Arrhythmias, Cardiac0
116
1994202310.6low1601336913
Arrhythmogenic Right Ventricular Cardiomyopathy0
5
1998202314.4low101211
Arrhythmogenic Right Ventricular Dysplasia0
5
1998202314.4low101211
Arterial Diseases, Carotid0
9
2003202210.7low000351
Arterial Obstructive Diseases0
6
2007202012.7low000330
Arterial Occlusive Diseases0
6
2007202012.7low000330
Arteriosclerosis0
9
1994201716.3low002340
Arteriosclerosis, Coronary0
388
2001202311.2low520013322431
Arthralgia0
1
2007200717.0low100100
Arthritis0
4
201320218.8low100031
Arthritis, Degenerative0
6
2005202113.3low100321
Arthritis, Psoriatic0
2
201920223.5low000011
Arthritis, Rheumatoid0
40
2005202310.9low40012253
Ascites0
9
1992202215.3low102241
Asphyxia0
3
2010201611.3low000120
Asphyxia Neonatorum0
10
1995201613.5low201270
Aspiration, Meconium0
1
2011201113.0low100010
Asthenia0
1
202120213.0low000001
Asthma0
26
1998202210.0low4014183
Asthma, Bronchial0
26
1998202210.0low4014183
Asthma, Cardiac0
3
200920199.3low100120
Astrocytoma0
2
1990199133.5low002000
Asymmetric Diabetic Proximal Motor Neuropathy0
6
2001202015.3low100510
Asymmetric Septal Hypertrophy, Familial0
2
2007201214.5low000110
Asymptomatic Colonization0
1
202020204.0low000010
Asymptomatic Conditions0
70
201020227.9low8002653
Asystole0
24
2004202111.1low1009141
Atelectasis0
1
2014201410.0low000010
Atheroembolism0
1
2008200816.0low000100
Atherogenesis0
108
200520238.5low500137718
Atheroma0
11
201220237.4low200092
Atherosclerosis0
108
200520238.5low500137718
Athletic Injuries0
1
2003200321.0low000100
Atresia, Biliary0
2
1996201817.0low001010
Atresia, Pulmonary0
1
201720177.0low000010
Atrial Ectopic Beats0
5
201720224.4low000041
Atrial Ectopic Tachycardia0
3
2009201511.0low000120
Atrial Fibrillation0
643
199220239.8low83010171352110
Atrial Flutter0
7
201220206.0low200070
Atrial Remodeling0
25
201320234.9low4000178
Atrial Septal Defect0
29
1998202212.9low00112151
Atrioventricular Block0
17
2007202110.6low7005111
Atrioventricular Conduction Block0
17
2007202110.6low7005111
Atrioventricular Nodal Re-Entrant Tachycardia0
52
1998202312.1low140217285
Atrophy0
8
1997201714.4low002240
Atrophy, Muscle0
5
2004202112.4low000311
Atypical Ductal Hyperplasia0
1
201520159.0low000010
Auditory Vertigo0
2
2002201714.5low100110
Aura0
7
2001202112.9low000421
Auricular Fibrillation0
643
199220239.8low83010171352110
Auricular Flutter0
7
201220206.0low200070
Autoimmune Diabetes0
44
2000202212.5low60121157
Autoimmune Disease0
10
200320219.6low100253
Autoimmune Diseases0
10
200320219.6low100253
Autokinetic Effect0
1
202320231.0low000001
Azotaemia0
2
2009201711.0low000110
B-Cell Lymphoma0
3
2006200817.3low200300
Babesia Infection0
1
2012201212.0low000010
Bacteremia0
4
201320169.8low000040
Bacterial Disease0
4
2004202010.0low000130
Bacterial Endocarditides0
7
200720229.1low000151
Bacterial Infections0
4
2004202010.0low000130
Bacterial Infections, Gram-Negative0
1
2007200717.0low000100
Bacterial Pneumonia0
1
201620168.0low000010
Bacteroidaceae Infections0
1
2014201410.0low000010
Bare Lymphocyte Syndrome0
1
2003200321.0low000100
Barth Syndrome0
1
2011201113.0low000010
Basedow Disease0
5
2001202114.2low000311
Basilar Artery Insufficiency0
1
2008200816.0low000100
Bayes Syndrome0
1
201820186.0low000010
Becker Muscular Dystrophy0
16
2001202014.2low200790
Beckwith-Wiedemann Syndrome0
1
202020204.0low000010
Bedwetting0
4
2008201711.5low000130
Behavior Disorders0
4
2010201811.0low000130
Behcet Syndrome0
2
2008201114.5low000110
Bell Palsy0
1
202120213.0low000001
Bends0
2
2010201014.0low000200
Benedict Syndrome0
1
2008200816.0low000100
Benign Intracranial Hypertension0
1
2010201014.0low000100
Benign Meningeal Neoplasms0
1
201620168.0low000010
Benign Neoplasms0
83
1990202310.5low60123509
Benign Neoplasms, Brain0
5
1997202015.0low002030
Benign Supratentorial Neoplasms0
2
201620168.0low000020
Berger Disease0
2
1998202313.5low001001
Beriberi0
3
201120199.3low000030
Besnier-Boeck Disease0
15
200520229.4low000564
beta-Thalassemia0
17
2006202314.1low2001241
Bewilderment0
3
2006202010.3low000120
Bicuspid Aortic Valve Disease0
1
202020204.0low000010
Bilateral Headache0
2
202020213.5low000011
Bile Duct Obstruction0
1
2001200123.0low000100
Bile Duct Obstruction, Intrahepatic0
2
201420216.5low000011
Bilharziasis0
1
2010201014.0low000100
Biliary Atresia0
2
1996201817.0low001010
Biliary Cirrhosis0
1
202120213.0low000001
Bilirubinemia0
1
2010201014.0low000100
Birth Weight0
22
2004202310.7low0004171
Black Fever0
1
201920195.0low000010
Bladder Cancer0
2
201120218.0low100011
Bladder Neck Obstruction0
1
2005200519.0low000100
Bladder, Overactive0
1
2007200717.0low000100
Bleeding0
14
200620236.7low4001112
Blood Clot0
36
200620238.4low5006228
Blood Coagulation Disorders0
1
2006200618.0low000100
Blood Diseases0
3
2008201214.0low000210
Blood Loss, Surgical0
2
201720186.5low000020
Blood Poisoning0
138
200420239.7low700358815
Blood Pressure, High0
720
1989202314.3low10538128530150
Blood Pressure, Low0
50
1991202311.2low160215258
Blunt Injuries0
1
201520159.0low000010
Body Weight0
119
1992202314.6low1801543538
Bone Cancer0
2
2007201015.5low000200
Bone Fractures0
2
2010201810.0low000110
Bone Loss, Osteoclastic0
1
2002200222.0low000100
Bone Loss, Perimenopausal0
1
2003200321.0low000100
Bone Marrow Diseases0
1
201720177.0low000010
Bone Neoplasms0
2
2007201015.5low000200
Bonnevie-Ullrich Syndrome0
4
2006201512.8low100130
Bouillaud Disease0
15
2004202113.2low000951
Bowel Diseases, Inflammatory0
1
2013201311.0low000010
Bradyarrhythmia0
16
1999202115.0low301951
Bradycardia0
16
1999202115.0low301951
Bradykinesia0
2
2005201613.5low000110
Brain Damage, Chronic0
1
202020204.0low000010
Brain Dead0
5
2004201215.8low000410
Brain Diseases0
3
2006202013.3low000210
Brain Disorders0
3
2006202013.3low000210
Brain Edema0
7
2003202112.0low000331
Brain Emboli0
12
2007202211.1low100561
Brain Hemorrhage0
9
201120206.8low100090
Brain Hemorrhage, Cerebral0
20
1997201912.6low3018110
Brain Hemorrhage, Putaminal0
1
2014201410.0low000010
Brain Infarction0
4
2005202112.0low000211
Brain Inflammation0
2
201120189.5low000020
Brain Injuries0
11
2002202314.5low100821
Brain Injuries, Traumatic0
3
201720225.3low000021
Brain Injury, Vascular0
1
202020204.0low000010
Brain Ischemia0
99
1997202310.5low403275712
Brain Neoplasms0
5
1997202015.0low002030
Brain Swelling0
7
2003202112.0low000331
Brain Vascular Disorders0
19
1997202113.2low1035101
Break-Bone Fever0
2
2009201313.0low000110
Breast Cancer0
85
200120238.4low1900116311
Breast Cancer, Male0
1
2011201113.0low100010
Breast Neoplasms0
85
200120238.4low1900116311
Breast Neoplasms, Male0
1
2011201113.0low100010
Breathing Sounds0
3
2008201213.7low000120
Breathlessness0
465
1994202314.1low630727416123
Bright Disease0
4
2006201712.0low100220
Brill-Symmers Disease0
1
2005200519.0low100100
Bronchial Hyperreactivity0
3
2009201411.7low000120
Bronchiolitis0
11
201520233.6low000047
Bronchiolitis, Viral0
1
2014201410.0low000010
Bronchitis0
1
2011201113.0low000010
Bronchitis, Chronic0
2
2010201312.5low000110
Bronchopulmonary Dysplasia0
22
201020237.1low4001183
Brugada ECG Pattern0
2
2013201510.0low000020
Brugada Syndrome0
2
2013201510.0low000020
Bruise0
1
201520159.0low000010
Budd-Chiari Syndrome0
1
2010201014.0low000100
Buerger Disease0
1
2009200915.0low000100
Bunostomiasis0
1
2006200618.0low000100
Burns0
21
200620229.5low1005142
CACH Syndrome0
3
2012201610.3low000030
Cachexia0
14
2007202110.4low1003101
Cadaver0
1
2009200915.0low000100
Calcification, Pathologic0
25
2006202112.6low40011131
Calcinosis0
25
2006202112.6low40011131
Calcium Metabolism Disorders0
1
2005200519.0low000100
Cancer of Cecum0
1
2014201410.0low000010
Cancer of Colon0
1
201820186.0low000010
Cancer of Digestive System0
2
2009200915.0low100200
Cancer of Esophagus0
10
2007202111.3low300451
Cancer of Gastrointestinal Tract0
2
201020199.5low000110
Cancer of Head0
2
202120213.0low000002
Cancer of Intestines0
1
201620168.0low000010
Cancer of Kidney0
5
2006201912.4low000320
Cancer of Larynx0
1
202120213.0low000001
Cancer of Liver0
6
1997201817.0low002220
Cancer of Lung0
40
1999202311.8low40116203
Cancer of Mouth0
1
202020204.0low000010
Cancer of Ovary0
4
1994201018.8low101300
Cancer of Pancreas0
1
201620168.0low000010
Cancer of Pituitary0
2
2007201712.0low000110
Cancer of Prostate0
9
200520218.0low200324
Cancer of Skin0
1
202120213.0low000001
Cancer of Stomach0
4
2001202210.0low100121
Cancer of Testis0
2
2009201114.0low000110
Cancer of the Thymus0
1
2008200816.0low000100
Cancer of the Thyroid0
2
201620177.5low000020
Cancer of the Urinary Tract0
1
2014201410.0low000010
Cancer, Embryonal0
1
2009200915.0low100100
Canine Diseases0
83
199920239.3low602165411
Capillary Leak Syndrome0
2
201120208.5low000020
Capillary Rarefaction0
1
201820186.0low000010
Carbon Monoxide Poisoning0
12
200520229.1low100453
Carcinogenesis0
2
201520235.0low000011
Carcinoid Heart Disease0
6
2008202210.5low000321
Carcinoma0
2
2008201413.0low100110
Carcinoma, Anaplastic0
2
2008201413.0low100110
Carcinoma, Ductal, Breast0
1
201520159.0low000010
Carcinoma, Epidermoid0
4
201420216.5low000031
Carcinoma, Hepatocellular0
3
1997201118.3low001110
Carcinoma, Intraductal, Noninfiltrating0
1
201520159.0low000010
Carcinoma, Non-Small Cell Lung0
6
2008201513.3low100420
Carcinoma, Non-Small-Cell Lung0
6
2008201513.3low100420
Carcinoma, Oat Cell0
2
1999200522.0low001100
Carcinoma, Renal Cell0
5
2006201912.4low000320
Carcinoma, Small Cell0
2
1999200522.0low001100
Carcinoma, Small Cell Lung0
2
2008201413.0low000110
Carcinoma, Squamous Cell0
4
201420216.5low000031
Carcinoma, Squamous Cell of Head and Neck0
1
202120213.0low000001
Cardiac Aneurysm0
7
2002201915.9low000610
Cardiac Arrest, Sudden0
109
2002202211.1low1700386110
Cardiac Cancer0
5
2006201614.2low000320
Cardiac Conduction Defect0
2
2013201510.0low000020
Cardiac Death0
20
200120239.5low2002162
Cardiac Diseases0
537
1991202312.7low4402520826935
Cardiac Edema0
17
1998201911.5low3013130
Cardiac Failure0
5,727
1990202411.9medium81701762,2562,619676
Cardiac Hypertrophy0
278
1992202313.8low602910612518
Cardiac Murmurs0
11
200620229.9low000452
Cardiac Output, High0
1
201520159.0low000010
Cardiac Output, Low0
150
1992202118.8low22018118131
Cardiac Remodeling, Ventricular0
452
1999202312.4low670818723225
Cardiac Rupture, Post-Infarction0
2
2001200919.0low000200
Cardiac Rupture, Traumatic0
37
200820237.4low4004258
Cardiac Septal Defect0
4
2002201513.8low100220
Cardiac Tamponade0
5
1992201715.2low001130
Cardiac Toxicity0
83
201420235.7low110006617
Cardio-embolic Stroke0
8
202020223.0low100017
Cardio-Renal Syndrome0
45
201120238.1low4000405
Cardiomegaly0
278
1992202313.8low602910612518
Cardiometabolic Syndrome0
50
2005202110.5low60012353
Cardiomyopathies0
328
1991202311.5low200711018130
Cardiomyopathies, Primary0
328
1991202311.5low200711018130
Cardiomyopathy, Chagas0
33
2003202213.1low20018132
Cardiomyopathy, Congestive0
271
1991202313.7low3301213311115
Cardiomyopathy, Dilated0
271
1991202313.7low3301213311115
Cardiomyopathy, Hypertrophic0
123
1991202313.1low20851577
Cardiomyopathy, Hypertrophic Obstructive0
123
1991202313.1low20851577
Cardiomyopathy, Restrictive0
12
2005202212.2low000741
Cardiotoxicity0
83
201420235.7low110006617
Cardiovascular Abnormalities0
5
200720235.2low200113
Cardiovascular Diseases0
879
1993202310.7low70014275490100
Cardiovascular Pregnancy Complications0
41
1993202212.0low00214232
Cardiovascular Stroke0
988
1991202313.5low14005943743260
Carditis0
66
199520229.9low001173414
Carotid Artery Diseases0
9
2003202210.7low000351
Carotid Artery Dissection, Internal0
1
2002200222.0low000100
Carotid Artery Narrowing0
8
201120236.1low200053
Carotid Stenosis0
8
201120236.1low200053
Cat Diseases0
30
200320229.2low1008202
Celiac Disease0
1
2010201014.0low000100
Celiac Sprue0
1
2010201014.0low000100
Cell Transformation, Neoplastic0
1
202320231.0low000001
Cells, Neoplasm Circulating0
1
201820186.0low000010
Central Hypothyroidism0
18
2004202311.7low200783
Cerebellar Ataxia0
1
201620168.0low000010
Cerebellar Diseases0
1
2014201410.0low000010
Cerebral Arteriosclerosis0
2
1997200821.5low001100
Cerebral Hemorrhage0
20
1997201912.6low3018110
Cerebral Hemorrhage, Hypertensive0
1
201820186.0low000010
Cerebral Infarction0
13
2002202311.8low100553
Cerebral Infarction, Middle Cerebral Artery0
4
201720234.2low000022
Cerebral Ischemia0
99
1997202310.5low403275712
Cerebral Microangiopathies0
1
201820186.0low000010
Cerebral Pseudosclerosis0
1
201520159.0low000010
Cerebral Small Vessel Diseases0
1
201820186.0low000010
Cerebrovascular Disorders0
19
1997202113.2low1035101
Chagas Cardiomyopathy0
33
2003202213.1low20018132
Chagas Disease0
25
2002202312.8low0001474
Chemical and Drug Induced Liver Injury0
1
201620168.0low000010
Chemical Dependence0
2
1996202115.5low001001
Chest Injuries0
1
201520159.0low000010
Chest Pain0
74
2003202112.7low90033374
Cheyne-Stokes Respiration0
16
2003202214.5low3001141
Child Development Deviations0
2
201120218.0low000011
Child Malnutrition0
1
2014201410.0low000010
Cholestasis0
1
2001200123.0low000100
Cholestasis, Intrahepatic0
2
201420216.5low000011
Choline Deficiency0
1
2013201311.0low000010
Chondrodystrophic Myotonia0
1
2014201410.0low000010
Chondrosarcoma0
1
2007200717.0low000100
Chorioamnionitis0
2
201220208.0low000020
Chromosomal Translocation0
1
202020204.0low000010
Chromosomal Triplication0
1
1996199628.0low001000
Chronic Bronchitis0
2
2010201312.5low000110
Chronic Disease0
746
1996202312.5low15701832535845
Chronic Fatigue and Immune Dysfunction Syndrome0
1
2008200816.0low000100
Chronic Hepatitis B0
1
2012201212.0low000010
Chronic Hepatitis C0
7
2006201314.6low100520
Chronic Illness0
746
1996202312.5low15701832535845
Chronic Insomnia0
1
2008200816.0low100100
Chronic Kidney Disease-Mineral and Bone Disorder0
1
201920195.0low000010
Chronic Kidney Diseases0
183
200520237.8low21001514028
Chronic Kidney Failure0
311
1992202313.8low2702013913913
Chronic Liver Failure0
8
201220217.1low000062
Chronic Lung Injury0
3
2006202011.7low100120
Chronic Pain0
1
201520159.0low000010
Churg-Strauss Syndrome0
1
201620168.0low000010
Chylopericardium0
26
1998202213.5low10111122
Cicatrix0
14
200420239.2low100473
Cicatrization0
14
200420239.2low100473
Circulatory Collapse0
18
2000202114.1low3011061
Cirrhoses, Experimental Liver0
3
1995201517.7low001110
Cirrhosis0
192
1997202310.4low6024912318
Cirrhosis, Liver0
51
1992202313.4low10617226
CKD-MBD0
1
201920195.0low000010
Cleft Spine0
1
2013201311.0low000010
Click-Murmur Syndrome0
2
201920204.5low000020
Clinical Deterioration0
2
201720186.5low200020
Clostridioides difficile Infection0
1
202020204.0low000010
Clostridium Infections0
1
202020204.0low000010
Co-infection0
2
201220217.5low000011
Coagulation Disorders, Blood0
1
2006200618.0low000100
Coarctation of Aorta0
9
1997201416.6low201620
Cocaine Abuse0
2
2013201410.5low000020
Cocaine-Related Disorders0
2
2013201410.5low000020
Cochlear Hearing Loss0
1
202020204.0low000010
Cognition Disorders0
28
2006202310.9low2008191
Cognitive Decline0
15
201120237.3low0000132
Cognitive Dysfunction0
15
201120237.3low0000132
Cold Fingers, Hereditary0
1
2003200321.0low000100
Colicky Pain0
2
202020213.5low000011
Colitis Gravis0
1
2013201311.0low000010
Colitis, Granulomatous0
2
201320198.0low000020
Colitis, Ulcerative0
1
2013201311.0low000010
Colonic Diseases0
2
201920204.5low100020
Colonic Neoplasms0
1
201820186.0low000010
Colorectal Cancer0
2
201020237.5low100101
Colorectal Neoplasms0
2
201020237.5low100101
Coma0
6
200720238.2low000222
Communicable Diseases0
2
201520159.0low000020
Community Acquired Infection0
22
200520229.8low1004162
Compensatory Hyperinsulinemia0
5
2005202012.0low000140
Complex Single Ventricle0
2
201920195.0low000020
Complication, Intraoperative0
14
2005202112.8low200941
Complication, Postoperative0
244
1994202311.2low33018513721
Complications of Diabetes Mellitus0
65
2002202014.1low80039260
Complications, Infectious Pregnancy0
2
202020232.5low000011
Complications, Pregnancy0
13
1996202113.4low201651
Concussive Convulsion0
1
2002200222.0low000100
Congenital Familial Lymphedema0
4
201120224.8low000013
Congenital Hyperinsulinism0
1
202020204.0low000010
Congenital Myotonic Dystrophy0
3
201620196.7low000030
Congenital Thrombotic Thrombocytopenic Purpura0
1
202220222.0low000001
Congenitally Corrected Transposition0
4
201220199.0low100040
Congestive Ophthalmopathy0
1
201820186.0low100010
Conjunctivitis0
1
202120213.0low000001
Connective Tissue Disease, Mixed0
2
2007201214.5low000110
Connective Tissue Diseases0
9
1996202211.7low101251
Consciousness, Loss of0
2
200920209.5low000110
Constriction, Pathologic0
10
200620238.5low000343
Constriction, Pathological0
10
200620238.5low000343
Constrictive Pericarditis0
18
2003202212.8low1001161
Contusions0
1
201520159.0low000010
Convalescence0
5
1998202017.0low101310
Convulsions, Febrile0
2
2007201513.0low000110
Convulsive Generalized Seizure Disorder0
3
200720218.3low000111
Cor Pulmonale0
20
1996202214.0low202981
Coronary Artery Disease0
388
2001202311.2low520013322431
Coronary Artery Stenosis0
39
2002202212.6low40021144
Coronary Artery Vasospasm0
3
1994202215.0low001011
Coronary Disease0
220
1991202315.6low310111445510
Coronary Heart Disease0
220
1991202315.6low310111445510
Coronary Occlusion0
8
200920228.4low100161
Coronary Restenosis0
14
2004201615.6low1001040
Coronary Stenosis0
39
2002202212.6low40021144
Coronary Thrombosis0
9
2006201614.0low000540
Coronary Vasospasm0
3
1994202215.0low001011
Coronary Vessel Anomalies0
1
201920195.0low000010
Coronavirus Infections0
28
202020204.0low1000280
Cortical Lewy Body Disease0
1
2013201311.0low000010
Cough0
4
2008202010.0low000130
Coxsackie Virus Infections0
2
2013201410.5low000020
Cramp0
1
201720177.0low100010
Craniocerebral Injuries0
3
2002201315.7low000210
Craniocerebral Trauma0
3
2002201315.7low000210
Craniopharyngioma0
2
2007201712.0low000110
Craniopharyngioma, Adamantinous0
2
2007201712.0low000110
Craniosynostoses0
1
201620168.0low000010
Critical Illness0
89
2001202312.1low50041444
Crohn Disease0
2
201320198.0low000020
Cross Infection0
1
201620168.0low000010
Cross-Transfusion, Intrauterine0
9
2002202212.7low000441
Crow-Fukase Syndrome0
1
2009200915.0low000100
Cruveilhier-Baumgarten Syndrome0
4
2010201810.2low000130
Cryoglobulinemia0
2
2009201014.5low000200
Cryptogenic Fibrosing Alveolitis0
7
2009201710.7low100250
Cushing Syndrome0
3
201020238.7low000111
Cushing's Syndrome0
3
201020238.7low000111
Cyanosis0
5
2004202011.2low000230
Cyst0
3
2005201711.0low000120
Cystic Fibrosis0
3
200720218.0low000111
Cystic Fibrosis of Pancreas0
3
200720218.0low000111
Cystic Kidney Diseases0
1
2007200717.0low000100
Cystic Periventricular Leukomalacia0
1
2002200222.0low000100
Cytokine Release Syndrome0
4
202020213.2low000013
Day Blindness0
2
1996201518.5low001010
Daytime Sleepiness0
5
200320248.2low100122
Deafness, Sudden0
1
202020204.0low000010
Death, Sudden0
9
2004201913.0low000450
Death, Sudden, Cardiac0
109
2002202211.1low1700386110
Debility0
7
202020222.6low000016
Decreased Muscle Tone0
1
202120213.0low000001
Deep Vein Thrombosis0
16
2004202010.8low2005110
Deficiency, Factor 110
1
2010201014.0low000100
Deficiency, Factor 70
1
2010201014.0low000100
Deficiency, Factor II0
1
2010201014.0low000100
Deficiency, Folic Acid0
1
201520159.0low000010
Deficiency, Glucosephosphatase0
1
2009200915.0low000100
Deficiency, Thiamine0
1
2014201410.0low000010
Deficiency, Vitamin B 120
1
201520159.0low000010
Deficiency, Vitamin D0
16
200920229.0low2004111
Deficiency, Vitamin K0
1
2014201410.0low100010
Deficiency, Yang0
1
202020204.0low100010
Degenerative Diseases, Central Nervous System0
1
201820186.0low000010
Deglutition Disorders0
1
201620168.0low000010
Dehydration0
7
1989201718.6low111140
Dejerine-Roussy Syndrome0
1
2014201410.0low000010
Delayed Effects, Prenatal Exposure0
5
1998202012.8low001130
Delayed Puberty0
1
2009200915.0low000100
Delirium0
1
201920195.0low000010
Delirium of Mixed Origin0
1
201920195.0low000010
Dementia0
17
200620228.9low1004121
Dementia Praecox0
2
2007201513.0low100110
Dementia, Vascular0
3
2006201314.7low000210
Dengue0
2
2009201313.0low000110
Dengue Hemorrhagic Fever0
1
202220222.0low000001
Depression0
38
2007202310.2low20011234
Depression, Endogenous0
8
2006202010.4low000350
Depression, Involutional0
4
2007201115.2low000310
Depressive Disorder0
8
2006202010.4low000350
Depressive Disorder, Major0
4
2007201115.2low000310
Dermatitis0
1
202120213.0low000001
Dermatitis Medicamentosa0
1
2009200915.0low100100
Dermatitis, Atopic0
1
201820186.0low000010
Dermatomyositis0
1
202120213.0low000001
Dermatomyositis, Adult Type0
1
202120213.0low000001
Dermatosclerosis0
1
2012201212.0low000010
Developmental Disabilities0
2
201120218.0low000011
Developmental Psychomotor Disorders0
1
2014201410.0low000010
Dextro-Looped Transposition of the Great Arteries0
30
2002201912.0low40012180
Diabetes Mellitus0
134
199620239.1low803287528
Diabetes Mellitus, Adult-Onset0
301
199520239.6low78047117452
Diabetes Mellitus, Gestational0
7
200820229.7low000241
Diabetes Mellitus, Type 10
44
2000202212.5low60121157
Diabetes Mellitus, Type 20
301
199520239.6low78047117452
Diabetes, Gestational0
7
200820229.7low000241
Diabetic Angiopathies0
55
1998201914.9low30136180
Diabetic Cardiomyopathies0
15
201020237.8low5001131
Diabetic Feet0
1
2008200816.0low100100
Diabetic Foot0
1
2008200816.0low100100
Diabetic Glomerulosclerosis0
44
2001202312.5low130020204
Diabetic Ketoacidosis0
2
202120213.0low100002
Diabetic Nephropathies0
44
2001202312.5low130020204
Diabetic Neuropathies0
6
2001202015.3low100510
Diabetic Retinopathy0
3
2006201315.7low000210
Diaphragmatic Hernia0
4
2005201016.2low000400
Diarrhea0
6
200620219.3low100303
Diastolic Heart Failure0
62
2007202211.3low110022355
Diathesis0
4
2004201913.0low000220
Diffuse Cutaneous Systemic Sclerosis0
4
201720196.0low000040
Diffuse Large B-Cell Lymphoma0
4
2006201912.2low200220
Diffuse Mixed Small and Large Cell Lymphoma0
11
1999202015.7low201550
Diffuse Parenchymal Lung Disease0
19
2005202112.4low0001072
Digestive System Neoplasms0
2
2009200915.0low100200
Dilatation, Pathologic0
8
2000202013.2low201250
Dirofilariasis0
1
202320231.0low000001
Disease Exacerbation0
478
1997202311.6low530716529214
Disease Models, Animal0
294
1991202312.1low20169317015
Disease, Pulmonary0
60
1994202015.1low30434220
Diseases in Twins0
2
2003201415.5low000110
Diseases of Endocrine System0
1
202120213.0low000001
Diseases, Metabolic0
2
201620196.5low000020
Diseases, Occupational0
1
2005200519.0low000100
Diseases, Peripheral Vascular0
8
2006201415.8low000710
Disorders of Excessive Somnolence0
5
200320248.2low100122
Dizziness0
5
2005201712.2low200230
Dizzyness0
5
2005201712.2low200230
Down Syndrome0
5
1996202212.0low101121
Drop Attack0
29
2003202210.9low0009182
Drowning0
2
2010201213.0low000110
Drug Overdose0
4
2006201912.0low000130
Drug Refractory Epilepsy0
1
202020204.0low000010
Drug Withdrawal Symptoms0
2
1995201917.0low001010
Drug-Related Side Effects and Adverse Reactions0
6
2002201815.7low100510
Ductus Arteriosus, Patent0
71
1999202311.3low90123443
Duncan Disease0
2
2005201215.5low000110
Duodenal Diseases0
1
2006200618.0low000100
Dwarfism0
1
2003200321.0low000100
Dysembryoma0
3
1994201814.3low001020
Dysesthesia0
1
201520159.0low000010
Dyslipidemia0
16
2005201911.6low0005110
Dyslipidemias0
16
2005201911.6low0005110
Dysmyelopoietic Syndromes0
4
1998201912.5low001030
Dysphagia0
1
201620168.0low000010
Dyspnea0
465
1994202314.1low630727416123
E coli Infections0
1
2003200321.0low000100
Ebstein Anomaly0
4
2006202010.2low100130
Eclampsia0
1
2013201311.0low000010
Eczema, Atopic0
1
201820186.0low000010
Edema0
59
1993202211.4low90314357
Edema-Proteinuria-Hypertension Gestosis0
61
1992202210.2low3059389
Edema, Cardiac0
17
1998201911.5low3013130
Edema, Fetal0
4
201220188.5low000040
Edema, Pulmonary0
102
1993202212.7low80147495
Eisenmenger Complex0
13
2008201910.2low3002110
Eisenmenger Syndrome0
13
2008201910.2low3002110
Electric Injuries0
1
2010201014.0low000100
Electrocardiogram QT Prolonged0
9
200620218.9low000252
Electrolytes0
17
1990202221.8low209341
Electron Transport Chain Deficiencies, Mitochondrial0
3
201620215.3low000021
Elevated Cholesterol0
9
2003202112.3low100432
Elevated ICP (Intracranial Pressure)0
2
2006201115.5low000110
Emaciation0
1
2005200519.0low000100
Embolism0
18
199720229.9low5013113
Embolism, Cholesterol0
1
2008200816.0low000100
Embolism, Pulmonary0
243
1997202311.7low19019213317
Embolus0
18
199720229.9low5013113
Embryopathies0
11
2007201910.1low200290
Emergencies0
27
2002201915.4low3002070
Emesis0
1
202120213.0low000001
Emphysema0
1
2008200816.0low000100
Empyema0
1
2013201311.0low000010
Encephalitis0
2
201120189.5low000020
Encephalitis, Herpes Simplex0
1
201920195.0low000010
Encephalitis, Viral0
1
201520159.0low000010
Encephalopathy, Hypertensive0
1
2002200222.0low100100
Encephalopathy, Traumatic0
3
201720225.3low000021
End Stage Liver Disease0
8
201220217.1low000062
Endocardial Fibroelastosis0
2
2008201711.5low100110
Endocarditis0
9
201020216.7low000171
Endocarditis, Bacterial0
7
200720229.1low000151
Endocrine System Diseases0
1
202120213.0low000001
Endomyocardial Fibrosis0
16
2001201715.1low2001150
Endotoxemia0
1
2014201410.0low000010
Endotoxin Shock0
86
1994202111.8low70135473
Enlarged Liver0
3
200620199.7low100120
Enlarged Spleen0
1
201820186.0low000010
Enterocolitis, Necrotizing0
3
201720186.7low000030
Enteropathy, Exudative0
2
2006201513.5low000110
Enterovirus Infections0
2
201320217.0low000011
Envenomation, Scorpion0
2
201820214.5low000011
Eosinophilia0
2
202020232.5low000011
Eosinophilia, Tropical0
2
202020232.5low000011
Epilepsy0
7
2001202112.9low000421
Erdheim-Chester Disease0
1
202220222.0low000001
Erectile Dysfunction0
1
201620168.0low000010
Erythema0
2
201320226.5low000011
Erythroblastosis Fetalis0
1
2011201113.0low100010
Erythrocytosis0
1
202020204.0low000010
Erythrophagocytic Lymphohistiocytosis, Familial0
1
202120213.0low000001
Escherichia coli Infections0
1
2003200321.0low000100
Esophageal and Gastric Varices0
1
2012201212.0low000010
Esophageal Hernia0
1
2012201212.0low000010
Esophageal Neoplasms0
10
2007202111.3low300451
Esophageal Varices0
1
2012201212.0low000010
Essential Hypertension0
9
201420228.2low000081
Essential Polyarteritis0
1
201620168.0low000010
Euthyroid Sick Syndromes0
3
201020219.0low000111
Exanthem0
3
200620227.7low000102
Exanthema0
3
200620227.7low000102
Excessive Periodic Sleep-Related Leg Movements0
1
2010201014.0low000100
Exertional Heat Illness0
1
2014201410.0low000010
Exfoliation Glaucoma0
1
2014201410.0low000010
Exfoliation Syndrome0
1
2014201410.0low000010
Exocrine Pancreatic Insufficiency0
1
201720177.0low000010
Experimental Lung Inflammation0
47
2002202310.0low40011315
Experimental Radiation Injuries0
1
2004200420.0low000100
Extrasystole, Ventricular0
19
2003202312.6low3008101
Extravascular Hemolysis0
6
201020218.7low200141
Fabry Disease0
9
2009201910.7low000270
Factor VII Deficiency0
1
2010201014.0low000100
Fallot's Tetralogy0
48
2003202212.6low80023241
Familial Hyperinsulinemic Hypoglycemia 10
1
202020204.0low000010
Familial Primary Pulmonary Hypertension0
70
201020239.0low40015415
Familial Turner Syndrome0
2
2009201910.0low000110
Fasting Hypoglycemia0
3
2007202112.0low200201
Fatigue0
17
2000202112.4low302681
Fatigue Syndrome, Chronic0
1
2008200816.0low000100
Fatty Liver0
3
200620218.7low000111
Fatty Liver, Nonalcoholic0
5
201520206.2low000050
Fetal Death0
1
201920195.0low100010
Fetal Distress0
4
1992201621.0low002020
Fetal Growth Restriction0
15
200720219.9low0004101
Fetal Growth Retardation0
15
200720219.9low0004101
Fetal Macrosomia0
3
2009201612.3low000210
Fetal Malnutrition0
1
201720177.0low000010
Fever0
17
199920239.4low002285
Fibrosis0
192
1997202310.4low6024912318
Fistula0
1
202220222.0low000001
Focal Segmental Glomerulosclerosis0
2
2004200420.0low000200
Folic Acid Deficiency0
1
201520159.0low000010
Follicle Stimulating Hormone, Inappropriate Secretion0
1
2002200222.0low000100
Foramen Ovale, Patent0
3
201620234.7low000021
Fractures, Bone0
2
2010201810.0low000110
Froehlich's Syndrome0
1
2011201113.0low100010
Fusiform Aneurysm0
5
2007202010.6low000230
Gammapathy, Monoclonal0
1
2011201113.0low000010
Gasser Syndrome0
1
2007200717.0low000100
Gastric Dilatation0
1
201720177.0low000010
Gastric Volvulus0
1
201720177.0low000010
Gastrointestinal Hemorrhage0
2
201720215.0low000011
Gastrointestinal Stromal Neoplasm0
2
2006200817.0low000200
Gastrointestinal Stromal Tumors0
2
2006200817.0low000200
Gaucher Disease0
1
2004200420.0low000100
Genetic Predisposition0
41
1999202111.9low00211271
Germinoblastoma0
5
2000201713.8low101130
Gestational Hypertension0
15
201020227.3low1001113
Glaucoma0
1
1998199826.0low001000
Glaucoma, Suspect0
1
201620168.0low000010
Glial Cell Tumors0
5
1992202017.0low002030
Glioma0
5
1992202017.0low002030
Glomerulonephritis0
4
2006201712.0low100220
Glomerulonephritis, IGA0
2
1998202313.5low001001
Glomerulonephritis, Lupus0
1
202120213.0low000001
Glomerulosclerosis, Focal Segmental0
2
2004200420.0low000200
Glucose Intolerance0
12
2006202010.8low000480
Glucose Metabolic Disorder0
1
2011201113.0low000010
Glycogen Storage Disease Type I0
1
2009200915.0low000100
Glycogen Storage Disease Type II0
2
2006200916.5low000200
Glycosuria0
2
201620177.5low100020
Goldblatt Syndrome0
12
1997201516.7low201830
Gout0
1
202120213.0low000001
Graft Occlusion, Vascular0
1
202020204.0low000010
Gram-Negative Bacterial Infections0
1
2007200717.0low000100
Granulocytic Leukemia0
1
2005200519.0low000100
Granulocytic Leukemia, Chronic0
5
2006201912.8low000230
Granuloma0
1
202120213.0low000001
Granuloma, Hodgkin0
2
2011201511.0low000020
Granulomas0
1
202120213.0low000001
Granulomatosis with Polyangiitis0
2
201620206.0low000020
Granulomatosis, Lipid0
1
202220222.0low000001
Granulomatosis, Wegener's0
2
201620206.0low000020
Graves Disease0
5
2001202114.2low000311
Graves Ophthalmopathy0
1
201820186.0low100010
Grippe0
6
201220207.2low000060
Group A Strep Infection0
1
2009200915.0low000100
Growth Disorders0
2
2006201414.0low000110
Guillain-Barre Syndrome0
1
2006200618.0low000100
Hand Foot and Mouth Disease0
7
201620186.9low200070
Hand, Foot and Mouth Disease0
7
201620186.9low200070
HbS Disease0
18
2006202111.7low2007101
Head and Neck Neoplasms0
2
202120213.0low000002
Headache0
2
202020213.5low000011
Health Care Associated Infection0
1
201620168.0low000010
Hearing Loss, Sensorineural0
1
202020204.0low000010
Heart Arrest0
24
2004202111.1low1009141
Heart Defects, Congenital0
246
1993202311.3low16057913824
Heart Disease, Ischemic0
325
1994202213.9low410121631437
Heart Diseases0
537
1991202312.7low4402520826935
Heart Failure0
5,727
1990202411.9medium81701762,2562,619676
Heart Failure, Diastolic0
62
2007202211.3low110022355
Heart Failure, Systolic0
154
2006202211.2medium3300548911
Heart Septal Defects, Ventricular0
22
2003202211.6low1008122
Heart Valve Diseases0
82
1991202312.5low50334396
Heat Stroke0
3
2012201311.7low000030
Heatstroke0
3
2012201311.7low000030
Helicobacter Infections0
1
2014201410.0low000010
Hemangioma, Capillary0
2
201220179.5low000020
Hemangiosarcoma0
1
2006200618.0low000100
Hematochezia0
2
201720215.0low000011
Hematologic Diseases0
3
2008201214.0low000210
Hematologic Malignancies0
4
1998201416.2low001120
Hematologic Neoplasms0
4
1998201416.2low001120
Hematoma0
2
201720186.5low000020
Hematoma, Subdural0
1
2013201311.0low000010
Hematoma, Subdural, Chronic0
1
202120213.0low000001
Hemoglobinopathies0
1
2014201410.0low000010
Hemoglobinuria, Paroxysmal0
2
2010201213.0low100110
Hemolysis0
6
201020218.7low200141
Hemolytic-Uremic Syndrome0
1
2007200717.0low000100
Hemoperitoneum0
1
2007200717.0low000100
Hemoptysis0
1
201720177.0low000010
Hemorrhage0
14
200620236.7low4001112
Hemorrhage, Intracranial, Traumatic0
1
2007200717.0low000100
Hemorrhage, Subarachnoid0
43
1994202215.6low00717163
Hemorrhagic Fever with Renal Syndrome0
3
2012201411.0low000030
Hemorrhagic Fever, Epidemic0
3
2012201411.0low000030
Hemorrhagic Shock0
1
201520159.0low000010
Hemorrhagic Stroke0
1
202220222.0low000001
Hemorrhagic Thrombocythemia0
1
201520159.0low100010
Hemosiderosis0
2
2007201314.0low000110
Hepatic Failure0
4
2004201216.2low000310
Hepatic Veno Occlusive Disease0
1
2010201014.0low000100
Hepatic Veno-Occlusive Disease0
1
2010201014.0low000100
Hepatitis0
1
2011201113.0low000010
Hepatitis B0
3
2009201712.3low000210
Hepatitis B Virus Infection0
3
2009201712.3low000210
Hepatitis B, Chronic0
1
2012201212.0low000010
Hepatitis C0
9
2005202113.9low000531
Hepatitis C, Chronic0
7
2006201314.6low100520
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted0
9
2005202113.9low000531
Hepato-Pulmonary Syndrome0
1
201520159.0low000010
Hepatocellular Carcinoma0
3
1997201118.3low001110
Hepatolenticular Degeneration0
1
201520159.0low000010
Hepatopulmonary Syndrome0
1
201520159.0low000010
Hepatorenal Syndrome0
2
201420207.0low000020
Hereditary Hemorrhagic Telangiectasia0
1
2014201410.0low000010
Heritable Pulmonary Arterial Hypertension0
70
201020239.0low40015415
Hernias, Diaphragmatic, Congenital0
17
200820226.5low100377
Hibernation, Myocardial0
11
1994201915.5low101640
High T4 Syndrome0
3
201020219.0low000111
Hip Fractures0
15
200920236.3low1001122
Hirsutism0
1
2012201212.0low000010
HIV0
2
201820205.0low000020
HIV Coinfection0
30
200220239.7low3007194
HIV Infections0
30
200220239.7low3007194
Hodgkin Disease0
2
2011201511.0low000020
Hookworm Infections0
1
2006200618.0low000100
Human Adenovirus Infections0
1
201520159.0low000010
Hydramnios0
1
2003200321.0low000100
Hydronephrosis0
1
201720177.0low000010
Hydrothorax0
3
2008201313.3low000120
Hyperaldosteronism0
8
1994201916.6low002240
Hypercalcemia0
1
2001200123.0low000100
Hypercapnia0
4
1997201317.5low101210
Hypercholesterolemia0
9
2003202112.3low100432
Hypercoagulability0
2
2001201914.0low100110
Hyperemia0
14
200820229.4low1002102
Hyperglycemia0
16
2000202210.5low201582
Hyperglycemia, Postprandial0
16
2000202210.5low201582
Hyperhidrosis0
2
2005200718.0low100200
Hyperhomocysteinemia0
10
2005202014.0low000730
Hyperidrosis0
2
2005200718.0low100200
Hyperinsulinism0
5
2005202012.0low000140
Hyperkalemia0
8
2005202010.9low300350
Hyperlipemia0
16
2005202013.4low0001060
Hyperlipidemias0
16
2005202013.4low0001060
Hyperlipoproteinemia Type II0
2
2010201710.5low000110
Hypernatremia0
3
201320217.0low100021
Hyperoxia0
3
2007201015.7low000300
Hyperparathyroidism0
2
2009201611.5low000110
Hyperparathyroidism, Primary0
3
2005201316.0low000210
Hyperparathyroidism, Secondary0
1
2009200915.0low000100
Hyperplasia0
1
2011201113.0low000010
Hyperpotassemia0
8
2005202010.9low300350
Hypersensitivity0
2
2009201711.0low100110
Hypertension0
720
1989202314.3low10538128530150
Hypertension, Essential0
9
201420228.2low000081
Hypertension, Malignant0
6
1992201622.3low004020
Hypertension, Portal0
4
2010201810.2low000130
Hypertension, Pregnancy-Induced0
15
201020227.3low1001113
Hypertension, Pulmonary0
502
1994202311.2low5001215529243
Hypertension, Renal0
9
1996201319.3low202520
Hypertension, Renovascular0
12
1997201516.7low201830
Hyperthyroid0
18
2004202314.4low4001341
Hyperthyroidism0
18
2004202314.4low4001341
Hypertriglyceridemia0
1
2007200717.0low000100
Hypertrophy0
46
1992202213.5low00222184
Hypertrophy, Left Ventricular0
361
1995202214.2low4202417215213
Hypertrophy, Right Ventricular0
32
1995202214.3low20414131
Hyperuricemia0
15
200620228.7low400393
Hyperventilation0
2
1994201320.5low101010
Hypoalbuminemia0
4
200620219.2low000121
Hypocalcemia0
1
201620168.0low000010
Hypocapnia0
1
1996199628.0low001000
Hypoglycemia0
3
2007202112.0low200201
Hypokalemia0
3
201520215.7low000021
Hyponatremia0
49
1997202213.3low40320233
Hypoparathyroidism0
1
202020204.0low000010
Hypopituitarism0
2
2012201212.0low100020
Hypoplastic Left Heart Syndrome0
5
2005202212.4low000311
Hypoproteinemia0
1
2008200816.0low000100
Hypotension0
50
1991202311.2low160215258
Hypotension, Orthostatic0
3
2004201811.7low000120
Hypotension, Postural0
3
2004201811.7low000120
Hypothermia0
2
2012201311.5low000020
Hypothermia, Accidental0
2
2012201311.5low000020
Hypothyroidism0
18
2004202311.7low200783
Hypovolemia0
5
201120219.0low100041
Hypovolemic0
5
201120219.0low100041
Hypoxia0
73
1992202314.1low801419337
Hypoxia-Ischemia, Brain0
6
2009202210.7low000141
Idiopathic Hypoparathyroidism0
1
202020204.0low000010
Idiopathic Inflammatory Myopathies0
2
201520225.5low000011
Idiopathic Parkinson Disease0
6
200820208.3low000240
Idiopathic Pulmonary Fibrosis0
7
2009201710.7low100250
Immunoglobulin Light-chain Amyloidosis0
38
201120225.9low5000308
Impaired Glucose Tolerance0
12
2006202010.8low000480
Impotence0
1
201620168.0low000010
Inadequate Sleep0
2
1999201318.0low001010
Inappropriate ADH Syndrome0
5
2000201813.0low001130
Inappropriate GH Secretion Syndrome (Acromegaly)0
8
2007202212.6low000521
Incompetence, Pulmonary Valve0
14
2003202212.2low100761
Infant Malnutrition0
1
2014201410.0low000010
Infant, Newborn, Diseases0
3
2009201213.3low000120
Infant, Premature, Diseases0
26
2002202211.2low3008171
Infant, Small for Gestational Age0
3
2009201910.0low000120
Infantile Respiratory Distress Syndrome0
7
2008201711.9low000340
Infarct0
2
202220222.0low000002
Infarct of the Spleen0
1
201920195.0low000010
Infarct, Lacunar0
3
201520235.3low000021
Infarction, Middle Cerebral Artery0
4
201720234.2low000022
Infection0
6
200420218.7low000132
Infection, Postoperative Wound0
3
2007200915.7low000300
Infections0
6
200420218.7low000132
Infections, Coronavirus0
28
202020204.0low1000280
Infections, Helicobacter0
1
2014201410.0low000010
Infections, Meningococcal0
1
2013201311.0low000010
Infections, Mycobacterium0
1
2009200915.0low000100
Infections, Plasmodium0
1
201920195.0low000010
Infections, Prosthesis-Related0
4
201120189.5low000040
Infections, Pseudomonas0
1
2003200321.0low000100
Infections, Respiratory0
5
2010202110.0low000131
Infections, Respiratory Syncytial Virus0
2
201420197.5low000020
Infections, Staphylococcal0
3
2010201810.7low000120
Infectious Diseases0
2
201520159.0low000020
Infective Endocarditis0
9
201020216.7low000171
Infertility, Male0
1
2011201113.0low000010
Inflammation0
268
2003202310.5low28008115928
Inflammatory Bowel Diseases0
1
2013201311.0low000010
Inflammatory Response Syndrome, Systemic0
28
200420227.1low1006913
Influenza, Human0
6
201220207.2low000060
Inhalation Injury, Smoke0
1
2010201014.0low000100
Injuries0
14
2004202112.7low000761
Injuries, Multiple0
2
2008201512.5low000110
Injuries, Radiation0
11
201020218.9low100191
Injury, Ischemia-Reperfusion0
19
200620239.6low4005131
Injury, Myocardial Reperfusion0
44
2001202112.1low80021221
Innate Inflammatory Response0
268
2003202310.5low28008115928
Insulin Resistance0
64
1995201911.8low110118450
Insulin Sensitivity0
64
1995201911.8low110118450
Intermittent Claudication0
4
201320198.8low100040
Intertrochanteric Fractures0
15
200920236.3low1001122
Intestinal Diseases, Parasitic0
1
2006200618.0low000100
Intestinal Neoplasms0
1
201620168.0low000010
Intestinal Obstruction0
1
2002200222.0low000100
Intracranial Aneurysm0
8
1997202216.5low002321
Intracranial Arteriosclerosis0
2
1997200821.5low001100
Intracranial Hemorrhages0
9
201120206.8low100090
Intracranial Hypertension0
2
2006201115.5low000110
Intraocular Pressure0
4
1996201620.2low002110
Intraventricular Septal Defects0
22
2003202211.6low1008122
Intussusception0
1
202120213.0low000001
Iron Metabolism Disorders0
1
201520159.0low000010
Iron Overload0
8
2006202311.2low100422
Ischemia0
18
2003202211.4low200864
Ischemic Attack, Transient0
26
2005202310.7low1006191
Ischemic Stroke0
26
202020232.4low1000620
Isolated Clinic Hypertension0
3
201620168.0low000030
Isolated Non-compaction of the Ventricular Myocardium0
4
201120217.8low000022
Itching0
11
201320226.6low000083
Joint Pain0
1
2007200717.0low100100
Kahler Disease0
12
200520219.4low100462
Kawasaki Disease0
74
200020238.8low401124912
Kidney Diseases0
156
1996202313.2low190480657
Kidney Diseases, Cystic0
1
2007200717.0low000100
Kidney Failure0
110
2002202113.3low130059501
Kidney Failure, Chronic0
311
1992202313.8low2702013913913
Kidney Neoplasms0
5
2006201912.4low000320
Kidney, Polycystic0
1
2006200618.0low000100
Klinefelter Syndrome0
1
2012201212.0low000010
Koch's Disease0
1
2013201311.0low000010
Labor, Premature0
3
2005201413.0low100120
Lactic Acidosis0
3
200820209.0low100120
Laryngeal Neoplasms0
1
202120213.0low000001
Lassitude0
17
2000202112.4low302681
Leanness0
3
2004201215.7low000210
Left Heart Hypoplasia Syndrome0
5
2005202212.4low000311
Left Sided Breast Cancer0
3
201520216.7low000021
Left Ventricular Dysfunction0
1,314
1994202414.2low16506869148372
Left Ventricular Hypertrophy0
361
1995202214.2low4202417215213
Left Ventricular Outflow Obstruction0
10
2000202011.9low101270
Leishmaniasis, Visceral0
1
201920195.0low000010
Leucocythaemia0
9
2000201716.1low102430
Leukemia0
9
2000201716.1low102430
Leukemia, Biphenotypic, Acute0
1
2012201212.0low000010
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0
5
2006201912.8low000230
Leukemia, Myeloid0
1
2005200519.0low000100
Leukemia, Myeloid, Acute0
4
200520239.5low000121
Leukemia, Promyelocytic, Acute0
1
2010201014.0low000100
Leukoaraiosis0
1
201820186.0low000010
Leukocytosis0
3
201320207.7low000030
Leukomalacia, Periventricular0
1
2002200222.0low000100
Lewy Body Disease0
1
2013201311.0low000010
Libman-Sacks Disease0
18
200720238.6low0004104
Limb-Girdle Muscular Dystrophies0
1
2012201212.0low000010
Limited Scleroderma0
2
201720177.0low000020
Liver Cirrhosis0
51
1992202313.4low10617226
Liver Cirrhosis, Alcoholic0
3
2009201213.7low000210
Liver Cirrhosis, Biliary0
1
202120213.0low000001
Liver Diseases0
10
2008202110.1low000361
Liver Dysfunction0
10
2008202110.1low000361
Liver Failure0
4
2004201216.2low000310
Liver Neoplasms0
6
1997201817.0low002220
Liver Steatosis0
3
200620218.7low000111
Local Neoplasm Recurrence0
1
2005200519.0low100100
Long QT Syndrome0
9
200620218.9low000252
Long Sleeper Syndrome0
2
2008202010.0low000110
Low Back Ache0
1
2008200816.0low000100
Low Back Pain0
1
2008200816.0low000100
Lung Adenocarcinoma0
1
201820186.0low000010
Lung Diseases0
60
1994202015.1low30434220
Lung Diseases, Interstitial0
19
2005202112.4low0001072
Lung Diseases, Obstructive0
10
1992200724.2low006400
Lung Injury, Acute0
15
2008201711.8low0005100
Lung Neoplasms0
40
1999202311.8low40116203
Lupus Erythematosus, Chronic Cutaneous0
1
202020204.0low000010
Lupus Erythematosus, Discoid0
1
202020204.0low000010
Lupus Erythematosus, Systemic0
18
200720238.6low0004104
Lupus Nephritis0
1
202120213.0low000001
Lymph Node Metastasis0
2
201020218.5low000101
Lymphedema0
4
201120224.8low000013
Lymphocytopenia0
4
200920226.2low100121
Lymphohistiocytosis, Hemophagocytic0
1
202120213.0low000001
Lymphoma0
5
2000201713.8low101130
Lymphoma, B-Cell0
3
2006200817.3low200300
Lymphoma, Follicular0
1
2005200519.0low100100
Lymphoma, Large B-Cell, Diffuse0
4
2006201912.2low200220
Lymphoma, Non-Hodgkin0
11
1999202015.7low201550
Lymphopenia0
4
200920226.2low100121
Lymphoproliferative Disorders0
2
2005201215.5low000110
Macrophage Activation Syndrome0
1
202020204.0low000010
Malaria0
1
201920195.0low000010
Malaria, Falciparum0
2
2004201813.0low000110
Malignant Hypertension0
6
1992201622.3low004020
Malignant Melanoma0
1
202120213.0low000001
Malignant Mesothelioma0
3
201820204.7low000030
Malnourishment0
21
2004202210.0low0006141
Malnutrition0
21
2004202210.0low0006141
Marasmus0
1
2009200915.0low000100
Marchiafava-Micheli Syndrome0
2
2010201213.0low100110
Marfan Syndrome0
5
201320198.8low000050
Marfan Syndrome, Type I0
5
201320198.8low000050
Masked Hypertension0
1
202020204.0low000010
Maternal Death0
1
201820186.0low000010
Meconium Aspiration Syndrome0
1
2011201113.0low100010
Melanoma0
1
202120213.0low000001
Meniere Disease0
2
2002201714.5low100110
Meningeal Neoplasms0
1
201620168.0low000010
Meningioma0
2
201620206.0low000020
Meningitis, Tuberculous0
1
201820186.0low000010
Meningococcal Infections0
1
2013201311.0low000010
Menopause0
2
201520168.5low000020
Menopause, Premature0
2
201520168.5low000020
Mental Disorders0
4
2010201811.0low000130
Mesothelioma0
1
201820186.0low000010
Metabolic Acidosis0
1
201920195.0low000010
Metabolic Diseases0
2
201620196.5low000020
Metabolic Syndrome0
50
2005202110.5low60012353
Metastase0
5
2006201911.2low100230
Migraine Disorders0
3
2011201610.0low000030
Migraine with Aura0
2
201620206.0low000020
Milk-Alkali Syndrome0
1
2001200123.0low000100
Mitochondrial Diseases0
3
201620215.3low000021
Mitral Incompetence0
152
1997202312.0low90360836
Mitral Stenosis0
34
1992202115.1low20513142
Mitral Valve Insufficiency0
152
1997202312.0low90360836
Mitral Valve Stenosis0
34
1992202115.1low20513142
MODS0
8
200620219.8low000341
Morbid Obesity0
18
2003202110.4low1004122
Mouth Neoplasms0
1
202020204.0low000010
MS (Multiple Sclerosis)0
5
2008202012.0low100320
Mucocutaneous Lymph Node Syndrome0
74
200020238.8low401124912
Mulibrey Nanism0
1
2009200915.0low000100
Multiple Myeloma0
12
200520219.4low100462
Multiple Organ Failure0
8
200620219.8low000341
Multiple Sclerosis0
5
2008202012.0low100320
Muscle Contraction0
10
1991201817.3low002530
Muscle Cramp0
1
201720177.0low100010
Muscle Disorders0
2
200920209.5low000110
Muscle Relaxation0
13
1988201824.2low018220
Muscle Spasm0
1
202220222.0low000001
Muscle Weakness0
2
2003200619.5low000200
Muscular Atrophy0
5
2004202112.4low000311
Muscular Diseases0
2
200920209.5low000110
Muscular Dystrophies0
7
1996202117.7low003211
Muscular Dystrophies, Limb-Girdle0
1
2012201212.0low000010
Muscular Dystrophy0
7
1996202117.7low003211
Muscular Dystrophy, Duchenne0
16
2001202014.2low200790
Muscular Weakness0
2
2003200619.5low000200
Musculoskeletal Pain0
1
201920195.0low000010
Myasthenia Gravis0
1
2011201113.0low000010
Mycobacterium Infections0
1
2009200915.0low000100
Mycoplasma dispar Infection0
1
2013201311.0low000010
Myelodysplastic Syndromes0
4
1998201912.5low001030
Myeloproliferative Disorders0
2
201720196.0low000020
Myocardial Infarction0
988
1991202313.5low14005943743260
Myocardial Ischemia0
325
1994202213.9low410121631437
Myocarditis0
66
199520229.9low001173414
Myoglobinuria0
1
2013201311.0low000010
Myositis0
2
201520225.5low000011
Myositis, Multiple0
3
201120217.0low000021
Myotonic Dystrophy0
3
201620196.7low000030
Nanism0
1
2003200321.0low000100
Nasal Polyps0
1
201620168.0low000010
Neck Pain0
1
202220222.0low000001
Necrosis0
32
2001202015.5low20022100
Necrotizing Enterocolitis0
3
201720186.7low000030
Negativistic Personality Disorder0
1
2010201014.0low000100
Neonatal Death0
2
201420188.0low000020
Neonatal Early-Onset Sepsis0
1
202220222.0low000001
Neonatal Sepsis0
1
202220222.0low000001
Neoplasm Metastasis0
5
2006201911.2low100230
Neoplasm Metastasis, Unknown Primary0
1
2009200915.0low100100
Neoplasms0
83
1990202310.5low60123509
Neoplasms, Germ Cell and Embryonal0
1
2009200915.0low100100
Neoplasms, Nervous System0
1
1991199133.0low001000
Neoplasms, Pleural0
1
2008200816.0low100100
Nephrosclerosis0
1
2011201113.0low000010
Nephrotic Syndrome0
3
1991200624.3low001200
Nerve Degeneration0
1
2010201014.0low000100
Nerve Pain0
1
201620168.0low000010
Nervous System Diseases0
4
1993201815.5low001120
Nervous System Disorders0
4
1993201815.5low001120
Neuralgia0
1
201620168.0low000010
Neurally Mediated Faint0
4
1996201417.0low001120
Neuroblastoma0
4
1990200031.0low004000
Neurodegenerative Diseases0
1
201820186.0low000010
Neuroendocrine Tumors0
4
200920189.8low000130
Neuroleptic Malignant Syndrome0
1
2007200717.0low000100
Neuromuscular Diseases0
1
201920195.0low000010
Neutropenia0
2
2010201113.5low000110
No-Reflow Phenomenon0
6
201020219.7low000231
Nocturia0
10
2007202110.2low000181
Nocturnal Enuresis0
4
2008201711.5low000130
Non-alcoholic Fatty Liver Disease0
5
201520206.2low000050
Non-ST Elevated Myocardial Infarction0
11
201620215.5low100083
Non-ST-Elevation Myocardial Infarction0
11
201620215.5low100083
Noonan Syndrome0
2
2009201910.0low000110
Nycturia0
10
2007202110.2low000181
Obesity0
172
1998202311.7low1802629414
Obesity, Morbid0
18
2003202110.4low1004122
Obstructive Lung Diseases0
10
1992200724.2low006400
Ocular Hypertension0
1
201620168.0low000010
Ocular Hypotension0
2
1996200424.0low001100
Oligohydramnios0
1
2003200321.0low000100
Oligomenorrhea0
1
2012201212.0low000010
Oliguria0
4
2005201712.8low000220
Organophosphate Poisoning0
4
201920223.2low000022
Organophosphorus Poisoning0
4
201920223.2low000022
Ornithosis0
1
202220222.0low000001
Orphan Diseases0
2
2007201911.0low000110
Orthostatic Intolerance0
1
201720177.0low000010
Osteoarthritis0
6
2005202113.3low100321
Osteogenic Sarcoma0
1
2007200717.0low000100
Osteoporosis0
2
201420216.5low000011
Osteoporosis, Postmenopausal0
1
2003200321.0low000100
Osteoporotic Fractures0
2
201920204.5low000020
Osteosarcoma0
1
2007200717.0low000100
Out-of-Hospital Cardiac Arrest0
5
201620224.8low100032
Ovarian Neoplasms0
4
1994201018.8low101300
Overweight0
14
2005202310.6low3003101
Pain0
5
2007201912.4low100320
Pain, Chronic0
1
201520159.0low000010
Pain, Postoperative0
4
2004202113.8low300211
Pain, Procedural0
1
201820186.0low000010
Palmoplantaris Pustulosis0
4
201520224.5low000022
Pancreatic Insufficiency0
1
201720177.0low000010
Pancreatic Neoplasms0
1
201620168.0low000010
Pancreatitis0
5
201220234.8low100023
Panic Attacks0
1
2007200717.0low000100
Panic Disorder0
1
2007200717.0low000100
Paraproteinemias0
1
2011201113.0low000010
Parasitemia0
1
2003200321.0low000100
Parkinson Disease0
6
200820208.3low000240
Parodontosis0
1
201720177.0low000010
Paroxysmal Reciprocal Tachycardia0
7
2005201613.9low000520
Patency of the Ductus Arteriosus0
71
1999202311.3low90123443
Patent Foramen Ovale0
3
201620234.7low000021
Perforated Appendicitis0
1
202120213.0low000001
Pericardial Effusion0
26
1998202213.5low10111122
Pericarditis0
4
201420224.5low000022
Pericementitis0
2
201420188.0low000020
Periodontal Diseases0
1
201720177.0low000010
Periodontitis0
2
201420188.0low000020
Peripheral Arterial Disease0
35
201120237.8low1000296
Peripheral Arterial Diseases0
35
201120237.8low1000296
Peripheral Nerve Diseases0
2
202320231.0low000002
Peripheral Nervous System Diseases0
2
202320231.0low000002
Peripheral Vascular Diseases0
8
2006201415.8low000710
Peritoneal Carcinomatosis0
1
201820186.0low000010
Peritoneal Diseases0
1
2014201410.0low100010
Peritoneal Neoplasms0
1
201820186.0low000010
Peritonitis0
1
202020204.0low000010
Persistent Fetal Circulation Syndrome0
7
2004202012.3low000250
Pheochromocytoma0
4
1991202119.8low102011
Pheochromocytoma, Extra-Adrenal0
4
1991202119.8low102011
Phlegmasia Alba Dolens0
1
2008200816.0low000100
Phosphorus Metabolism Disorders0
1
2005200519.0low000100
Pink Eye0
1
202120213.0low000001
Pituitary ACTH Hypersecretion0
1
2009200915.0low000100
Pituitary Diseases0
1
2005200519.0low000100
Pituitary Neoplasms0
2
2007201712.0low000110
Placenta Accreta0
2
201620215.5low000011
Placenta Increta0
2
201620215.5low000011
Placenta Praevia0
1
201620168.0low000010
Placenta Previa0
1
201620168.0low000010
Placental Insufficiency0
2
2007201314.0low000110
Plasmodium falciparum Malaria0
2
2004201813.0low000110
Pleural Effusion0
46
2004202312.7low20023212
Pleural Effusion, Malignant0
7
2006201613.4low000430
Pleurisy, Tuberculous0
2
2008201015.0low000200
Pleuropericarditis0
4
201420224.5low000022
Pneumonia0
47
2002202310.0low40011315
Pneumonia, Bacterial0
1
201620168.0low000010
Pneumonia, Pneumococcal0
2
2013201510.0low000020
Pneumonia, Ventilator-Associated0
1
2014201410.0low000010
Pneumonia, Viral0
28
202020204.0low1000280
Pneumothorax0
1
201520159.0low000010
Pneumothorax, Primary Spontaneous0
1
201520159.0low000010
POEMS Syndrome0
1
2009200915.0low000100
Poisoning0
4
2005201711.2low000130
Polyarthritis0
4
201320218.8low100031
Polycystic Kidney Diseases0
1
2006200618.0low000100
Polycystic Kidney, Autosomal Dominant0
3
1996202014.7low101020
Polycystic Kidney, Autosomal Recessive0
1
201720177.0low000010
Polycystic Ovarian Syndrome0
5
2007201911.2low000140
Polycystic Ovary Syndrome0
5
2007201911.2low000140
Polymyositis0
3
201120217.0low000021
Polyneuropathies0
1
2013201311.0low000010
Polyneuropathy, Acquired0
1
2013201311.0low000010
Polyuria0
9
2005201911.8low000270
Post-operative Vasoplegic Syndrome0
1
202120213.0low000001
Postoperative Complications0
244
1994202311.2low33018513721
Postpartum Amenorrhea0
1
2011201113.0low100010
Pre-Eclampsia0
61
1992202210.2low3059389
Pre-Hypertension0
1
201720177.0low000010
Precordial Catch0
74
2003202112.7low90033374
Precursor Cell Lymphoblastic Leukemia-Lymphoma0
9
2006201911.7low100270
Prediabetes0
11
201120236.1low300065
Prediabetic State0
11
201120236.1low300065
Pregnancy0
255
1992202311.5low60236013834
Pregnancy in Diabetes0
7
1995202117.9low002401
Premature Birth0
7
201120216.9low100061
Premenstrual Syndrome0
2
1997201120.0low101010
Premenstrual Tension0
2
1997201120.0low101010
Preterm Birth0
7
201120216.9low100061
Priapism0
1
2010201014.0low000100
Primary Graft Dysfunction0
2
201620187.0low000020
Primary Hyperparathyroidism0
3
2005201316.0low000210
Primary Myelofibrosis0
1
202020204.0low000010
Primary Peritonitis0
1
202020204.0low000010
Primate Diseases0
1
202020204.0low000010
Prinzmetal Angina0
2
1994201121.5low001010
Prostatic Hyperplasia0
1
2005200519.0low000100
Prostatic Neoplasms0
9
200520218.0low200324
Prostatitis0
2
201220198.5low000020
Prosthesis Durability0
3
201320169.3low000030
Protein-Energy Malnutrition0
1
2009200915.0low000100
Protein-Losing Enteropathies0
2
2006201513.5low000110
Proteinuria0
17
2004202211.1low2004121
Pruritus0
11
201320226.6low000083
Pseudohypoparathyroidism0
2
201620206.0low000020
Pseudomonas Infections0
1
2003200321.0low000100
Pseudotumor Cerebri0
1
2010201014.0low000100
Psittacosis0
1
202220222.0low000001
Psoriasis0
4
201520224.5low000022
Psoriasis Arthropathica0
2
201920223.5low000011
Psychomotor Agitation0
1
2014201410.0low000010
Puerperal Disorders0
8
2006202211.0low000431
Pulmonary Arterial Hypertension0
56
201920233.0low40002432
Pulmonary Arterial Remodeling0
18
201420216.7low0000153
Pulmonary Consumption0
3
2009201512.3low000120
Pulmonary Disease, Chronic Obstructive0
148
2001202310.9low800429511
Pulmonary Edema0
102
1993202212.7low80147495
Pulmonary Embolism0
243
1997202311.7low19019213317
Pulmonary Fibrosis0
7
2003201614.9low100340
Pulmonary Hypertension0
502
1994202311.2low5001215529243
Pulmonary Sarcoidosis0
5
2007201613.0low000230
Pulmonary Stenoses0
8
2003202012.8low100440
Pulmonary Veno Occlusive Disease0
3
201220198.0low000030
Pulmonary Veno-Occlusive Disease0
3
201220198.0low000030
Pulsatile Tinnitus0
1
2011201113.0low000010
Purpura, Thrombotic Thrombocytopenic0
1
202220222.0low000001
Pyrexia0
17
199920239.4low002285
Raynaud Disease0
1
2003200321.0low000100
Recrudescence0
127
2000202311.7low2102486512
Rectal Diseases0
2
201920204.5low100020
Reflex, Abnormal0
2
2003201714.0low000110
Remission, Spontaneous0
4
2003201116.0low000310
Renal Artery Obstruction0
12
2005201514.1low200750
Renal Artery Stenosis0
12
2005201514.1low200750
Renal Insufficiency0
110
2002202113.3low130059501
Renal Insufficiency, Chronic0
183
200520237.8low21001514028
Reperfusion Injury0
19
200620239.6low4005131
Respiration Disorders0
7
2004201316.7low000610
Respiratory Distress Syndrome0
46
2002202311.5low50020206
Respiratory Distress Syndrome, Newborn0
7
2008201711.9low000340
Respiratory Insufficiency0
45
1997202113.9low30219222
Respiratory Sounds0
3
2008201213.7low000120
Respiratory Syncytial Virus Infections0
2
201420197.5low000020
Respiratory Tract Diseases0
12
1996201713.2low001470
Respiratory Tract Infections0
5
2010202110.0low000131
Retinal Diseases0
2
201620225.0low000011
Retinopathy of Prematurity0
4
201120236.8low000031
Retrolental Fibroplasia0
4
201120236.8low000031
Rhabdomyolysis0
3
2006200916.0low000300
Rhabdomyosarcoma0
1
2000200024.0low101000
Rheumatic Diseases0
4
2012201810.5low000040
Rheumatic Heart Disease0
15
2004202113.2low000951
Rheumatism0
4
2012201810.5low000040
Rheumatoid Arthritis0
40
2005202310.9low40012253
Rhinitis, Allergic0
1
201620168.0low000010
Right Ventricular Dysfunction0
218
1998202312.7low260210310211
Rotavirus Infections0
1
201520159.0low000010
Rupture, Spontaneous0
1
2014201410.0low000010
Sarcoidosis0
15
200520229.4low000564
Sarcoidosis, Pulmonary0
5
2007201613.0low000230
Sarcopenia0
6
201620206.7low000060
Schistosomiasis0
1
2010201014.0low000100
Schizophrenia0
2
2007201513.0low100110
Scleroderma, Diffuse0
4
201720196.0low000040
Scleroderma, Limited0
2
201720177.0low000020
Scleroderma, Localized0
1
2012201212.0low000010
Scleroderma, Systemic0
71
2003202211.2low10028376
Sclerosis0
2
2010201312.5low000110
Sclerosis, Systemic0
71
2003202211.2low10028376
Secondary Hyperparathyroidism0
1
2009200915.0low000100
Seizures0
7
2005202010.4low000340
Seizures, Febrile0
2
2007201513.0low000110
Sensitivity and Specificity0
1,016
1993202314.6low9102657740211
Sepsis0
138
200420239.7low700358815
Severe Acute Malnutrition0
1
202020204.0low000010
Severe Combined Immunodeficiency0
1
2003200321.0low000100
Severe Dengue0
1
202220222.0low000001
Shock0
18
2000202114.1low3011061
Shock, Cardiogenic0
51
2005202310.6low40015315
Shock, Septic0
86
1994202111.8low70135473
Sicca Syndrome0
2
2010201611.0low000110
Sick Sinus Node Syndrome0
16
2000201714.9low601780
Siderosis0
1
2008200816.0low100100
Silicosis0
1
2014201410.0low100010
Sinus Tachycardia0
3
2006201216.0low000210
Sjogren's Syndrome0
2
2010201611.0low000110
Skin Neoplasms0
1
202120213.0low000001
Skin Ulcer0
1
201920195.0low000010
Sleep Apnea Syndromes0
45
1998202212.6low100120213
Sleep Apnea, Central0
17
2003202213.1low600971
Sleep Apnea, Obstructive0
64
2005202311.2low140020422
Sleep Initiation and Maintenance Disorders0
1
2008200816.0low100100
Sleep Wake Disorders0
2
2008202010.0low000110
Small Cell Lung Carcinoma0
2
2008201413.0low000110
Smoking Cessation0
5
2006201314.2low000320
Snoring0
8
2004202411.9low100341
Spasm0
1
202220222.0low000001
Spherocytosis, Hereditary0
1
2011201113.0low000010
Spinal Stenosis0
2
200820238.5low000101
Spondylitis, Ankylosing0
2
2013201311.0low000020
Sprains0
1
1998199826.0low001000
Sprains and Strains0
1
1998199826.0low001000
Squamous Cell Carcinoma of Head and Neck0
1
202120213.0low000001
ST Elevated Myocardial Infarction0
69
201620235.1low160004920
ST Elevation Myocardial Infarction0
69
201620235.1low160004920
Staphylococcal Infections0
3
2010201810.7low000120
Starvation0
1
1998199826.0low101000
Sterility, Male0
1
2011201113.0low000010
Stillbirth0
1
202120213.0low000001
Stomach Neoplasms0
4
2001202210.0low100121
Streptococcal Infections0
1
2009200915.0low000100
Stress Disorders, Post-Traumatic0
3
201220207.7low000030
Stroke0
306
199920239.5low36016720236
Stunted Growth0
2
2006201414.0low000110
Subarachnoid Hemorrhage0
43
1994202215.6low00717163
Substance Withdrawal Syndrome0
2
1995201917.0low001010
Substance-Related Disorders0
2
1996202115.5low001001
Suffocation0
3
2010201611.3low000120
Superior Vena Cava Obstruction0
1
2004200420.0low000100
Symptom Cluster0
80
2002202416.2low90062153
Syncope0
29
2003202210.9low0009182
Syndrome0
80
2002202416.2low90062153
Systemic Inflammatory Response Syndrome0
28
200420227.1low1006913
Systolic Heart Failure0
154
2006202211.2medium3300548911
Tachyarrhythmia0
39
1997202312.4low40414183
Tachycardia0
39
1997202312.4low40414183
Tachycardia, Paroxysmal0
7
2005201613.9low000520
Tachycardia, Supraventricular0
12
1992202113.3low101461
Tachycardia, Ventricular0
52
1998202312.1low140217285
Tachypnea0
2
202120213.0low000002
Takayasu Arteritis0
2
201420159.5low000020
Takotsubo Cardiomyopathy0
67
200820229.1low4006583
Telangiectasia, Hereditary Hemorrhagic0
1
2014201410.0low000010
Temporomandibular Disorders0
1
2004200420.0low000100
Temporomandibular Joint Disorders0
1
2004200420.0low000100
Teratoma0
3
1994201814.3low001020
Testicular Neoplasms0
2
2009201114.0low000110
Tetralogy of Fallot0
48
2003202212.6low80023241
Thalassemia0
1
2008200816.0low100100
Thalassemias0
1
2008200816.0low100100
Thiamine Deficiency0
1
2014201410.0low000010
Thoracic Neoplasms0
2
201420207.0low100020
Thrombocythemia, Essential0
1
201520159.0low100010
Thrombocytopenia0
2
201920214.0low100011
Thromboembolism0
38
2002202211.6low90013232
Thromboembolism, Venous0
9
201020228.7low000171
Thrombopenia0
2
201920214.0low100011
Thrombophilia0
2
2001201914.0low100110
Thrombophlebitis0
1
2008200816.0low000100
Thrombosis0
36
200620238.4low5006228
Thymus Neoplasms0
1
2008200816.0low000100
Thyroid Diseases0
3
2004201215.3low000210
Thyroid Neoplasms0
2
201620177.5low000020
Thyroiditis0
1
202120213.0low000001
Thyrotoxicosis0
3
200920208.3low000120
Tick Infestations0
1
201620168.0low000010
Tick Paralysis0
1
201620168.0low000010
Tinnitus0
1
2011201113.0low000010
Tooth Loss0
3
201720224.0low100012
Transfusion Reaction0
7
2005201911.9low000340
Transient Tachypnea of Newborn0
5
201220237.6low100041
Transposition of Great Vessels0
30
2002201912.0low40012180
Tricuspid Incompetence0
37
2003202210.0low20011215
Tricuspid Valve Stenosis0
1
2004200420.0low000100
Tuberculosis0
1
2013201311.0low000010
Tuberculosis, Meningeal0
1
201820186.0low000010
Tuberculosis, Pulmonary0
3
2009201512.3low000120
Turner Syndrome0
4
2006201512.8low100130
Uremia0
10
2004201714.0low300550
Ureteral Obstruction0
2
2002201515.5low000110
Urinary Bladder Neoplasms0
2
201120218.0low100011
Urinary Bladder, Overactive0
1
2007200717.0low000100
Urinary Tract Diseases0
1
2013201311.0low000010
Urinary Tract Infections0
1
201620168.0low000010
Vascular Calcification0
13
201220207.8low0000130
Vascular Diseases0
20
1999202212.5low101883
Vasculitis0
4
2004201913.2low000220
Vasospasm, Intracranial0
9
2000201218.9low001620
Venous Insufficiency0
4
201120224.8low100013
Venous Thromboembolism0
9
201020228.7low000171
Venous Thrombosis0
16
2004202010.8low2005110
Ventilator-Associated Pneumonia0
1
2014201410.0low000010
Ventricular Dysfunction0
82
1996202215.0low130449272
Ventricular Dysfunction, Left0
1,314
1994202414.2low16506869148372
Ventricular Fibrillation0
18
2006202111.7low100792
Ventricular Flutter0
1
2009200915.0low000100
Viral Diseases0
3
2000202013.3low001020
Viremia0
1
202120213.0low000001
Virus Diseases0
3
2000202013.3low001020
Vitamin B 12 Deficiency0
1
201520159.0low000010
Vitamin D Deficiency0
16
200920229.0low2004111
Vitamin K Deficiency0
1
2014201410.0low100010
Vomiting0
1
202120213.0low000001
Wasting Disease0
5
2005201912.0low000230
Water Intoxication0
3
2001202315.0low000201
Water-Electrolyte Imbalance0
47
1994202210.4low70111296
Weight Gain0
16
2003202210.0low7003121
Weight Loss0
35
2003202110.9low120010205
Weight Reduction0
35
2003202110.9low120010205
Wolff-Parkinson-White Syndrome0
3
2008201710.3low000120
Wounds and Injuries0
14
2004202112.7low000761

Safety/Toxicity (214)

ArticleYear
Efficacy and safety of Zhenyuan capsule in the treatment of chronic heart failure: A meta-analysis and trial sequential analysis.
Medicine, , Sep-08, Volume: 102, Issue:36		2023
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Scientific reports, , 08-07, Volume: 13, Issue:1		2023
Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
International journal of cardiology, , 07-01, Volume: 382		2023
Efficacy and safety evaluation of Shenmai injections for dilated cardiomyopathy: A systematic review and meta-analysis of randomised controlled trials.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , Volume: 110		2023
Continuous Renal Replacement Therapy for Hypertension Complicated by Refractory Heart Failure: An Analysis of Safety and Nursing Highlights.
Computational and mathematical methods in medicine, , Volume: 2022		2022
Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C-Related Dilated Cardiomyopathy.
The American journal of cardiology, , 11-15, Volume: 183		2022
Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
Journal of clinical pharmacy and therapeutics, , Volume: 47, Issue:10		2022
Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure.
Journal of cardiac failure, , Volume: 28, Issue:8		2022
Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT.
Journal of the American Heart Association, , 03-15, Volume: 11, Issue:6		2022
Evaluation of Ibrutinib Cardiotoxicity By Comparative Use of Speckle-Tracking Technique and Biomarkers.
American journal of therapeutics, , Volume: 29, Issue:1
Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments.
Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, , Dec-31, Volume: 36, Issue:4		2021
Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
BMC cancer, , Oct-18, Volume: 21, Issue:1		2021
Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects.
European journal of preventive cardiology, , 08-09, Volume: 28, Issue:9		2021
Effectiveness and Safety of Intravenous Nicorandil Application in Patients With Acute Heart Failure With Low Baseline Blood Pressure.
Heart, lung & circulation, , Volume: 31, Issue:1		2022
Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up.
Circulation. Cardiovascular imaging, , Volume: 14, Issue:6		2021
Circulating Biomarkers for Cardiotoxicity Risk Prediction.
Current treatment options in oncology, , 04-17, Volume: 22, Issue:6		2021
Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques.
Current problems in cardiology, , Volume: 46, Issue:6		2021
Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial.
European heart journal. Cardiovascular pharmacotherapy, , 02-16, Volume: 8, Issue:2		2022
Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study.
Immunological investigations, , Volume: 51, Issue:4		2022
Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.
Disease markers, , Volume: 2020		2020
Effectiveness and safety of Xinyin tablet in treatment of chronic heart failure: A protocol of systematic review and meta-analysis of randomized controlled trials.
Medicine, , Dec-18, Volume: 99, Issue:51		2020
Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University, , Volume: 29, Issue:11		2020
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
American heart journal, , Volume: 232		2021
Scorpion sting: N-terminal fragment of proB-type natriuretic peptide as an early predictor of pediatric cardiotoxicity.
Human & experimental toxicology, , Volume: 40, Issue:5		2021
Markers of Cardiotoxicity in Early Breast Cancer Patients Treated With a Hypofractionated Schedule: A Prospective Study.
Clinical breast cancer, , Volume: 21, Issue:3		2021
NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Breast (Edinburgh, Scotland), , Volume: 54		2020
Cardiac serum marker alterations after intraoperative radiotherapy with low-energy x-rays in early breast cancer as an indicator of possible cardiac toxicity.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 197, Issue:1		2021
Risk Factors for Cardiac Adverse Events in Infants and Children with Complex Heart Disease Scheduled for Bi-ventricular Repair: Prognostic Value of Pre-operative B-Type Natriuretic Peptide and High-Sensitivity Troponin T.
Pediatric cardiology, , Volume: 41, Issue:8		2020
Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Journal of healthcare engineering, , Volume: 2020		2020
Current Possibilities of Early Detection of Cardiotoxicity of Cytostatic Treatment.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Spring, Volume: 33, Issue:3		2020
Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
BMC cardiovascular disorders, , 07-17, Volume: 20, Issue:1		2020
Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.
Cardiovascular journal of Africa, , Volume: 31, Issue:4
A multi-center, randomized, double-blind, placebo-parallel controlled trial for the efficacy and safety of shenfuqiangxin pills in the treatment of chronic heart failure (Heart-Kidney yang deficiency syndrome).
Medicine, , May-22, Volume: 99, Issue:21		2020
GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Archives of toxicology, , Volume: 94, Issue:6		2020
[Сurrent views on predictors and biomarkers of early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer (review of literature).]
Klinicheskaia laboratornaia diagnostika, , Volume: 65, Issue:3		2020
Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
ESC heart failure, , Volume: 7, Issue:2		2020
Non-Invasive Hemodynamic Whole-Body Bioimpedance Indices for the Early Detection of Cancer Treatment-Related Cardiotoxicity: A Retrospective Observational Study.
Cardiology, , Volume: 145, Issue:6		2020
Predictive Value of Electromechanical Activation Time for In-Hospital Major Cardiac Adverse Events in Heart Failure Patients.
Cardiovascular therapeutics, , Volume: 2020		2020
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Drug discoveries & therapeutics, , Volume: 13, Issue:6		2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Circulation, , 01-14, Volume: 141, Issue:2		2020
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.
European journal of heart failure, , Volume: 22, Issue:2		2020
Assessment of Pregabalin-Induced Cardiotoxicity in Rats: Mechanistic Role of Angiotensin 1-7.
Cardiovascular toxicology, , Volume: 20, Issue:3		2020
The Safety and Hemodynamic Effects of Pneumatic Sleeves in Patients with Severe Left Ventricular Dysfunction.
The Israel Medical Association journal : IMAJ, , Volume: 21, Issue:10		2019
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
European journal of heart failure, , Volume: 21, Issue:11		2019
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
European journal of heart failure, , Volume: 21, Issue:11		2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
JACC. Heart failure, , Volume: 7, Issue:9		2019
Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Trials, , Jul-15, Volume: 20, Issue:1		2019
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Heart failure reviews, , Volume: 24, Issue:5		2019
Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
European journal of haematology, , Volume: 102, Issue:6		2019
Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction　- The CIBIS-J Trial.
Circulation journal : official journal of the Japanese Circulation Society, , 05-24, Volume: 83, Issue:6		2019
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Medicine, , Volume: 98, Issue:13		2019
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
British journal of clinical pharmacology, , Volume: 85, Issue:6		2019
The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, , Volume: 23, Issue:7		2018
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Cardiovascular research, , 04-15, Volume: 115, Issue:5		2019
The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Medicine, , Volume: 97, Issue:41		2018
[The role of biochemical markers with special regard to troponin, CK-MB, NT-proBNP as early biomarkers of cardiotoxicity among women after chemotherapy due to breast cancer].
Przeglad lekarski, , Volume: 73, Issue:6
Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
International journal of cardiology, , 08-01, Volume: 264		2018
Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial.
BMJ open, , 02-14, Volume: 8, Issue:2		2018
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
European journal of heart failure, , Volume: 20, Issue:7		2018
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Breast cancer research and treatment, , Volume: 168, Issue:3		2018
Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial.
American heart journal, , Volume: 194		2017
[Perioperative safety of Tibetan children with congenital heart disease undergoing cardiac surgery and anesthesia in low-altitude area].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Nov-28, Volume: 42, Issue:11		2017
Parathyroid hormone, calcidiol, calcitriol and adverse events in the acute coronary syndrome.
Medicina intensiva, , Volume: 42, Issue:2		2018
Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1 Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D).
Journal of the American Heart Association, , Oct-24, Volume: 6, Issue:10		2017
Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
Trials, , Oct-10, Volume: 18, Issue:1		2017
Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Respiratory medicine, , Volume: 131		2017
The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
European journal of heart failure, , Volume: 19, Issue:12		2017
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
JAMA cardiology, , 09-01, Volume: 2, Issue:9		2017
[Effects of dexmedetomidine on perioperative cardiac adverse events in elderly patients with 
coronary heart disease].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , May-28, Volume: 42, Issue:5		2017
[Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with severe heart failure: a prospective multicenter clinical study].
Zhonghua wei zhong bing ji jiu yi xue, , Volume: 29, Issue:6		2017
Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, , Volume: 19, Issue:3		2017
High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Breast cancer (Tokyo, Japan), , Volume: 24, Issue:6		2017
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Journal of cardiology, , Volume: 70, Issue:3		2017
Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
Yonsei medical journal, , Volume: 58, Issue:1		2017
Role of biomarkers in monitoring antiblastic cardiotoxicity.
Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 17 Suppl 1 Special issue on Cardiotoxicity fr		2016
[Predictive value of proteinuria for in-hospital severe adverse events and prognosis of the patients with heart failure].
Zhonghua yi xue za zhi, , Aug-09, Volume: 96, Issue:30		2016
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
JAMA oncology, , Aug-01, Volume: 2, Issue:8		2016
A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Arquivos brasileiros de cardiologia, , Volume: 107, Issue:1		2016
A simple sarcopenia screening test predicts future adverse events in patients with heart failure.
International journal of cardiology, , Jul-15, Volume: 215		2016
The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.
Journal of cardiac failure, , Volume: 22, Issue:6		2016
Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies.
Journal of cardiac failure, , Volume: 22, Issue:6		2016
Prospective evaluation of Doppler echocardiography, tissue Doppler imaging and biomarkers measurement for the detection of doxorubicin-induced cardiotoxicity in dogs: A pilot study.
Research in veterinary science, , Volume: 105		2016
Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial.
American journal of respiratory and critical care medicine, , 10-15, Volume: 194, Issue:8		2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-
European journal of cancer (Oxford, England : 1990), , Volume: 58		2016
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
The oncologist, , Volume: 21, Issue:4		2016
Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats.
BMC complementary and alternative medicine, , Feb-11, Volume: 16		2016
2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers.
International journal of toxicology, , Volume: 35, Issue:3		2016
Carbohydrate-antigen-125 levels predict hospital stay duration and adverse events at long-term follow-up in Takotsubo cardiomyopathy.
Internal and emergency medicine, , Volume: 11, Issue:5		2016
Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials.
BMJ open, , Jan-06, Volume: 6, Issue:1		2016
Natriuretic Peptides as Cardiovascular Safety Biomarkers in Rats: Comparison With Blood Pressure, Heart Rate, and Heart Weight.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 149, Issue:2		2016
Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, , Volume: 37, Issue:3		2016
[Efficacy and safety of delayed thrombolytic therapy for acute massive pulmonary throboembolism].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, , Volume: 38, Issue:4		2015
Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Clinical chemistry, , Volume: 61, Issue:9		2015
Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.
Current cardiology reports, , Volume: 17, Issue:7		2015
New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, , Volume: 20, Issue:2		2015
Increased Transforming Growth Factor-β Levels Associated With Cardiac Adverse Events in Hypertrophic Cardiomyopathy.
Clinical cardiology, , Volume: 38, Issue:6		2015
NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Disease markers, , Volume: 2015		2015
Acute cardiotoxicity evaluation of the marine biotoxins OA, DTX-1 and YTX.
Toxins, , Mar-27, Volume: 7, Issue:4		2015
The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.
Experimental oncology, , Volume: 37, Issue:1		2015
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.
COPD, , Volume: 12, Issue:5		2015

Long-term Use (22)

ArticleYear
Statin reload before off-pump coronary artery bypass graft: Effect on biomarker release kinetics.
Annals of cardiac anaesthesia, , Volume: 23, Issue:1
Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial.
BMJ open, , 02-14, Volume: 8, Issue:2		2018
Hypermethylation of brain natriuretic peptide gene is associated with the risk of rheumatic heart disease.
Bioscience reports, , 02-28, Volume: 37, Issue:1		2017
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
The Lancet. Respiratory medicine, , Volume: 4, Issue:5		2016
Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
Journal of cardiology, , Volume: 67, Issue:3		2016
Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist.
Molecular medicine reports, , Volume: 11, Issue:3		2015
The effect of atenolol on NT-proBNP and troponin in asymptomatic cats with severe left ventricular hypertrophy because of hypertrophic cardiomyopathy: a pilot study.
Journal of veterinary internal medicine, , Volume: 25, Issue:5
A novel and integrated approach for the identification and characterization of drug-induced cardiac toxicity in the dog.
Toxicologic pathology, , Volume: 39, Issue:2		2011
Pharmacotherapy for acute heart failure syndromes.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jan-01, Volume: 68, Issue:1		2011
Impact of preoperative nesiritide on renal function after mitral valve surgery.
The heart surgery forum, , Volume: 12, Issue:4		2009
Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.
Journal of hypertension, , Volume: 26, Issue:8		2008
Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease.
Trends in cardiovascular medicine, , Volume: 17, Issue:1		2007
[Regression of cardiac hypertrophy using angiotensin II receptor blocker in patients with chronic kidney diseases].
Nihon Jinzo Gakkai shi, , Volume: 48, Issue:8		2006
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Journal of the American Society of Nephrology : JASN, , Volume: 17, Issue:10		2006
Effects of medium-chain triglyceride (MCT) application to SHR on cardiac function, hypertrophy and expression of endothelin-1 mRNA and other genes.
Journal of cardiovascular pharmacology, , Volume: 44 Suppl 1		2004
AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure.
Pharmaceutical research, , Volume: 21, Issue:11		2004
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
Circulation, , Aug-26, Volume: 108, Issue:8		2003
Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 10, Issue:3		2003
Long-term adrenomedullin administration in experimental heart failure.
Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:5		2002
Present and future pharmacotherapy for heart failure.
Expert opinion on pharmacotherapy, , Volume: 3, Issue:7		2002
Subcutaneous administration of brain natriuretic peptide in experimental heart failure.
Journal of the American College of Cardiology, , Nov-01, Volume: 36, Issue:5		2000
Induction of heme oxygenase produces load-independent cardioprotective effects in hypertensive rats.
Life sciences, , Volume: 65, Issue:10		1999

Pharmacokinetics (233)

ArticleYear
Exercise performance is not improved in mice with skeletal muscle deletion of natriuretic peptide clearance receptor.
PloS one, , Volume: 18, Issue:11		2023
Impact of the time-to-target rate of urine volume concept on the outcome of acute decompensated heart failure.
International journal of cardiology, , 05-15, Volume: 379		2023
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
JAMA cardiology, , 04-01, Volume: 8, Issue:4		2023
The interaction of forced expiratory volume in 1 s and N-terminal pro-B-type natriuretic peptide with outcomes after transcatheter aortic valve replacement.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, , 04-03, Volume: 63, Issue:4		2023
A new composite indicator consisting of left ventricular extracellular volume, N-terminal fragment of B-type natriuretic peptide, and left ventricular end-diastolic volume is useful for predicting reverse remodeling after catheter ablation for atrial fibr
Heart and vessels, , Volume: 38, Issue:5		2023
Prediction of incident atrial fibrillation with cardiac biomarkers and left atrial volumes.
Heart (British Cardiac Society), , 02-14, Volume: 109, Issue:5		2023
Elevated NT-proBNP levels are associated with CTP ischemic volume and 90-day functional outcomes in acute ischemic stroke: a retrospective cohort study.
BMC cardiovascular disorders, , 09-30, Volume: 22, Issue:1		2022
Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
BMC cardiovascular disorders, , 09-03, Volume: 22, Issue:1		2022
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
The New England journal of medicine, , 09-29, Volume: 387, Issue:13		2022
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
Clinical pharmacology and therapeutics, , Volume: 112, Issue:5		2022
Platelet volume indices correlate to severity of heart failure and have prognostic value for both cardiac and thrombotic events in patients with congenital heart disease.
Heart and vessels, , Volume: 37, Issue:12		2022
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.
European journal of heart failure, , Volume: 24, Issue:9		2022
Diuretics Versus Volume Expansion in the Initial Management of Acute Intermediate High-Risk Pulmonary Embolism.
Lung, , Volume: 200, Issue:2		2022
The answer at our fingertips: Volume status in cirrhosis determined by machine learning and pulse oximeter waveform.
Physiological reports, , Volume: 10, Issue:5		2022
Estimation of the plasma volume status of elderly patients with acute decompensated heart failure using bedside clinical, biological, and ultrasound parameters.
Clinical cardiology, , Volume: 45, Issue:4		2022
Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function.
American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 80, Issue:1		2022
Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction.
Physiological reports, , Volume: 9, Issue:16		2021
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Cardiovascular diabetology, , 06-28, Volume: 20, Issue:1		2021
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Clinical pharmacokinetics, , Volume: 60, Issue:11		2021
Plasma Clearance of B-Type Natriuretic Peptide (BNP) before and after Bariatric Surgery for Morbid Obesity.
Clinical chemistry, , 03-31, Volume: 67, Issue:4		2021
Effect of Supervised Training Therapy on Pulmonary Arterial Compliance and Stroke Volume in Severe Pulmonary Arterial Hypertension and Inoperable or Persistent Chronic Thromboembolic Pulmonary Hypertension.
Respiration; international review of thoracic diseases, , Volume: 100, Issue:5
Body volume is the major determinant of worsening renal function in acutely decompensated heart failure with reduced left ventricular ejection fraction.
Postgraduate medical journal, , Volume: 98, Issue:1159		2022
Association of Longitudinal Changes in NT-proBNP With Changes in Left Atrial Volume and Function: MESA.
American journal of hypertension, , 06-22, Volume: 34, Issue:6		2021
The impact of volume substitution on post-operative atrial fibrillation.
European journal of clinical investigation, , Volume: 51, Issue:5		2021
Does the volume overload exaggerate the severity of mitral regurgitation in patients with decompensated heart failure?
Turkish journal of medical sciences, , 10-22, Volume: 50, Issue:6		2020
Clinical efficacy of biomarkers for evaluation of volume status in dialysis patients.
Medicine, , Jul-31, Volume: 99, Issue:31		2020
B-type natriuretic peptide levels and diagnostic accuracy: excess fluid volume.
Revista gaucha de enfermagem, , Volume: 41, Issue:spe		2020
Myocardial peak systolic velocity-a tool for cardiac screening of HIV-exposed uninfected children.
European journal of pediatrics, , Volume: 179, Issue:3		2020
Long-term Prognostic Value of Estimated Plasma Volume in Heart Failure with Preserved Ejection Fraction.
Scientific reports, , 10-07, Volume: 9, Issue:1		2019
Relationship between volume status and possibility of pulmonary hypertension in dialysis naive CKD5 patients.
PloS one, , Volume: 14, Issue:9		2019
Mean platelet volume as a prognostic factor for venous thromboembolic disease.
Revista medica de Chile, , Volume: 147, Issue:2		2019
Left atrial stiffness is superior to volume and strain parameters in predicting elevated NT-proBNP levels in systemic sclerosis patients.
The international journal of cardiovascular imaging, , Volume: 35, Issue:10		2019
Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study.
Arthritis research & therapy, , 12-03, Volume: 20, Issue:1		2018
Do Pre-Hemodialysis Estimates of Extracellular Volume Excess Using Bioimpedance and N-Terminal Brain Natriuretic Peptide Correlate With Cardiac Chamber Size Measured by Magnetic Resonance Imaging?
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, , Volume: 23, Issue:4		2019
Plasma syndecan-1 in hemodialysis patients associates with survival and lower markers of volume status.
American journal of physiology. Renal physiology, , 01-01, Volume: 316, Issue:1		2019
Biochemical Determinants of Changes in Plasma Volume After Decongestion Therapy for Worsening Heart Failure.
Journal of cardiac failure, , Volume: 25, Issue:3		2019
Usefulness of Estimated Plasma Volume at Postdischarge Follow-Up to Predict Recurrent Events in Patients With Heart Failure.
The American journal of cardiology, , 10-01, Volume: 122, Issue:7		2018
Evaluation of NT-ProBNP as a marker of the volume status of neurosurgical patients developing hyponatremia and natriuresis: A pilot study.
Neurology India, , Volume: 66, Issue:5
Association of left atrial pressure with left atrial volume and N-terminal prohormone brain natriuretic peptide in children with cardiomyopathy.
Cardiology in the young, , Volume: 28, Issue:11		2018
B-type natriuretic peptide is a useful biomarker for the estimation of volume overload in children with hypertension on peritoneal dialysis.
Nephrology (Carlton, Vic.), , Volume: 24, Issue:3		2019
Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
Journal of pharmacokinetics and pharmacodynamics, , Volume: 45, Issue:3		2018
Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, , Volume: 22, Issue:3		2018
Longer Ischemic Time is Associated with Increased Ventricular Stiffness as Measured by Pressure-Volume Loop Analysis in Pediatric Heart Transplant Recipients.
Pediatric cardiology, , Volume: 39, Issue:2		2018
Diuretics versus volume expansion in acute submassive pulmonary embolism.
Archives of cardiovascular diseases, , Volume: 110, Issue:11		2017
Randomized Crossover Trial of Blood Volume Monitoring-Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis.
Clinical journal of the American Society of Nephrology : CJASN, , Nov-07, Volume: 12, Issue:11		2017
The role of bioelectrical impedance analysis, NT-ProBNP and inferior vena cava sonography in the assessment of body fluid volume in children with nephrotic syndrome.
Nefrologia, , Volume: 38, Issue:1
Atrial function, atrial volume and cardiovascular clinical outcomes in patients with end-stage renal disease - A study of cardiac computed tomography.
Journal of cardiovascular computed tomography, , Volume: 11, Issue:5
Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension.
The European respiratory journal, , Volume: 49, Issue:6		2017
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Journal of the American Society of Hypertension : JASH, , Volume: 11, Issue:7		2017
Impact of Diabetes on Extracellular Volume Status in Patients Initiating Peritoneal Dialysis.
American journal of nephrology, , Volume: 46, Issue:1		2017
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
CPT: pharmacometrics & systems pharmacology, , Volume: 6, Issue:7		2017
Long-term outcome of patients with triphasic mitral flow with a mid-diastolic L wave: prognostic role of left atrial volume and N-terminal pro-brain natriuretic peptide.
The international journal of cardiovascular imaging, , Volume: 33, Issue:9		2017
Impact of Volume Management on Volume Overload and Rehospitalization in CAPD Patients.
Western journal of nursing research, , Volume: 40, Issue:5		2018
B-type natriuretic peptide and echocardiography reflect volume changes during pregnancy.
Journal of perinatal medicine, , Jul-26, Volume: 45, Issue:5		2017
Extracellular Fluid/Intracellular Fluid Volume Ratio as a Novel Risk Indicator for All-Cause Mortality and Cardiovascular Disease in Hemodialysis Patients.
PloS one, , Volume: 12, Issue:1		2017
Long-term prognostic impact of left atrial volumes and emptying fraction in a community-based cohort.
Heart (British Cardiac Society), , Volume: 103, Issue:9		2017
Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Advances in therapy, , Volume: 34, Issue:2		2017
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Lancet (London, England), , 12-10, Volume: 388, Issue:10062		2016
Determinants of Left Atrial Volume in Patients with Atrial Fibrillation.
PloS one, , Volume: 11, Issue:10		2016
Subacute lesion volume as a potential prognostic biomarker for acute ischemic stroke after intravenous thrombolysis.
Journal of the neurological sciences, , Oct-15, Volume: 369		2016
Impact of BNP level and peak VO
Heart and vessels, , Volume: 32, Issue:4		2017
Left ventricular pressure-volume measurements and myocardial gene expression profile in type 2 diabetic Goto-Kakizaki rats.
American journal of physiology. Heart and circulatory physiology, , 10-01, Volume: 311, Issue:4		2016
Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.
British journal of clinical pharmacology, , Volume: 82, Issue:3		2016
The Association between N-terminal Pro-Brain Natriuretic Peptide Levels in the Umbilical Vein and Amniotic Fluid Volume Abnormalities.
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, , Volume: 38, Issue:4		2016
Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.
European heart journal, , 06-14, Volume: 37, Issue:23		2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Cardiovascular therapeutics, , Volume: 34, Issue:4		2016
Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
International heart journal, , Volume: 57, Issue:2		2016
Usefulness of anaerobic threshold to peak oxygen uptake ratio to determine the severity and pathophysiological condition of chronic heart failure.
Journal of cardiology, , Volume: 68, Issue:5		2016
Relationship of left atrial global peak systolic strain with left ventricular diastolic dysfunction and brain natriuretic peptide level in end-stage renal disease patients with preserved left ventricular ejection fraction.
Journal of echocardiography, , Volume: 14, Issue:2		2016
The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients.
BMC nephrology, , Dec-29, Volume: 16		2015
Left atrial minimum volume is more strongly associated with N-terminal pro-B-type natriuretic peptide than the left atrial maximum volume in a community-based sample.
The international journal of cardiovascular imaging, , Volume: 32, Issue:3		2016
Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study.
Heart (British Cardiac Society), , Volume: 102, Issue:1		2016
Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, , Volume: 47, Issue:12		2015
Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention.
Indian heart journal, , Volume: 67, Issue:4
[Peak oxygen consumption, NT-proBNP and echocardiographic changes in patients with chronic heart failure].
Zhonghua xin xue guan bing za zhi, , Volume: 43, Issue:3		2015
Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, , Aug-12, Volume: 17		2015
Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial.
European heart journal, , Jan-01, Volume: 37, Issue:1		2016
Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis.
Journal of cardiovascular computed tomography, , Volume: 9, Issue:6
Impact of endoscopic lung volume reduction on right ventricular myocardial function.
PloS one, , Volume: 10, Issue:4		2015
Correlation between mean platelet volume and B-type natriuretic peptide concentration in emergency patients with heart failure.
Biochemia medica, , Volume: 25, Issue:1		2015
[Correlation between submaximal exercise measurements and peak oxygen uptake in patients with pulmonary arterial hypertension].
Zhonghua yi xue za zhi, , Aug-26, Volume: 94, Issue:32		2014
Relationship of left atrial global peak systolic strain with left ventricular diastolic dysfunction and brain natriuretic peptide level in patients presenting with non-ST elevation myocardial infarction.
Medical science monitor : international medical journal of experimental and clinical research, , Oct-22, Volume: 20		2014
Predialysis NTproBNP predicts magnitude of extracellular volume overload in haemodialysis patients.
American journal of nephrology, , Volume: 40, Issue:3		2014
[Study of the effects of high volume hemofiltration on extra vascular lung water and alveolar-arterial oxygen exchange in patients with septic shock].
Zhonghua wei zhong bing ji jiu yi xue, , Volume: 26, Issue:9		2014
Targeting of high peak respiratory exchange ratio is safe and enhances the prognostic power of peak oxygen uptake for heart failure patients.
Circulation journal : official journal of the Japanese Circulation Society, , Volume: 78, Issue:9		2014
Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.
Journal of cardiac failure, , Volume: 20, Issue:9		2014
The total right/left-volume index: a new and simplified cardiac magnetic resonance measure to evaluate the severity of Ebstein anomaly of the tricuspid valve: a comparison with heart failure markers from various modalities.
Circulation. Cardiovascular imaging, , Volume: 7, Issue:4		2014
Extravascular lung water, B-type natriuretic peptide, and blood volume contraction enable diagnosis of weaning-induced pulmonary edema.
Critical care medicine, , Volume: 42, Issue:8		2014
A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients.
BMC nephrology, , Apr-04, Volume: 15		2014
Do optimal prognostic thresholds in continuous physiological variables really exist? Analysis of origin of apparent thresholds, with systematic review for peak oxygen consumption, ejection fraction and BNP.
PloS one, , Volume: 9, Issue:1		2014
Evaluation of volume overload by bioelectrical impedance analysis, NT-proBNP and inferior vena cava diameter in patients with stage 3&4 and 5 chronic kidney disease.
Renal failure, , Volume: 36, Issue:4		2014
Rapid upregulation and clearance of distinct circulating microRNAs after prolonged aerobic exercise.
Journal of applied physiology (Bethesda, Md. : 1985), , Mar-01, Volume: 116, Issue:5		2014
The effect of strict volume control on cardiac biomarker and arterial stiffness in peritoneal dialysis patients.
Clinical nephrology, , Volume: 81, Issue:4		2014
Prognostic value of alveolar volume in systolic heart failure: a prospective observational study.
BMC pulmonary medicine, , Nov-22, Volume: 13		2013
Brain-type natriuretic peptide and right ventricular end-diastolic volume index measurements are imprecise estimates of circulating blood volume in critically ill subjects.
The journal of trauma and acute care surgery, , Volume: 75, Issue:5		2013
Usefulness of mean platelet volume as a biomarker for long-term clinical outcomes after percutaneous coronary intervention in Korean cohort: a comparable and additive predictive value to high-sensitivity cardiac troponin T and N-terminal pro-B type natriu
Platelets, , Volume: 25, Issue:6		2014
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis.
PloS one, , Volume: 8, Issue:8		2013
Serum levels of N-terminal proB-type natriuretic peptide in mechanically ventilated critically ill patients--relation to tidal volume size and development of acute respiratory distress syndrome.
BMC pulmonary medicine, , Jul-09, Volume: 13		2013
Relation of left atrial peak systolic strain with left ventricular diastolic dysfunction and brain natriuretic peptide level in patients presenting with ST-elevation myocardial infarction.
Cardiovascular ultrasound, , Jul-05, Volume: 11		2013
Correlation of plasma B-type natriuretic peptide with shunt volume in children with congenital heart disease involving left-to-right shunt.
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, , Volume: 54, Issue:3

Bioavailability (14)

ArticleYear
Brain Natriuretic Peptide Protects Cardiomyocytes from Apoptosis and Stimulates Their Cell Cycle Re-Entry in Mouse Infarcted Hearts.
Cells, , 12-20, Volume: 12, Issue:1		2022
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Clinical pharmacokinetics, , Volume: 60, Issue:11		2021
A Low-Sodium Diet Boosts Ang (1-7) Production and NO-cGMP Bioavailability to Reduce Edema and Enhance Survival in Experimental Heart Failure.
International journal of molecular sciences, , Apr-14, Volume: 22, Issue:8		2021
In Vitro Demonstration of Drug-Reagent Interactions Among Commonly Used Parenteral Drugs in Cardiology.
Cardiovascular & hematological agents in medicinal chemistry, , Volume: 19, Issue:1		2021
Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
American journal of physiology. Renal physiology, , 01-01, Volume: 318, Issue:1		2020
The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
European heart journal, , 05-21, Volume: 39, Issue:20		2018
B-type natriuretic peptide and plasma hemoglobin levels following transfusion of shorter-storage versus longer-storage red blood cells: Results from the TOTAL randomized trial.
American heart journal, , Volume: 183		2017
Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.
JACC. Heart failure, , Volume: 3, Issue:9		2015
A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients.
Cardiovascular therapeutics, , Volume: 33, Issue:4		2015
Possible mechanisms for brain natriuretic peptide resistance in heart failure with a focus on interspecies differences and canine BNP biology.
Veterinary journal (London, England : 1997), , Volume: 194, Issue:1		2012
B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications.
Biomarkers in medicine, , Volume: 4, Issue:2		2010
Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension.
The American journal of the medical sciences, , Volume: 339, Issue:1		2010
Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside.
Clinical chemistry and laboratory medicine, , Volume: 47, Issue:3		2009
Role of oxidative and nitrosative stress biomarkers in chronic heart failure.
Frontiers in bioscience (Landmark edition), , 01-01, Volume: 14, Issue:6		2009

Dosage (180)

ArticleYear
The role of laboratory medicine in a value-based healthcare system: the example of heart failure patient management in the Italian context.
European review for medical and pharmacological sciences, , Volume: 27, Issue:21		2023
Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients.
Journal of internal medicine, , Volume: 294, Issue:4		2023
A case-cohort study of the association between adiponectin and mortality in EPIC-Heidelberg: NT-proBNP may explain the adiponectin paradox.
Nutrition, metabolism, and cardiovascular diseases : NMCD, , Volume: 33, Issue:4		2023
MARKER DIAGNOSTIC HEART FAILURE PROGRESSION IN THE POST-INFARCTION PERIOD.
Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 75, Issue:10		2022
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
Journal of the American College of Cardiology, , 10-18, Volume: 80, Issue:16		2022
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
Clinical pharmacology and therapeutics, , Volume: 112, Issue:5		2022
3-Month Enalapril Treatment in Pediatric Fontan Patients With Moderate to Good Systolic Ventricular Function.
The American journal of cardiology, , 01-15, Volume: 163		2022
PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study.
Open heart, , Volume: 8, Issue:2		2021
Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
PloS one, , Volume: 16, Issue:9		2021
Prognostic Significance of Pre-Discharge Plasma BNP among Heart Failure Patients in Ilorin, Nigeria.
West African journal of medicine, , 08-30, Volume: 38, Issue:8		2021
Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients.
Yonsei medical journal, , Volume: 62, Issue:5		2021
Lung ultrasound and BNP to detect hidden pulmonary congestion in euvolemic hemodialysis patients: a single centre experience.
BMC nephrology, , 01-21, Volume: 22, Issue:1		2021
Pulmonary Hypertension Following Increased Dosing of Diazoxide in an Infant.
International heart journal, , Sep-29, Volume: 61, Issue:5		2020
Inpatient Initiation of Sacubitril/Valsartan.
The Annals of pharmacotherapy, , Volume: 55, Issue:4		2021
[Different methods to manage dry weight in hemodialysis patients].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Feb-12, Volume: 37, Issue:1		2020
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
European journal of heart failure, , Volume: 21, Issue:11		2019
High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, in Escherichia coli.
Applied microbiology and biotechnology, , Volume: 103, Issue:12		2019
Effect of Testosterone on Natriuretic Peptide Levels.
Journal of the American College of Cardiology, , 03-26, Volume: 73, Issue:11		2019
Manifestations of and risk factors for acute myocardial injury after acute organophosphorus pesticide poisoning.
Medicine, , Volume: 98, Issue:6		2019
Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
Journal of clinical hypertension (Greenwich, Conn.), , Volume: 20, Issue:10		2018
[CLINICAL SIGNIFICANCE OF CARDIAC BIOMARKERS INCREASING AND THEIR INTERRELATIONS IN SURGERY WITH CARDIO-PULMONARY BYPASS.]
Anesteziologiia i reanimatologiia, , Volume: 61, Issue:5		2016
Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
Journal of pharmacokinetics and pharmacodynamics, , Volume: 45, Issue:3		2018
Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice.
International immunopharmacology, , Volume: 55		2018
Adherence to guidelines in patients with chronic heart failure in primary health care.
Scandinavian journal of primary health care, , Volume: 35, Issue:4		2017
Brain-Heart Interactions in Traumatic Brain Injury.
Cardiology in review, , Volume: 25, Issue:6
Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients.
Journal of interventional cardiology, , Volume: 30, Issue:6		2017
Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, , Volume: 19, Issue:3		2017
Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches.
Annales de biologie clinique, , Jun-01, Volume: 75, Issue:3		2017
Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.
BMC pulmonary medicine, , 02-23, Volume: 17, Issue:1		2017
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Lancet (London, England), , 12-10, Volume: 388, Issue:10062		2016
Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Hypertension (Dallas, Tex. : 1979), , Volume: 69, Issue:1		2017
[The impact of the dosing, a 12-week physical training on the concentration of NT-proBNP and D-Dimer in patients with heart failure and impaired functional capacity in VII-X decade of life].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Jul-29, Volume: 41, Issue:241		2016
Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.
Pharmacological research, , Volume: 113, Issue:Pt A		2016
Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
Cardiovascular therapeutics, , Volume: 34, Issue:3		2016
Recombinant human brain natriuretic peptide attenuates trauma-/haemorrhagic shock-induced acute lung injury through inhibiting oxidative stress and the NF-κB-dependent inflammatory/MMP-9 pathway.
International journal of experimental pathology, , Volume: 96, Issue:6		2015
Prognostic Value of Preoperative Brain Natriuretic Peptide Serum Levels in Liver Transplantation.
Transplantation, , Volume: 100, Issue:4		2016
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
JAMA, , Dec-01, Volume: 314, Issue:21		2015
Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study.
Heart (British Cardiac Society), , Volume: 102, Issue:1		2016
A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients.
Cardiovascular therapeutics, , Volume: 33, Issue:4		2015
Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report.
BMC research notes, , Apr-23, Volume: 8		2015
Exercise capacity in children and adolescents with corrected congenital heart disease.
Pediatric cardiology, , Volume: 36, Issue:5		2015
[Effect of Xuebijing injection on hemodynamics and endothelial function in patients with severe sepsis: a prospective study].
Zhonghua wei zhong bing ji jiu yi xue, , Volume: 27, Issue:2		2015
[Value of pulse indicator continuous cardiac output monitoring of cardiac function in septic shock patients: a prospective study].
Zhonghua wei zhong bing ji jiu yi xue, , Volume: 27, Issue:1		2015
Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study.
Circulation. Cardiovascular genetics, , Volume: 8, Issue:1		2015
The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins.
Current pharmaceutical biotechnology, , Volume: 15, Issue:9		2014
Weaning the cardiac patient from mechanical ventilation.
Current opinion in critical care, , Volume: 20, Issue:5		2014
No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients.
Kidney international, , Volume: 86, Issue:3		2014
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Journal of cardiovascular pharmacology, , Volume: 64, Issue:1		2014
B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 15, Issue:2		2014
Protective effect of time spent walking on risk of stroke in older men.
Stroke, , Volume: 45, Issue:1		2014
[Is BNP assay useful for the diagnosis of acute dyspnea in emergencies departments?].
La Tunisie medicale, , Volume: 91, Issue:8-9
Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides.
PloS one, , Volume: 8, Issue:9		2013
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
Journal of the American College of Cardiology, , Oct-08, Volume: 62, Issue:15		2013
Acute decompensated heart failure: update on new and emerging evidence and directions for future research.
Journal of cardiac failure, , Volume: 19, Issue:6		2013
Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
International heart journal, , Volume: 54, Issue:1		2013
[Performance of natriuretic peptide as a marker in patients with chronic obstructive pulmonary disease].
Revue medicale suisse, , Oct-17, Volume: 8, Issue:358		2012
Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure.
American heart journal, , Volume: 164, Issue:6		2012
Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women.
Sleep, , Nov-01, Volume: 35, Issue:11		2012
Association of objectively measured physical activity with established and novel cardiovascular biomarkers in elderly subjects: every step counts.
Journal of epidemiology and community health, , Volume: 67, Issue:2		2013
Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia.
International journal of clinical oncology, , Volume: 18, Issue:5		2013
Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
Arquivos brasileiros de cardiologia, , Volume: 99, Issue:1		2012
Effect of lipopolysaccharide, cytokines, and catecholamines on brain natriuretic peptide release from human myocardium.
Acta anaesthesiologica Scandinavica, , Volume: 56, Issue:7		2012
Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study.
Journal of hypertension, , Volume: 30, Issue:5		2012
Efficacy and safety of a modified dosage regimen of nesiritide in patients older than 75 years with acute heart failure.
Aging clinical and experimental research, , Volume: 24, Issue:5		2012
Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF).
Journal of cardiology, , Volume: 59, Issue:3		2012
[Application of B type natriuretic peptide in fluid therapy after major abdominal operations].
Zhonghua yi xue za zhi, , Oct-11, Volume: 91, Issue:37		2011
The cause of B-type natriuretic peptide elevation and the dose-dependent effect of angiotensin-converting enzyme inhibitor on patients late after tetralogy of Fallot repair.
Pediatric cardiology, , Volume: 33, Issue:2		2012
In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
Cardiovascular drugs and therapy, , Volume: 26, Issue:2		2012
Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
The American journal of cardiology, , Mar-01, Volume: 109, Issue:5		2012
Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease.
Swiss medical weekly, , Volume: 141		2011
[Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: a multicenter, randomized, open label, controlled study].
Zhonghua xin xue guan bing za zhi, , Volume: 39, Issue:4		2011
[Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry].
Wiener klinische Wochenschrift, , Volume: 123, Issue:11-12		2011
Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure.
Journal of cardiac failure, , Volume: 17, Issue:3		2011
Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster.
Human molecular genetics, , Apr-15, Volume: 20, Issue:8		2011
B-type natriuretic peptide pretreatment attenuates heart ischemia-reperfusion injury in rats.
Transplantation proceedings, , Volume: 42, Issue:10		2010
[Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo].
Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 21, Issue:1		2005
Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system.
Journal of hypertension, , Volume: 29, Issue:2		2011
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
Vascular health and risk management, , Aug-09, Volume: 6		2010
Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
American heart journal, , Volume: 159, Issue:4		2010
Impaired tissue clearance of verapamil in rat cardiac hypertrophy results in transcriptional repression of ion channels.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 40, Issue:4		2010
Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Clinical journal of the American Society of Nephrology : CJASN, , Volume: 5, Issue:5		2010
Hyponatremia and brain injury: absence of alterations of serum brain natriuretic peptide and vasopressin.
Arquivos de neuro-psiquiatria, , Volume: 67, Issue:4		2009
Measurement of Type B natriuretic peptide in heparin and K(2) EDTA plasma.
Clinical biochemistry, , Volume: 43, Issue:4-5		2010
[BNP-guided therapy of chronic heart failure: what is the evidence?].
Revue medicale suisse, , Oct-14, Volume: 5, Issue:221		2009
[B-type natriuretic peptide and Doppler echocardiography in the diagnosis of heart failure: alternative or complementary tools?].
Giornale italiano di cardiologia (2006), , Volume: 10, Issue:8		2009
Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Clinical drug investigation, , Volume: 29, Issue:2		2009
Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Pediatric blood & cancer, , Volume: 52, Issue:5		2009
Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
The American journal of cardiology, , Jan-01, Volume: 103, Issue:1		2009
Brain natriuretic peptide variations are linked to volume status in hemodialysis patients.
Clinical nephrology, , Volume: 70, Issue:6		2008
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.
Archives of disease in childhood. Fetal and neonatal edition, , Volume: 94, Issue:3		2009
Nesiritide following maze and mitral valve surgery.
Journal of cardiac surgery, , Volume: 23, Issue:5
Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension.
Circulation, , Oct-21, Volume: 118, Issue:17		2008
Hemodynamic effects and safety of nesiritide in neonates with heart failure.
Journal of intensive care medicine, , Volume: 23, Issue:6
Insights into natriuretic peptides in heart failure: an update.
Current heart failure reports, , Volume: 5, Issue:2		2008
Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemic hypertension.
Journal of human hypertension, , Volume: 23, Issue:1		2009
Nesiritide: the clinical experience.
The Canadian journal of cardiology, , Volume: 24 Suppl B		2008
Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.
International journal of hematology, , Volume: 88, Issue:2		2008
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction.
Journal of cardiac failure, , Volume: 14, Issue:4		2008
Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide.
Current opinion in critical care, , Volume: 14, Issue:3		2008
N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
Angiology, , Volume: 59, Issue:3

Interactions (34)

ArticleYear
Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure.
Medicine, , Nov-10, Volume: 102, Issue:45		2023
Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction.
Medicine, , Dec-02, Volume: 101, Issue:48		2022
Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction.
Disease markers, , Volume: 2022		2022
Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure.
Clinical cardiology, , Volume: 45, Issue:7		2022
The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure.
Computational and mathematical methods in medicine, , Volume: 2022		2022
Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention.
Bioengineered, , Volume: 12, Issue:1		2021
Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance.
The Libyan journal of medicine, , Volume: 16, Issue:1		2021
The role of acute heart failure index (AHFI) combined with emergency heart failure mortality risk grade (EHMRG) in the evaluation of clinical outcomes and prognosis in patients with acute heart failure.
Acta cardiologica, , Volume: 77, Issue:6		2022
BNP combined with echocardiographic parameters to predict the risk of cardioembolic stroke.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 88		2021
Effect of norepinephrine combined with sodium phosphocreatine on cardiac function and prognosis of patients with septic shock.
International journal of immunopathology and pharmacology, , Volume: 34
[Meta-analysis of Naoxintong Capsules combined with Western medicine in treatment of chronic heart failure].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 45, Issue:17		2020
Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, , Volume: 40, Issue:5		2020
Balloon Valvuloplasty to Treat Adult Symptomatic Pulmonary Valve Stenosis with Sequential Follow-Up Using Cardiac Magnetic Resonance Imaging in Combination with Echocardiography.
International heart journal, , Sep-29, Volume: 61, Issue:5		2020
Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure.
Acta cardiologica, , Volume: 76, Issue:1		2021
Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels.
European review for medical and pharmacological sciences, , Volume: 24, Issue:10		2020
Effect of trimetazidine combined with perindopril on NT-proBNP level in rats with dilated cardiomyopathy.
Cellular and molecular biology (Noisy-le-Grand, France), , May-16, Volume: 66, Issue:2		2020
Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure.
The Korean journal of internal medicine, , Volume: 34, Issue:4		2019
Doppler myocardial performance index combined with plasma B-type natriuretic peptide levels as a marker of cardiac function in patients with decompensated cirrhosis.
Medicine, , Volume: 97, Issue:48		2018
Therapeutic strategy for multiple VSD combined with MVSD in infants and young children.
European review for medical and pharmacological sciences, , Volume: 21, Issue:4 Suppl		2017
Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension.
Pakistan journal of pharmaceutical sciences, , Volume: 30, Issue:4(Suppl.)		2017
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
JACC. Heart failure, , Volume: 4, Issue:9		2016
Vitamin D should be supplemented more actively in elderly patients with coronary heart disease combined with COPD.
International journal of chronic obstructive pulmonary disease, , Volume: 11		2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
Clinical and experimental rheumatology, , Volume: 34 Suppl 100, Issue:5
Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
European review for medical and pharmacological sciences, , Volume: 19, Issue:7		2015
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
European review for medical and pharmacological sciences, , Volume: 19, Issue:5		2015
Cardiac structure and function improvements in coronary artery disease combined with severe obstructive sleep apnea/hypopnea syndrome patients via noninvasive positive pressure ventilation therapy.
Coronary artery disease, , Volume: 25, Issue:6		2014
Predictive value of N-terminal pro-brain natriuretic peptide in combination with the sequential organ failure assessment score in sepsis.
Chinese medical journal, , Volume: 125, Issue:11		2012
Prognostic utility of changes in N-terminal pro-brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock.
Shock (Augusta, Ga.), , Volume: 36, Issue:2		2011
Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
The American journal of cardiology, , Jan-15, Volume: 105, Issue:2		2010
Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, , Volume: 11, Issue:2		2009
Noninvasive estimation of left ventricular end-diastolic pressure using tissue Doppler imaging combined with pulsed-wave Doppler echocardiography in patients with ventricular septal defects: a comparison with the plasma levels of the B-type natriuretic Pe
Echocardiography (Mount Kisco, N.Y.), , Volume: 25, Issue:3		2008
On-chip enzyme immunoassay of a cardiac marker using a microfluidic device combined with a portable surface plasmon resonance system.
Analytical chemistry, , Aug-01, Volume: 78, Issue:15		2006
Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure.
American heart journal, , Volume: 150, Issue:3		2005
Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure.
Journal of cardiac failure, , Volume: 11, Issue:1		2005